Decoding the Proliferative Phase Endometrium: A Foundational Transcriptomic Atlas for Reproductive Research and Therapy

Abstract

The proliferative phase of the human endometrium, traditionally viewed merely as a period of estrogen-driven growth, is now recognized as a complex and critical window for establishing endometrial receptivity. This article synthesizes recent transcriptomic advances, from single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics, to provide a comprehensive landscape of the proliferative phase. We explore the dynamic gene expression profiles, distinct immune cell dynamics—including newly identified uterine dendritic cell (uDC) subsets and progenitor populations—and the critical transition at the late proliferative stage. Furthermore, we detail methodological approaches for analyzing this data, discuss transcriptomic aberrations linked to clinical conditions like thin endometrium and recurrent implantation failure (RIF), and validate findings through genetic regulation studies. This resource aims to equip researchers and drug developers with the foundational knowledge and tools to advance diagnostics and therapeutics for endometrial-related infertility and disorders.

Unraveling the Dynamic Transcriptomic and Cellular Architecture of the Proliferative Phase

The endometrium, the inner mucosal lining of the uterus, undergoes complex molecular and cellular changes across the menstrual cycle to prepare for embryo implantation [1]. While extensive transcriptome-wide analyses have focused on endometrial receptivity during the secretory phase, the proliferative phase has traditionally been simplified as a period of continuous tissue growth in response to estradiol stimulation [1]. However, emerging research reveals the proliferative phase, particularly the transition from mid-proliferative (MP) to late proliferative (LP)/peri-ovulatory stage, involves intricate transcriptomic reprogramming essential for subsequent endometrial function [1] [2]. This whitepaper synthesizes current research to delineate the transcriptional dynamics characterizing this critical transition, providing researchers and drug development professionals with a detailed framework for investigating endometrial biology during this foundational period.

The endometrial cycle aligns with ovarian follicular maturation, comprising menstrual, proliferative (follicular phase), and secretory (luteal phase) stages [1]. The proliferative phase encompasses endometrial regeneration and growth post-menses, culminating in the peri-ovulatory period when sperm transit the uterus toward the fallopian tube for fertilization [1]. Understanding the temporal transcriptome across this phase is crucial, as transcriptomic signatures in proliferative phase endometrium may predict pregnancy outcomes in assisted reproduction, and aberrations detected during the window of implantation often reflect disrupted proliferative processes [1]. This review centers on the MP to LP transition, an essential pivot point directing endometrial maturation toward receptivity.

Experimental Designs for Proliferative Phase Transcriptome Analysis

Key Methodologies for Temporal Transcriptome Profiling

Comprehensive transcriptome analysis requires precise experimental design to capture the dynamic nature of the proliferative phase. The following protocol outlines the primary methodology for a complete endometrial cycle investigation.

dot code for Experimental Workflow for Endometrial Transcriptome Analysis

Figure 1: Experimental workflow for comprehensive endometrial transcriptome analysis across five key cycle phases. MP serves as the reference for comparative analysis of subsequent phases, including the critical LP transition.

Tissue Collection and Phase Classification

Endometrial biopsies should be obtained from healthy, ovulating women with confirmed cycle regularity. Cycle phase is determined by combining last menstrual period date with histological dating according to standardized criteria (e.g., Noyes' criteria) [1]. For proliferative phase-centered studies, key time points include:

• Mid-Proliferative (MP) Phase: Serves as an optimal reference state for comparing subsequent transcriptomic changes.
• Late Proliferative (LP) Phase/Peri-Ovulatory Period: The critical transition phase immediately preceding ovulation.
• Secretory Phase Controls: Early (ES), mid (MS), and late secretory (LS) phases provide context for understanding downstream consequences of proliferative phase programming.

RNA Sequencing and Data Processing

Current studies utilize massively parallel shotgun RNA sequencing (RNA-seq), which provides greater depth and specificity than microarray-based technologies [1]. RNA-exome sequencing is particularly effective for transcriptome analysis. Following sequencing:

• Read Alignment and Quantification: Map sequences to a reference genome and quantify gene expression levels.
• Differential Expression Analysis: Identify differentially expressed genes (DEGs) using statistical packages (e.g., DESeq2, edgeR), comparing each phase to the MP reference (padj < 0.05 considered significant) [1].
• Validation: Confirm key findings with reverse transcription quantitative PCR (RT-qPCR) or other orthogonal methods.

The Scientist's Toolkit: Essential Research Reagents

Table 1: Key Research Reagents for Endometrial Transcriptome Studies

Reagent/Category	Specific Examples	Function/Application
RNA Sequencing Kits	RNA-exome sequencing kits	Comprehensive transcriptome profiling with high specificity and depth [1]
Histological Staining	Hematoxylin and Eosin (H&E)	Histological dating of endometrial biopsies according to Noyes' criteria [1]
Hormone Assays	ESTRONE-3-GLUCURONIDE (E3G), PdG, LH, FSH immunoassays	Confirm cycle phase and correlate transcriptomic changes with hormonal milieu [3]
Bioinformatics Tools	DESeq2, edgeR, clusterProfiler	Differential expression analysis, gene ontology, and pathway enrichment analysis [1]
Single-Cell RNA Seq	10x Genomics Platform	Resolution of cell-type-specific transcriptomic changes within endometrial tissue [1]

Transcriptional Dynamics Across the Proliferative Phase

Global Transcriptome Changes from MP to LP Transition

Temporal transcriptome analysis reveals substantial reprogramming during the LP transition. A recent study identified 5,082 significantly differentially expressed genes (DEGs) when comparing MP phase to LP, ES, MS, and LS phases [1]. The LP phase demonstrates a unique transcriptional signature, with many genes exhibiting phase-specific expression patterns, while other DEGs are shared across multiple phases, suggesting both transient and sustained regulatory mechanisms [1].

dot code for Functional Biological Transition from MP to LP Phase

Figure 2: The functional biological transition from MP to LP phase involves a shift from active proliferation to preparatory metabolic and transcriptional reprogramming for the forthcoming secretory phase, including activation of the HIST gene cluster.

Key Differentially Expressed Genes and Chromosomal Clusters

Substantial transcriptomic changes occur during the LP transition, with numerous genes showing significant expression differences compared to the MP phase. Analysis of chromosomal locations reveals co-expressed gene clusters, notably histone-encoding genes within the HIST cluster on chromosome 6, which demonstrates coordinated increased activity during the LP phase followed by decline in the MS phase [1].

Table 2: Selected Differentially Expressed Genes During the LP vs. MP Transition

Gene Name	Log2 Fold Change	P adj Value	Function / Significance
RNA5-8SN3	+7.61	2.38 × 10⁻⁵	Phase-specific marker [1]
SNORD14B	+6.19	1.93 × 10⁻¹²	Phase-specific marker [1]
PLA2G4F	+5.80	9.48 × 10⁻⁴	Phospholipase activity, potential signaling role [1]
NLGN4Y	+6.06	2.10 × 10⁻²	Neuronal signaling protein, potential novel role [1]

Beyond individual genes, the LP phase involves significant functional transitions apparent through Gene Ontology and hallmark gene enrichment analysis of DEGs [1]. These analyses indicate a shift from active cellular proliferation toward preparatory processes for the forthcoming secretory phase, including metabolic reprogramming and initial expression of genes that will facilitate implantation.

Beyond Gene-Level Expression: Splicing Dynamics and Genetic Regulation

RNA Splicing Variations Across the Cycle

Transcript isoform-level and RNA splicing changes represent an additional layer of endometrial regulation that varies by menstrual cycle phase [4]. These splicing dynamics are not detectable through conventional gene-level expression analyses [4]. Endometriosis exhibits particularly pronounced splicing differences during the mid-secretory phase, suggesting disruption of normal post-transcriptional regulation in this condition [4].

Integration of genotype data reveals splicing quantitative trait loci (sQTLs) that influence RNA splicing in the endometrium. One study identified 3,296 sQTLs, with 67.5% of genes harboring sQTLs not discovered through gene-level eQTL analysis [4]. This highlights the specificity and importance of splicing-level genetic regulation. Furthermore, integration of sQTLs with endometriosis genome-wide association study (GWAS) data implicates GREB1 and WASHC3 in endometriosis risk through genetically regulated splicing events [4].

Genetic Regulation of Endometrial Gene Expression

Genetic variation between individuals significantly influences endometrial gene expression. Expression quantitative trait loci (eQTL) mapping studies demonstrate that genetic variants regulate the expression of many genes in endometrium [2]. These genetic effects show high correlation with genetic effects on expression in other reproductive tissues (e.g., uterus, ovary) and certain digestive tissues, suggesting shared genetic regulation across biologically similar tissues [2].

There is also emerging evidence for cell-specific genetic effects within distinct endometrial cell populations [2]. As sample sizes in endometrial studies increase and approach those of larger blood eQTL resources (e.g., eQTLGen), the proportion of genes with detected genetic regulation will likely expand substantially, offering greater insights into the genetic architecture of endometrial gene expression.

Implications for Reproductive Pathology and Drug Development

The transcriptional landscape of the proliferative phase, particularly the LP transition, has significant implications for understanding endometrial pathologies and developing targeted therapies. Transcriptomic aberrations detected during the window of implantation in patients with recurrent implantation failure (RIF) often reflect decreased cellular proliferation, a process normally active during the proliferative phase [1]. This suggests that defective proliferative phase programming may contribute to subsequent receptivity failure.

Furthermore, endometriosis genetic risk factors may operate through effects on proliferative phase biology. Integration of sQTL data with endometriosis GWAS has identified GREB1 and WASHC3 as risk genes mediating their effects through genetically regulated splicing events [4]. This provides a mechanistic link between genetic risk variants and molecular pathways operative in endometrial tissue.

For drug development, understanding the phase-specific transcriptome enables identification of novel therapeutic targets operating during specific windows of the cycle. The coordinated histone gene expression during the LP phase suggests potential for cell cycle-targeted interventions, while the splicing mechanisms identified offer opportunities for RNA-targeted therapeutics in endometriosis and other reproductive disorders.

The transition from mid-proliferative to late proliferative (peri-ovulatory) phase represents a critical window in endometrial programming, characterized by significant transcriptomic reprogramming that extends beyond gene-level expression to include alternative splicing and genetically regulated expression variation. Comprehensive characterization of this transition using RNA-sequencing technologies reveals phase-specific gene expression patterns, coordinated chromosomal cluster activity, and functional shifts that prepare the endometrium for the subsequent secretory phase and potential implantation.

Future research should leverage single-cell resolution transcriptomics to delineate cell-type-specific contributions to these transcriptomic dynamics and explore how perturbations during the proliferative phase contribute to reproductive pathologies and implantation failure. The experimental frameworks and molecular insights detailed in this whitepaper provide a foundation for advancing both fundamental understanding of endometrial biology and translational applications in women's health.

The human endometrium's proliferative phase has been historically simplified as a period of uniform, estrogen-mediated growth. However, emerging high-resolution transcriptomic studies reveal a more complex reality characterized by dynamic, phase-specific gene expression signatures that extend far beyond mere cellular proliferation. This whitepaper synthesizes recent evidence demonstrating that the proliferative phase comprises distinct functional substages—early, mid, and late proliferative—each defined by unique transcriptional programs governing tissue remodeling, immune modulation, and preparation for endometrial receptivity. By integrating findings from microarray, bulk RNA-sequencing, and single-cell transcriptomic analyses, we provide a comprehensive overview of the temporal gene expression patterns that orchestrate these phase-specific transformations. Understanding these sophisticated regulatory mechanisms provides crucial insights for developing targeted therapeutic strategies for endometrial-factor infertility and other reproductive disorders.

The traditional characterization of the proliferative phase as a homogeneous period of estrogen-driven endometrial thickening requires substantial revision in light of contemporary transcriptomic evidence. The proliferative phase, spanning approximately days 1-14 of the typical 28-day menstrual cycle, demonstrates remarkable molecular complexity when analyzed through temporal genomic frameworks [5] [6]. Rather than exhibiting linear growth kinetics, the endometrium displays a patterned thickening that plateaus around days 9-10 despite persistently high estrogen levels, suggesting the involvement of estrogen-independent regulatory mechanisms [5].

Advanced transcriptomic profiling now reveals that the proliferative phase consists of functionally distinct substages characterized by unique gene expression signatures that coordinate sequential biological processes including tissue regeneration, structured proliferation, and immune system preparation [5]. This temporal precision in gene expression extends beyond preparation for the secretory phase, representing instead an independently regulated developmental trajectory essential for endometrial function and embryo implantation competence [6].

Temporal Transcriptomic Dynamics Across Proliferative Subphases

Early Proliferative Phase (Days 1-3): Regeneration and Repair

The early proliferative phase is characterized by a transcriptional signature dominated by genes mediating tissue regeneration, angiogenesis, and inflammatory response modulation following menstrual shedding [5].

Table 1: Key Upregulated Genes in Early Proliferative Phase

Gene Symbol	Gene Name	Fold Change	Primary Function
TGFB2	Transforming Growth Factor β2	2.9	Tissue remodeling, cell differentiation
MT2A	Metallothionein 2A	3.3	Cellular repair, antioxidant defense
PLIN2	Perilipin 2	3.4	Lipid metabolism
F2RL2	Coagulation Factor II Receptor-like 2	3.9	Angiogenesis, vascular repair
CCL18	Chemokine (C-C motif) Ligand 18	3.9	Immune cell recruitment, inflammation modulation

Microarray analysis of human endometrial samples reveals significant upregulation of TGFB2, which coordinates extracellular matrix modification and cellular differentiation essential for reconstructing the functionalis layer [5]. Concurrent elevation of pro-angiogenic factors like F2RL2 facilitates revascularization, while CCL18 modulates the inflammatory response to create a tissue environment conducive to repair.

Mid-Proliferative Phase (Days 5-8): Proliferation and Receptivity Initiation

The mid-proliferative phase represents a critical transition point where the transcriptional landscape shifts toward structured proliferation and early preparation for endometrial receptivity [5].

This phase demonstrates upregulation of 62 significantly elevated genes, including members of the Wnt signaling pathway and implantation-associated genes such as Indian hedgehog (IHH) and secreted frizzled protein 4 [5]. Notably, progesterone receptor (PGR) expression increases during this period, enabling future responsiveness to progesterone during the secretory phase despite its current absence [5]. Heat shock proteins also feature prominently, suggesting protein quality control mechanisms supporting rapid cellular expansion.

Late Proliferative Phase (Days 9-14): Immune Modulation and Functional Transition

The late proliferative phase is distinguished by a transcriptional shift toward immune regulation and preparation for the impending secretory phase, with particular emphasis on natural killer (NK) cell function modulation [5].

Transcriptomic profiling identifies increased expression of angiotensin II receptor, type 2, alongside a pronounced decrease in genes associated with NK cell function [5]. This coordinated dampening of cytotoxic immune activity may represent a preparatory step for potential embryo implantation. Additionally, comprehensive transcriptome analysis reveals significant upregulation of 804 genes during this period, exceeding the number of downregulated genes (391), indicating active preparation for phase transition rather than simple proliferation cessation [6].

Table 2: Phase-Specific Biological Processes and Representative Markers

Proliferative Subphase	Dominant Biological Processes	Key Gene Expression Markers
Early (Days 1-3)	Tissue remodeling, angiogenesis, inflammation modulation	TGFB2, MT2A, F2RL2, CCL18
Mid (Days 5-8)	Structured proliferation, receptivity pathway initiation	IHH, SFRP4, PGR, HSP genes
Late (Days 9-14)	Immune modulation, functional transition	AGTR2, NK cell function genes ↓

Methodological Approaches for Transcriptomic Analysis

Microarray Analysis Protocol

Microarray analysis provides a robust methodology for identifying phase-specific gene expression signatures across proliferative phase substages [5].

Sample Collection and Preparation:

• Endometrial biopsies are obtained using a Pipelle catheter during surgically indicated procedures
• Samples are divided according to menstrual cycle timing: early proliferative (days 1-3), mid-proliferative (days 5-8), and late proliferative (days 11-13)
• Total RNA is isolated using Trizol reagent followed by purification with RNAeasy Kit
• RNA quality assessment includes gel electrophoresis, spectrophotometry (A260/A280 >1.8), and Agilent Bioanalyzer analysis (RIN >7.0)

Microarray Processing:

• Purified RNA is analyzed using Affymetrix GeneChip Human Gene 1.0 ST Array probing 28,869 genes
• Data normalization is performed using Robust Multichip Average (RMA) method
• Statistical analysis identifies genes with significant differential expression (P < .05, fold change ≥2) between phase groups
• Pathway analysis is conducted using MetaCore software

Single-Cell RNA Sequencing Approaches

Single-cell RNA sequencing (scRNA-seq) enables high-resolution characterization of cellular heterogeneity and transcriptional dynamics within the endometrium [7] [8].

Sample Processing and Sequencing:

• Endometrial tissues are collected across menstrual cycle phases and enzymatically dispersed into single-cell suspensions
• Single cells are captured using 10X Chromium system
• Library preparation follows standard protocols with sequencing on Illumina platforms

Data Analysis Pipeline:

• Quality control filters remove low-quality cells (gene count <500, mitochondrial gene percentage >20%)
• Cell clustering and population identification performed using Seurat package
• Dimensionality reduction via UMAP reveals distinct cell subtypes
• Differential expression analysis identifies cell-type specific markers
• RNA velocity analysis predicts cellular trajectory and differentiation potential

Spatial Transcriptomics Integration

Spatial transcriptomics provides contextual information by mapping gene expression within tissue architecture [9].

Spatial Transcriptomics Workflow:

• Fresh frozen endometrial tissues are sectioned and placed on 10x Visium Spatial slides
• Tissue permeabilization releases mRNA for capture by barcoded spots
• Library construction and sequencing on Illumina NovaSeq 6000
• Alignment with Space Ranger and analysis with Seurat
• Integration with scRNA-seq data using CARD deconvolution determines cellular composition within spatial spots

Figure 1: Experimental Workflow for Endometrial Transcriptomic Analysis

Signaling Pathways and Regulatory Networks

Phase-Specific Pathway Activation

Distinct signaling pathways are sequentially activated throughout proliferative phase substages, coordinating the transition from regeneration to receptivity preparation [5].

The early proliferative phase is characterized by TGF-β signaling activation, which directs tissue remodeling and extracellular matrix reorganization. During the mid-proliferative phase, Wnt and hedgehog signaling pathways become prominent, with Indian hedgehog (IHH) playing a particularly crucial role in initiating molecular programs related to endometrial receptivity [5]. The late proliferative phase demonstrates upregulation of angiotensin signaling pathways alongside modulation of immune-related pathways, particularly those regulating natural killer cell function.

Chromosomal Coordination of Gene Expression

Recent transcriptomic analyses reveal non-random chromosomal distribution of co-expressed genes, suggesting coordinated regulatory mechanisms [6]. Genes within the HIST cluster on chromosome 6 demonstrate synchronized activity, showing increased expression during the late proliferative phase and subsequent decline during the mid-secretory phase [6]. This pattern indicates potential chromatin-level regulation of endometrial gene expression across the menstrual cycle.

Figure 2: Signaling Pathway Activation Across Proliferative Subphases

Table 3: Research Reagent Solutions for Endometrial Transcriptomic Studies

Category	Specific Product/Platform	Application	Key Features
RNA Isolation	Trizol Reagent (Invitrogen)	Total RNA extraction from endometrial tissues	Maintains RNA integrity, effective for fibrous tissues
RNA Purification	RNeasy Kit (Qiagen)	RNA purification after extraction	Removes contaminants, improves sample quality
Microarray	Affymetrix GeneChip Human Gene 1.0 ST Array	Genome-wide expression profiling	Probes 28,869 genes, high reproducibility
Single-Cell Platform	10X Chromium System	Single-cell RNA sequencing	High-throughput cell capture, barcoding
Spatial Transcriptomics	10x Visium Spatial Platform	Spatial gene expression mapping	Tissue context preservation, integration with histology
Bioinformatics	Partek Genomic Suite	Microarray data analysis	RMA normalization, statistical analysis
Bioinformatics	Seurat R Package	Single-cell data analysis	Dimensionality reduction, clustering, visualization
Bioinformatics	MetaCore Software	Pathway analysis	Functional annotation, network visualization
Validation	iScript cDNA Synthesis Kit (Bio-Rad)	Reverse transcription for qPCR	High efficiency, suitable for low-abundance targets
Validation	iQ SYBR Green Supermix (Bio-Rad)	Quantitative real-time PCR	Sensitive detection, melting curve analysis

Clinical Implications and Therapeutic Perspectives

Understanding phase-specific gene expression signatures has profound implications for diagnosing and treating endometrial disorders and optimizing assisted reproductive outcomes.

Disordered Proliferative Endometrium

Disordered proliferative endometrium represents aberrant endometrial growth patterns characterized by irregular glandular distribution and architectural complexity without cytological atypia [10] [11]. This condition frequently manifests with clinical symptoms including irregular menstrual bleeding, menorrhagia, and intermenstrual spotting [11]. Underlying causes typically involve unopposed estrogen stimulation, which may occur in anovulatory cycles, polycystic ovary syndrome, or obesity [10].

Transcriptomic analyses of disordered proliferative endometrium reveal disruption of the precisely timed gene expression patterns observed in normal endometrium, particularly affecting TGF-β signaling and immune modulation pathways [5]. These molecular aberrations may contribute to the impaired endometrial receptivity observed in some infertility cases.

Implications for Recurrent Implantation Failure

Recurrent implantation failure (RIF) represents a significant challenge in reproductive medicine, with endometrial factors contributing substantially to pathogenesis [8] [9]. Single-cell transcriptomic studies of RIF endometria have identified dysregulated gene expression in epithelial, stromal, and immune cell populations during the window of implantation [8]. Notably, some RIF cases demonstrate transcriptional signatures resembling disordered proliferative phase patterns, including decreased expression of proliferation-associated genes during the mid-secretory phase [8].

Spatial transcriptomics of RIF endometrium has identified distinct cellular niches with altered gene expression profiles, particularly in unciliated epithelial cells which dominate the endometrial cellular landscape [9]. These findings suggest that abnormalities originating during the proliferative phase may propagate through the menstrual cycle, ultimately compromising endometrial receptivity.

Future Research Directions

The emerging understanding of phase-specific gene expression signatures opens several promising research avenues with potential clinical applications.

Future studies should prioritize longitudinal sampling designs to capture complete transcriptional trajectories across the entire menstrual cycle in individual patients. Integration of multi-omics approaches, including epigenomic and proteomic analyses, will provide deeper mechanistic insights into the regulation of phase-specific gene expression [6]. Additionally, developing organoid and microfluidic culture systems that recapitulate phase-specific endometrial environments will enable functional validation of identified gene signatures and screening of therapeutic compounds.

From a clinical perspective, translating these molecular findings into diagnostic tools requires identifying minimal gene panels that reliably distinguish proliferative phase substages and detect pathological deviations. Such panels could enhance endometrial dating precision and identify molecular aberrations contributing to infertility long before histological changes become apparent.

The transcriptional landscape of the proliferative phase endometrium extends far beyond simple estrogen-mediated proliferation, comprising instead a sophisticated temporal sequence of gene expression signatures that coordinate tissue regeneration, structured growth, and receptivity preparation. The identification of distinct early, mid, and late proliferative phase gene expression patterns challenges the traditional view of this phase as a homogeneous period of endometrial growth, revealing instead a complex developmental trajectory with critical implications for endometrial function and reproductive success.

These phase-specific transcriptional programs provide a new framework for understanding endometrial pathologies and developing targeted therapeutic interventions. As single-cell and spatial transcriptomic technologies continue to evolve, they will undoubtedly uncover additional layers of complexity in endometrial biology, ultimately advancing both fundamental knowledge and clinical practice in reproductive medicine.

The endometrium, the inner lining of the uterus, is a uniquely dynamic tissue that undergoes cyclical phases of breakdown, regeneration, and differentiation in response to ovarian hormones. The proliferative phase, primarily driven by estrogen, is characterized by rapid tissue growth and rebuilding. Recent transcriptomic analyses reveal that this phase is not merely a period of simple growth but involves complex, coordinated gene expression programs that are fundamental for subsequent endometrial function and receptivity [6]. A comprehensive view of the transcriptional landscape shows significant and dynamic changes, particularly during the late proliferative (peri-ovulatory) phase, which serves as an essential transition point to the secretory phase [6]. Within this transforming tissue, immune cells, particularly uterine Dendritic Cells (uDCs), are integral players, orchestrating immune tolerance and tissue remodeling.

This technical guide synthesizes recent advancements in characterizing uDC subsets and their developmental trajectories, with a specific emphasis on insights gained from transcriptomic and single-cell analyses. It provides a foundational reference for researchers aiming to understand the role of uDCs in female reproductive health and disease, from embryo implantation to endometrial cancer.

The Transcriptional Framework of the Proliferative Phase

A proliferative phase-centered transcriptome analysis across the menstrual cycle highlights the profound molecular shifts that occur. One study identified 5,082 differentially expressed genes (DEGs) when comparing the mid-proliferative phase to later stages [6].

• Phase-Specific Signatures: The late proliferative (LP) and mid-secretory (MS) phases exhibit the highest numbers of unique DEGs. The LP phase is marked by a predominance of upregulated genes (804 upregulated vs. 391 downregulated), indicating a state of active transcriptional activation [6].
• Coordinated Biological Functions: The DEGs specific to the LP phase are enriched in pathways related to cell proliferation, metabolism, and immune activation, setting the stage for the forthcoming window of implantation.
• Hormonal Regulation: The estrogen receptor alpha (ESR1) is the dominant mediator of estrogen signaling in the endometrium. CRISPR-mediated activation of ESR1 in endometrial stromal cells restores estrogen responsiveness and reveals widespread transcriptomic changes regulating inflammation, proliferation, and cancer-related pathways, with 72% of these changes overlapping with genes active in the proliferative-phase endometrium in vivo [12].

Table 1: Key Transcriptomic Changes During the Late Proliferative Phase

Feature	Observation in Late Proliferative Phase	Functional Implication
Differentially Expressed Genes (DEGs)	804 upregulated, 391 downregulated [6]	High transcriptional activity preparing the tissue for ovulation and potential implantation.
Example Upregulated Genes	STEAP4, SCGB1D2, PLA2G4F [6]	Involvement in metal ion reduction, secretoglobin function, and lipid signaling.
Chromatin Architecture	ESR1 binding at distal regulatory elements linked to gene promoters via chromatin looping [12]	Estrogen-driven regulation of key genes involved in decidualization (e.g., FOXO1).
Biological Theme	Upregulation of proliferation, metabolic, and immune-regulatory pathways [12] [6]	Creates a tissue environment conducive to growth and early immune preparation.

Uterine Dendritic Cell (uDC) Subsets: A Comprehensive Classification

uDCs are specialized antigen-presenting cells that bridge innate and adaptive immunity. Recent single-cell RNA sequencing (scRNA-seq) and protein expression studies have unveiled a previously unappreciated heterogeneity within the uDC population.

Major uDC Subsets and Their Markers

Research has identified at least seven distinct uDC subtypes in the human endometrium [13]. These can be broadly categorized into the following main groups, consistent with DC biology in other tissues [14]:

• Conventional DCs (cDC1): Characterized by high expression of XCR1 and CLEC9A. In the uterus, CD103 is a key marker for a subset of cDC1s [15]. Their primary function is cross-presentation of antigens to CD8+ T cells and promoting T-helper 1 (Th1) immunity [14].
• Conventional DCs (cDC2): Traditionally identified by the expression of SIRPα (CD172a). Uterine studies show that CD103 can also be expressed on a population of XCR1– cDC2s [15]. This subset is specialized in presenting antigens to CD4+ T cells [14].
• Plasmacytoid DCs (pDCs): Identified by markers like CD123 and BDCA-2. They are key producers of type I interferons in response to viral infections [15] [14].
• Monocyte-Derived DCs (moDCs): Arise from monocytes during inflammatory conditions and express markers like CD14 and CD172a [14].
• Progenitor/Tolerogenic DCs: A recently identified tissue-resident progenitor DC population is believed to give rise to implantation-relevant DCs [13]. These cells are critical for establishing immune tolerance.

Dynamic Phenotypic Changes Across the Cycle and Pregnancy

uDCs are not static; their abundance and maturation status change dramatically in response to hormonal cues and seminal fluid.

• Maturation States: Following coitus in mouse models, there is a rapid increase in mature uDCs (CD11c+CD103–MHC-IIhighCD86high) on day 0.5 post-coitus. Just before implantation (day 3.5 pc), there is a distinct shift towards an increase in immature uDCs (CD11c+CD103+MHC-IIdimCD86dim) [15].
• Impact of Insemination: The post-coital mature DC wave occurs in both allogeneic and syngeneic mating, suggesting it is triggered by sexual intercourse or semen itself. In contrast, the pre-implantation rise in immature DCs was observed only in allogeneic mating, pointing to a role for paternal allo-antigens [15].
• Migration and Turnover: Studies using photoconvertible proteins in mice reveal that before implantation, uDCs are primarily composed of migratory DCs that have recently entered the uterus from the periphery, rather than cells that have resided in the tissue [15].

Table 2: Phenotypic and Functional Characteristics of Uterine DC Subsets

DC Subset	Key Identifying Markers	Primary Functional Role	Contextual Dynamics
cDC1	XCR1+, CLEC9A+, CD103+ (subset) [15] [14]	Cross-presentation to CD8+ T cells; Th1 immunity [14]	Increased immature CD103+ cDC1s before implantation [15].
cDC2	SIRPα+, CD11c+, CD103+ (subset) [15] [14]	Antigen presentation to CD4+ T cells [14]	Presence of CD103 on a subset of uterine cDC2s [15].
pDC	CD123+, BDCA-2+ [14]	Type I interferon production; antiviral defense [15] [14]	Minor population in uterus; numbers begin to increase post-coitus [15].
Progenitor DC	(Identified via scRNA-seq) [13]	Origin for implantation-relevant DCs; immune tolerance [13]	Tissue-resident population giving rise to other subtypes.
Mature DC	MHC-IIhigh, CD86high [15]	Immunogenic antigen presentation; immune activation	Surge after coitus, likely for clearing semen debris [15].
Immature DC	MHC-IIdim, CD86dim [15]	Tolerogenic antigen presentation; immune regulation	Increase prior to implantation; express immunoregulatory PD-L2 [15].

Experimental Protocols for uDC Research

Integrative Single-Cell Omics for uDC Mapping

Objective: To comprehensively identify uDC subtypes, their developmental trajectories, and functional roles across menstrual cycles and early pregnancy [13].

Detailed Methodology:

• Sample Collection: Uterine tissues are collected from human donors across different menstrual phases (proliferative, secretory) and during early pregnancy.
• Single-Cell Suspension: Tissues are dissociated into single-cell suspensions using enzymatic digestion (e.g., collagenase, DNAse).
• Single-Cell RNA Sequencing (scRNA-seq): Cells are loaded onto a microfluidic platform (e.g., 10x Genomics) to capture transcriptomes of thousands of individual cells. This allows for the identification of distinct cell clusters, including uDC subtypes, based on their unique gene expression profiles.
• Cellular Indexing of Transcriptomes and Epitopes (CITE-seq): In parallel, single-cell suspensions are stained with oligonucleotide-conjugated antibodies against surface proteins (e.g., CD11c, CD123, CD141, HLA-DR). Cells are then co-processed through the scRNA-seq workflow, enabling simultaneous measurement of surface protein expression and transcriptome in the same single cell. This links key genes identified by RNA-seq to definitive protein markers.
• Bioinformatic Analysis:
  • Cluster Identification: Unsupervised clustering algorithms (e.g., Seurat, Scanpy) are applied to group cells with similar expression patterns. uDC subsets are annotated based on canonical gene and protein markers.
  • Trajectory Inference: Computational tools (e.g., Monocle, PAGA) are used to reconstruct developmental lineages from progenitor DCs to mature subtypes.
  • Functional Annotation: Differential expression analysis and gene set enrichment analysis (GSEA) reveal the potential functional specializations of each uDC subset (e.g., antigen presentation, immune regulation).

In Vivo Dynamics and Migration Studies

Objective: To characterize the spatiotemporal dynamics, turnover, and migration of uDCs during the implantation period [15].

Detailed Methodology:

• Animal Models: Virgin and time-mated mice (allogeneic and syngeneic) are used.
• Flow Cytometry Analysis:
  • Tissue Processing: Uteri and uterine-draining lymph nodes are harvested at specific time points (e.g., days 0.5, 1.5, 2.5, 3.5 post-coitus), digested into single-cell suspensions, and stained with a panel of fluorescent antibodies.
  • Cell Staining and Gating: Cells are stained for lineage exclusion (CD3, CD19, Gr-1, etc.) and inclusion of DC markers (CD11c, MHC class II, CD103, CD86, PD-L2, XCR1). This allows for the quantification of absolute numbers and proportions of uDC subsets and their maturation status.
• In Vivo Migration Tracking using KikGR Mice:
  • Photoconversion: Transgenic mice expressing the photoconvertible protein Kikume Green-Red (KikGR) are used. Under violet light (405 nm), KikGR fluoresces green. Exposure to specific wavelengths converts the protein to emit red fluorescence.
  • Experimental Procedure: The uterus of a pregnant KikGR mouse is exposed and subjected to violet light at a specific time point (e.g., day 2.5 pc), photoconverting all cells within the tissue from green to red.
  • Tracking Migration: At a later time point (e.g., day 3.5 pc), cells in the uterus and draining lymph nodes are analyzed by flow cytometry. Cells that remain red were present in the uterus at the time of photoconversion ("remaining DCs"). Cells that are green have entered the uterus from the circulation after photoconversion ("migratory DCs"). This allows for precise quantification of DC turnover and migration.

Visualizing uDC Biology: Pathways and Workflows

uDC Subset Identification and Developmental Trajectory

This diagram illustrates the integrated omics approach to classifying uDCs and the proposed developmental pathway from a resident progenitor.

In Vivo Dynamics of uDCs from Coitus to Implantation

This workflow summarizes the key findings from in vivo studies on the dynamic changes in uDC populations during early pregnancy.

The Scientist's Toolkit: Key Research Reagents and Models

Table 3: Essential Research Reagents for uDC and Endometrial Stroma Research

Reagent / Model	Specification / Example	Primary Function in Research
Antibodies for Flow Cytometry	Anti-CD11c, MHC-II, CD103, CD86, XCR1, SIRPα, CD123, PD-L2 [15]	Identification, quantification, and phenotypic characterization of uDC subsets from tissue digests.
Single-Cell Omics Platforms	10x Genomics Chromium System [13]	Partitioning single cells for parallel RNA and protein (CITE-seq) sequencing to define cellular heterogeneity.
Oligonucleotide-Conjugated Antibodies	TotalSeq Antibodies for CITE-seq [13]	Simultaneous measurement of surface protein abundance and transcriptome in single cells.
CRISPR Activation System	dCas9-VPR with ESR1-targeting gRNA (e.g., ESR1-3) [12]	Engineered overexpression of ESR1 in stromal cells to restore estrogen responsiveness for functional studies.
Immortalized Stromal Cell Line	Telomerase-immortalized hESCs (THESCs) [12]	Provides a scalable and consistent in vitro model for studying human endometrial stromal cell biology.
Photoconvertible Mouse Model	Kikume Green-Red (KikGR) transgenic mice [15]	In vivo tracking of cell migration and turnover by photoconverting proteins in specific tissues at set times.
Hormone Treatments	17β-estradiol (E2), Medroxyprogesterone Acetate (MPA), cAMP [12]	Mimicking physiological conditions in vitro (e.g., decidualization cocktail) or in vivo.

Clinical and Translational Perspectives

Understanding uDC biology has direct implications for reproductive health and disease. The cellular roadmap provided by uDC subsets serves as a reference for understanding conditions like infertility and pregnancy complications [13]. Furthermore, the tumor immune microenvironment (TIME), which includes DCs, is a critical determinant of progression and therapeutic response in endometrial cancer (EC) [16].

Notably, significant racial disparities exist in EC outcomes, with African American (AA) women experiencing higher mortality. Recent computational image and bioinformatic analyses reveal that the immune architecture within EC tumors differs between AA and European American (EA) populations. Population-specific prognostic models based on tumor-infiltrating lymphocyte (TIL) patterns were more accurate than population-agnostic models, suggesting that the underlying tumor biology and immune interactions may be distinct [17]. This highlights the need for tailored immunotherapeutic strategies and a deeper investigation into how uDC and other immune cell functions may vary in pathological contexts.

The human endometrium exhibits a remarkable capacity for cyclical regeneration, undergoing approximately 400-500 cycles of proliferation, differentiation, shedding, and scarless repair throughout a woman's reproductive lifespan [18]. This extraordinary regenerative capability is driven by fluctuating levels of estrogen and progesterone, which regulate structural remodeling across menstrual, proliferative, and secretory phases [18]. Within the broader context of transcriptional landscape research on proliferative phase endometrium, a key focus has been the identification and characterization of tissue-resident stem/progenitor cells that orchestrate endometrial repair and regeneration.

Accumulating evidence underscores the pivotal role of endometrial stem/progenitor cells (ESCs) located primarily within the basalis layer in driving endometrial repair and regeneration [18]. These cells possess self-renewal and multipotent differentiation capabilities, sustaining epithelial and stromal homeostasis after menstruation, delivery, or injury [18]. Among the various progenitor populations identified, stage-specific embryonic antigen-1 positive (SSEA-1+) endometrial epithelial cells have emerged as a crucial component of the postulated stem/progenitor cell niche within the human endometrium [19]. Their unique transcriptional profile and functional characteristics position them as key regulators of endometrial regeneration, remodeling, and homeostasis, offering new insights into the molecular mechanisms underlying the proliferative phase of the menstrual cycle.

SSEA-1+ Epithelial Progenitor Cells: Identification and Characterization

Discovery and Marker Profile

SSEA-1+ endometrial epithelial cells assume a critical position within the stem/progenitor cell niche of the human endometrium [19]. These cells were identified following the initial discovery of rare clonogenic cells within the human endometrial epithelium, comprising approximately 0.22% of the EpCAM+ epithelial cell population [20]. The SSEA-1 antigen (also known as CD15 or Lewis X) is a carbohydrate glycosphingolipid typically associated with embryonic stem cells and various tissue-specific progenitor populations.

Research has revealed that SSEA-1 co-localizes with other putative progenitor markers in a hierarchical organization within the endometrial glands [20]. A proposed epithelial hierarchy exists based on the location of marker-positive cells within the glandular architecture. N-cadherin+ SSEA-1+ nuclear SOX9+ epithelial cells are found in the deepest bases of the branching glands in the basalis, adjacent to the myometrium [20]. These appear to give rise to N-cadherin+ SSEA-1- cells and N-cadherin- SSEA-1+ nuclear SOX9+ cells located more proximally toward the functionalis-basalis junction. The majority of the functionalis comprises epithelial cells negative for all three markers, though the luminal epithelium itself is SSEA-1+ and nuclear SOX9+, suggesting their role in rapid re-epithelialization during endometrial repair [20].

The ALDH1A1 isoform of aldehyde dehydrogenase co-localizes with 78% of N-cadherin+ epithelial cells, suggesting a role for retinoic acid signaling in the progenitor function of these basal epithelial cells [20]. This complex marker expression pattern reflects a sophisticated differentiation hierarchy within the endometrial epithelium that facilitates both routine regeneration and rapid repair following menstruation.

Location and Hierarchy Within the Endometrial Epithelium

SSEA-1+ epithelial progenitor cells are predominantly located in the basalis layer of the endometrium, which remains intact during menstruation and serves as the reservoir for regenerating the functionalis layer each cycle [20]. The basalis epithelial cells are relatively quiescent, proliferating only occasionally, while the functionalis glandular epithelium acts as the rapidly proliferating transit amplifying population in endometrial regeneration [20].

Spatial transcriptomics studies have revealed that SOX9-expressing epithelial cells with a cell-cycling profile are widely distributed in proliferative-stage endometrium, though the SOX9-expressing basalis epithelial cells maintain a non-cycling gene expression profile indicating their quiescence [20]. This distribution pattern suggests that nSOX9+ SSEA-1+ epithelial cells may extend further into the functionalis than initially observed and function as transit amplifying cells that contribute to the rapidly expanding glandular epithelium during endometrial regeneration.

Table 1: Marker Expression in the Proposed Endometrial Epithelial Hierarchy

Location in Gland	N-cadherin	SSEA-1	Nuclear SOX9	Presumed Function
Base (deep basalis)	+	+	+	Putative stem cell
Lower gland	+	-	Variable	Early progenitor
Mid gland	-	+	+	Transit amplifying cell
Upper gland/functionalis	-	-	-	Differentiated cell
Luminal epithelium	-	+	+	Repair/regeneration

Transcriptional Profiling and Functional Attributes

Key Transcriptomic Features

Recent transcriptional profiling of isolated SSEA-1+ endometrial epithelial cells (EECs) from eight endometrial biopsies compared to SSEA-1- EECs has revealed distinct molecular characteristics that underpin their progenitor properties [19]. Transcriptome and pathway analyses indicate that SSEA-1+ EECs play important roles in endometrial regeneration, remodeling, and neovascularization, consistent with their function as a basal progenitor population [19].

SSEA-1+ cells exhibit a unique transcriptional profile characterized by lower expression of steroid hormone receptors and higher telomerase activity with longer telomere lengths compared to SSEA-1- cells [19]. This molecular signature supports their capacity for sustained self-renewal and proliferation. Bioinformatic analyses have identified potential upstream regulators such as SPDEF and TGFB1 that may be involved in the mechanisms governing SSEA-1+ cell function in endometrial tissue homeostasis and tumor suppression [19].

The transcriptomic data further suggest a more quiescent, less hormone-responsive phenotype for a subpopulation of SSEA-1+ EECs that co-localize to SOX9+ EECs, validating previous studies on the hierarchical organization of the endometrial epithelium [19]. This quiescent characteristic is typical of many adult stem cell populations that must maintain their replicative potential over long periods.

Functional Characteristics in Regeneration

Functionally, isolated SSEA-1+ cells demonstrate a higher capacity to generate organoids in three-dimensional matrices compared to their SSEA-1- counterparts [19]. This enhanced organoid-forming efficiency represents a key functional assay for stem/progenitor cell activity and demonstrates the robust regenerative potential of this population.

In vitro EEC organoid models demonstrate that SSEA-1+ EECs exhibit estrogen-responsive proliferation, evidenced by stronger immunostaining for progesterone receptor and Ki-67 following estrogen stimulation [19]. This controlled responsiveness to hormonal cues enables these progenitor cells to coordinate their regenerative activity with the cyclical hormonal changes that characterize the menstrual cycle.

Table 2: Functional Characteristics of SSEA-1+ Versus SSEA-1- Endometrial Epithelial Cells

Functional Attribute	SSEA-1+ EECs	SSEA-1- EECs	Experimental Evidence
Organoid formation capacity	High	Low	3D culture assays [19]
Telomerase activity	Higher	Lower	Telomeric repeat amplification protocol [19]
Telomere length	Longer	Shorter	Quantitative FISH [19]
Steroid hormone receptor expression	Lower	Higher	Immunostaining [19]
Estrogen-responsive proliferation	Present	Reduced	Ki-67 staining in organoids [19]
In vivo regenerative potential	High	Limited	Transplantation models [20]

Experimental Models and Methodologies

Isolation and Culture Protocols

The isolation of SSEA-1+ endometrial epithelial cells for transcriptional profiling and functional analysis typically follows a standardized protocol. Endometrial biopsies are first collected under appropriate ethical approval and patient consent, then processed through mechanical dissection and enzymatic digestion using collagenase and DNase to create single-cell suspensions [19] [20].

SSEA-1+ cells are isolated using fluorescence-activated cell sorting (FACS) or magnetic-activated cell sorting (MACS) with anti-SSEA-1 antibodies. The sorted populations are then cultured in specialized media optimized for epithelial progenitor growth, typically containing factors such as FGF, EGF, and Wnt agonists that support stem/progenitor maintenance [20]. For 3D organoid culture, the isolated cells are embedded in Matrigel or similar extracellular matrix substitutes and cultured in media containing Noggin, R-spondin, and other niche factors that promote organoid formation and expansion [19].

Lineage Tracing and Fate Mapping

Genetic lineage tracing represents a powerful approach for investigating the fate and plasticity of endometrial progenitor populations in vivo. While direct lineage tracing of human SSEA-1+ cells is not feasible, mouse models utilizing analogous marker genes have provided valuable insights. One such approach uses Nestin-CreER mice crossed with Rosa-Tomato reporter mice to permanently label Nestin+ perivascular cells and their progeny [21].

In these experiments, tamoxifen administration induces CreER activity, leading to Tomato expression in Nestin+ cells and all their descendants. Tissue collection at various time points post-induction allows tracking of the contribution of these labeled cells to endometrial regeneration [21]. This methodology has demonstrated that Nestin+ perivascular cells can undergo mesenchymal-to-epithelial transition and contribute to re-epithelialization during endometrial repair [21].

Diagram 1: SSEA-1+ Cell Isolation Workflow. This flowchart outlines the key steps in isolating and characterizing SSEA-1+ endometrial epithelial progenitor cells from tissue biopsy to functional analysis.

Signaling Pathways Regulating SSEA-1+ Cell Function

Hormonal Regulation

The function of SSEA-1+ epithelial progenitor cells is intricately regulated by ovarian steroid hormones throughout the menstrual cycle. During the proliferative phase, rising estrogen levels drive robust tissue regeneration, including polarized expansion of glandular epithelium with lumen formation, stromal thickening, and coordinated angiogenesis [18]. Estrogen stimulates the proliferation of SSEA-1+ cells through estrogen receptor alpha (ESR1)-mediated mechanisms [21].

Notch signaling plays a crucial role in maintaining Nestin+ perivascular cells (which may include a stromal progenitor population that interacts with epithelial progenitors) in a quiescent state [21]. Estrogen-stimulated suppression of Notch signaling, dependent on ESR1, allows these cells to re-enter the cell cycle and differentiate, demonstrating cross-talk between hormonal signaling and developmental pathways in regulating endometrial progenitor activity [21].

Developmental Signaling Pathways

Multiple evolutionarily conserved developmental signaling pathways work in concert to regulate SSEA-1+ progenitor cell behavior. Bioinformatic analyses of SSEA-1+ cell transcriptomes have identified potential upstream regulators such as SPDEF and TGFB1 that may be involved in the mechanisms governing their function in endometrial tissue homeostasis and tumor suppression [19].

Wnt/β-catenin signaling represents another critical pathway in endometrial stem/progenitor cell regulation. AXIN2, a marker of endometrial epithelial progenitors and a negative regulator of Wnt signaling, is expressed in a population of basal epithelial cells that overlaps partially with SSEA-1+ cells [20]. Wnt signaling activity appears to be essential for maintaining the progenitor state, while its modulation facilitates differentiation along the epithelial lineage.

Diagram 2: Signaling Pathways in SSEA-1+ Cell Regulation. This diagram illustrates the key signaling pathways that regulate SSEA-1+ epithelial progenitor cell behavior, including hormonal inputs, developmental signaling cascades, and functional outcomes.

The Scientist's Toolkit: Essential Research Reagents and Methodologies

Table 3: Essential Research Reagents for Studying SSEA-1+ Endometrial Epithelial Progenitor Cells

Reagent/Material	Specific Example	Application/Function	Experimental Context
SSEA-1 Antibody	Anti-SSEA-1 (CD15) monoclonal antibody	Identification and isolation of SSEA-1+ epithelial progenitors	FACS, MACS, immunohistochemistry [19]
Epithelial Marker	Anti-EpCAM antibody	General epithelial cell identification	Pre-enrichment for epithelial cells [20]
Basalis Markers	Anti-N-cadherin, anti-AXIN2, anti-SOX9	Identification of basal progenitor niche	Co-localization studies with SSEA-1 [20]
3D Culture Matrix	Matrigel, collagen gels	Support 3D organoid formation and growth	Organoid culture assays [19]
Cytokines/Growth Factors	FGF, EGF, R-spondin, Noggin	Maintenance of progenitor state in culture	Organoid media formulation [19]
Lineage Tracing System	Nestin-CreER; Rosa-Tomato mice	Fate mapping of perivascular progenitors	In vivo lineage tracing [21]
Hormonal Regulators	17β-estradiol, progesterone	Simulation of menstrual cycle phases	Hormonal response assays [19]

Pathological Implications and Therapeutic Potential

Role in Endometrial Disorders

Dysregulation of SSEA-1+ endometrial epithelial progenitor cells is increasingly implicated in various gynecological pathologies. In endometriosis, aberrant stem/progenitor activity in ectopic lesions disrupts cyclic regeneration, leading to glandular disorganization, stromal fibrosis, and chronic inflammation [18]. SSEA-1+ epithelial cells have been identified in endometriotic lesions, where they may contribute to the persistence and growth of ectopic endometrial tissue [20].

Similarly, disturbances in the function of endometrial progenitor populations are linked to Asherman's syndrome (intrauterine adhesions), where impaired regeneration leads to scar tissue formation instead of functional endometrium [20]. In endometrial carcinoma, Axin2+ epithelial stem cells (which partially overlap with SSEA-1+ cells) can initiate tumorigenesis when mutations accumulate in pathways such as Wnt/β-catenin, PTEN/PI3K-AKT, or p53 [18]. Single-cell profiling has revealed stem-like subpopulations with heightened plasticity capable of engaging in epithelial-mesenchymal transition (EMT) cycles that promote invasive behavior and therapeutic resistance [18].

Therapeutic Applications and Future Directions

The regenerative capacity of SSEA-1+ epithelial progenitor cells holds significant promise for developing novel therapeutic approaches to endometrial disorders. Organoid technology derived from these progenitors provides unprecedented opportunities for modeling endometrial physiology and disease states, drug screening, and potentially regenerative medicine applications [18].

Advanced 3D in vitro platforms, including organoids, assembloids, and microfluidic "organ-on-chip" systems, now enable recapitulation of the endometrium's architecture, multicellular interactions, and hormone responsiveness [18]. When coupled with single-cell transcriptomics and lineage-tracing models, these systems allow high-resolution interrogation of regeneration, implantation, and disease pathogenesis, potentially leading to precision regenerative therapies for conditions such as infertility, endometriosis, and endometrial atrophy.

Understanding the molecular mechanisms that govern SSEA-1+ cell function may also inform new strategies for targeting these populations in pathological contexts. For instance, modulating the signaling pathways that control their proliferation and differentiation could provide approaches to managing endometriosis or preventing malignant transformation in high-risk individuals.

The human endometrium undergoes precisely orchestrated molecular and cellular changes to transition from a proliferative state to a receptive environment capable of supporting embryo implantation. This transition, central to the broader thesis of proliferative phase endometrial research, involves complex transcriptomic reprogramming that directs functional pathway enrichment in tissue remodeling and immune regulation. Recent technological advances in transcriptomic profiling have enabled researchers to decode these molecular signatures with unprecedented resolution, moving beyond traditional histological assessments to uncover the fundamental pathways that govern endometrial receptivity. The identification of these functional pathways provides not only crucial insights into the mechanisms of successful implantation but also reveals potential therapeutic targets for addressing endometrial-factor infertility, recurrent implantation failure (RIF), and other reproductive disorders that affect millions worldwide.

Within the context of proliferative phase research, understanding the preparatory events that occur during this window is essential, as transcriptomic aberrations in the proliferative phase can profoundly impact the achievement of a receptive state in the subsequent secretory phase [6]. This technical guide synthesizes current findings from transcriptomic studies to elucidate how enriched biological pathways contribute to tissue remodeling and the establishment of endometrial receptivity, providing researchers and drug development professionals with a comprehensive framework for experimental design and data interpretation in this rapidly advancing field.

Core Pathways and Functional Enrichment in Receptivity

Transcriptomic analyses across multiple studies have consistently identified key biological pathways that become enriched during the acquisition of endometrial receptivity. These pathways collectively facilitate the structural and functional transformation of the endometrium from a proliferative state to a receptive state capable of supporting embryo implantation.

Table 1: Key Enriched Biological Processes in Endometrial Receptivity

Biological Process	Functional Role in Receptivity	Transcriptomic Evidence
Immune Activation & Regulation	Establishes immunotolerant environment for semi-allogeneic embryo	Adaptive immune response (GO:0002250) enrichment [22]; Cytotoxic gene activation (CORO1A, GNLY, GZMA) in thin endometrium [23]
Ion Homeostasis & Transmembrane Transport	Regulates uterine fluid microenvironment for embryo communication	Ion homeostasis (GO:0050801) and inorganic cation transmembrane transport (GO:0098662) enrichment [22]
Extracellular Matrix (ECM) Remodeling	Facilitates tissue restructuring for embryo invasion and decidualization	ECM remodeling pathway enrichment in non-receptive states [24]; Structural constituent of ribosome (GO:0003735) enrichment [22]
Angiogenesis & Vascular Remodeling	Establishes vascular support for implantation and placental development	Angiogenesis and lymphangiogenesis functional terms predominating in receptive state [25]
Cellular Proliferation & Differentiation	Drives epithelial and stromal transformation during WOI	Two-stage stromal decidualization and gradual epithelial transition [8]; Estrogen-regulated proliferation networks [12]

The integrative analysis of these pathways reveals a coordinated program where immune modulation, tissue restructuring, and cellular differentiation occur in parallel to establish receptivity. Notably, the proliferative phase, particularly the late proliferative (peri-ovulatory) period, serves as a critical transition point where initial transcriptional programming for receptivity begins [6]. Single-cell transcriptomic profiling has further refined our understanding of these processes, revealing a clear two-stage decidualization process for stromal cells and a more gradual transition for epithelial cells across the window of implantation (WOI) [8].

Transcriptomic Signatures of Receptive versus Non-Receptive Endometrium

Differential gene expression analysis between receptive and non-receptive endometrium has revealed distinct molecular signatures that correlate with functional receptivity and pregnancy success. These signatures provide valuable biomarkers for assessing endometrial status and potential therapeutic targets for receptivity disorders.

Table 2: Differential Gene Expression Signatures in Receptivity

Gene/Transcript	Expression Pattern	Functional Significance	Study Context
RPL10P9, LINC00621	Upregulated in pregnancy	Potential regulatory roles in implantation success	UF-EV transcriptome in ART cycles [22]
BMP4	Near-significant upregulation (padj=0.058)	Bone morphogenetic protein signaling in tissue remodeling	UF-EV transcriptome analysis [22]
CORO1A, GNLY, GZMA	Significantly upregulated in thin endometrium	Immune dysregulation and cytotoxic responses	Thin endometrium immune profiling [23]
STEAP4, SCGB1D2, PLA2G4F	Peak expression in mid-secretory phase	Metal ion reduction, lipid metabolism, secretory functions	Menstrual cycle phase comparison [6]
FOXO1, ERRFI1, NRIP1	ESR1-regulated expression	Decidualization and endometrial cancer pathways	ESR1-driven transcription in stromal cells [12]

The analysis of extracellular vesicles isolated from uterine fluid (UF-EVs) has emerged as a particularly promising non-invasive approach for assessing receptivity. One study analyzing UF-EVs from 82 women undergoing ART with single euploid blastocyst transfer revealed 966 differentially expressed genes between women who achieved pregnancy and those who did not, with pregnant women showing globally higher gene expression [22]. A Bayesian logistic regression model integrating gene expression modules with clinical variables achieved a predictive accuracy of 0.83 and an F1-score of 0.80 for pregnancy outcome prediction, demonstrating the clinical potential of transcriptomic signatures [22].

Beyond individual gene markers, co-expression network analysis has identified functionally relevant gene modules associated with receptivity. Weighted Gene Co-expression Network Analysis (WGCNA) of differentially expressed genes clustered them into four modules with varying correlations to pregnancy outcome, highlighting the power of systems biology approaches in deciphering the complex regulatory networks governing receptivity [22].

Experimental Design and Methodological Frameworks

Transcriptomic Profiling Approaches

The investigation of endometrial receptivity employs multiple transcriptomic profiling strategies, each with distinct advantages and applications:

• Bulk RNA-seq:

  • Protocol: Endometrial tissue samples are collected via biopsy, followed by total RNA extraction using reagents such as RNA-easy isolation reagent. Ribosomal RNA is removed to enrich for mRNA, which is then fragmented and used for strand-specific library construction. Libraries are sequenced on platforms such as BGISEQ or Illumina, with typical sequencing depth of 6Gb per sample [23].
  • Applications: Ideal for identifying differentially expressed genes between patient groups (e.g., receptive vs. non-receptive endometrium) and for pathway enrichment analysis.

• Single-cell RNA-seq:

  • Protocol: Endometrial biopsies are enzymatically dispersed into single-cell suspensions. Cells are captured using a 10X Chromium system, followed by library preparation and sequencing. Typical quality thresholds include a median of 8481 unique transcripts and 2983 genes per cell, with doublet removal and low-quality cell filtering [8].
  • Applications: Resolves cellular heterogeneity and identifies cell-type specific expression patterns during the window of implantation.

• Uterine Fluid Extracellular Vesicle (UF-EV) Transcriptomics:

  • Protocol: UF-EVs are isolated from uterine fluid samples, followed by RNA extraction and sequencing. This non-invasive approach circumvents the need for endometrial biopsy [22].
  • Applications: Provides a surrogate for endometrial tissue transcriptomics while enabling same-cycle embryo transfer in ART contexts.

Integrated Multi-Omics Approaches

Advanced studies now combine transcriptomic data with other molecular profiles to gain mechanistic insights:

• Cistrome and Chromatin Architecture Analysis: Cleavage Under Targets and Release Using Nuclease (Cut&Run) assays profile transcription factor binding sites (e.g., ESR1), while H3K27ac HiChIP maps chromatin looping interactions [12].
• Multi-omic Integration: Combining RNA-seq with chromatin accessibility data links distal regulatory elements to gene promoters, revealing transcriptional networks controlling decidualization and receptivity [12] [26].

Diagram 1: Experimental workflow for transcriptomic analysis of endometrial receptivity, showing parallel approaches that converge through integrative analysis.

Visualization of Key Signaling Pathways

The transition from proliferative to secretory endometrium involves coordinated activity across multiple signaling pathways that direct tissue remodeling and receptivity establishment. Estrogen signaling through ESR1 serves as a master regulator during the proliferative phase, priming the endometrium for subsequent progesterone-mediated differentiation.

Diagram 2: Signaling pathway from estrogen-dependent proliferation to progesterone-driven receptivity, highlighting key transcriptional networks.

Immune pathway dysregulation represents another critical axis in receptivity disorders, particularly in conditions such as thin endometrium and recurrent implantation failure. Single-cell transcriptomic studies have revealed how distinct immune cell populations contribute to either receptive or non-receptive microenvironments.

Diagram 3: Immune pathway dysregulation in thin endometrium and RIF, contrasting with normal immune tolerance in receptivity.

The Scientist's Toolkit: Essential Research Reagents and Materials

Table 3: Research Reagent Solutions for Endometrial Receptivity Studies

Reagent/Material	Specification	Research Application	Example Vendor/Source
RNA-easy Isolation Reagent	Total RNA extraction from tissue	Bulk and single-cell RNA-seq library preparation	Vazyme [23]
10X Chromium System	Single-cell partitioning and barcoding	Single-cell RNA-seq of endometrial cell suspensions	10X Genomics [8]
dCas9-VPR Lentivirus	CRISPR activation system	ESR1 overexpression in stromal cells	Dharmacon [12]
Charcoal-Stripped FBS	Hormone-depleted serum	Estradiol treatment studies in cell culture	Various suppliers [12]
17β-estradiol (E2)	10nM in culture media	Estrogen response experiments in stromal cells	Sigma-Aldrich [12]
Decidualization Cocktail	E2 + MPA + cAMP	In vitro decidualization of stromal cells	Custom formulation [12]
Estrotect Heat Detection	Estrus synchronization device	Animal model cycle synchronization	Rockway, Inc. [24]
Prostaglandin F2α Analog	500μg sodium cloprostenol	Estrous synchronization in bovine models	Ouro Fino Animal Health [24]

The integration of transcriptomic signatures with functional pathway analysis has fundamentally advanced our understanding of endometrial receptivity, moving the field beyond morphological assessment to molecular precision. The proliferative phase-centered view reveals that transcriptional programming for receptivity begins well before the window of implantation, with the late proliferative phase serving as a critical transition point that establishes the foundation for subsequent secretory differentiation [6]. The emergence of UF-EV transcriptomics as a non-invasive alternative to endometrial biopsy represents a significant clinical advance, potentially enabling receptivity assessment within the same ART cycle [22].

Future research directions will likely focus on several key areas: First, the integration of multi-omic datasets (transcriptome, epigenome, proteome) to build comprehensive regulatory networks of receptivity. Second, the application of spatial transcriptomics to preserve architectural context while capturing molecular signatures. Third, the development of refined computational models that can predict individualized receptivity status and guide personalized embryo transfer timing. Finally, the translation of transcriptomic findings into targeted therapeutic interventions for receptivity disorders, particularly for conditions like thin endometrium and RIF where current treatments remain limited.

For drug development professionals, the identified pathway enrichments offer promising targets for therapeutic intervention, particularly in the areas of immune modulation, vascular remodeling, and estrogen signaling. The research tools and methodologies outlined in this guide provide a framework for continued investigation into the complex molecular landscape of endometrial receptivity, ultimately advancing both fundamental knowledge and clinical applications in reproductive medicine.

Advanced Transcriptomic Technologies and Analytical Frameworks for Endometrial Research

Single-cell RNA sequencing (scRNA-seq) has established itself as the state-of-the-art approach for unravelling the heterogeneity and complexity of RNA transcripts within individual cells, as well as revealing the composition of different cell types and functions within highly organized tissues and organs [27]. Unlike bulk RNA sequencing, which provides population-averaged data that can obscure important biological differences, scRNA-seq detects cell subtypes or gene expression variations that would otherwise be overlooked [28]. This capability is particularly valuable for understanding complex tissues like the human endometrium during its proliferative phase—a period of dynamic remodeling and regeneration driven by hormonal influences.

The application of scRNA-seq to endometrial research has opened new avenues for investigating cellular heterogeneity, rare progenitor populations, and molecular mechanisms underlying both normal physiological processes and pathological conditions. In the context of the proliferative phase endometrium, scRNA-seq enables researchers to profile the transcriptional landscape at unprecedented resolution, identifying distinct cell types, states, and trajectories that contribute to endometrial regeneration and function [29]. This technical guide explores the core methodologies, analytical frameworks, and applications of scRNA-seq with specific emphasis on its utility for deconvoluting cellular heterogeneity and identifying rare cell populations within the proliferative phase endometrial microenvironment.

ScRNA-seq Technologies and Experimental Workflows

Core Technological Principles

The fundamental principle underlying scRNA-seq is the ability to capture and sequence the transcriptome of individual cells, allowing for the classification, characterization, and distinction of each cell at the transcriptome level [27]. Since its conceptual breakthrough in 2009, when Tang et al. first sequenced the transcriptome of a single blastomere and oocytes, scRNA-seq technologies have evolved dramatically, with significant improvements in throughput, cost reduction, and automation [27]. The technology now enables analysis of transcriptomes at single-cell resolution for over millions of cells in a single study.

Current high-throughput scRNA-seq platforms employ various strategies for single-cell capture, including microfluidic-, microwell-, droplet-based, and in situ barcoding approaches [27]. Each method involves isolating individual cells, capturing their mRNA, converting RNA to cDNA with cell-specific barcodes, amplifying the cDNA, and preparing sequencing libraries. The incorporation of unique molecular identifiers (UMIs) has been particularly important for enhancing the quantitative nature of scRNA-seq by effectively eliminating PCR amplification bias and improving reading accuracy [27].

Standardized Experimental Protocol

A typical scRNA-seq experiment involves multiple critical steps that must be carefully optimized to ensure high-quality data:

• Single-Cell Isolation and Capture: Individual cells are isolated from endometrial tissue specimens using methods such as fluorescence-activated cell sorting (FACS), magnetic-activated cell sorting, microfluidic systems, or laser microdissection [27]. For endometrial tissues, which contain multiple cell types with different physical properties, optimization of dissociation protocols is essential to minimize artificial transcriptional stress responses that can occur during tissue processing [27]. Working at 4°C during tissue dissociation has been suggested to minimize isolation procedure-induced gene expression changes.

• Cell Lysis and Reverse Transcription: Captured cells are lysed to release RNA, which is then reverse-transcribed into complementary DNA (cDNA) using reverse transcriptase enzymes. Template-switching oligonucleotides are often employed to incorporate universal adapter sequences during cDNA synthesis [27].

• cDNA Amplification: The resulting cDNA is amplified by either polymerase chain reaction (PCR) or in vitro transcription (IVT). PCR-based amplification, utilized in platforms such as Smart-seq2, 10x Genomics, and Drop-seq, provides non-linear amplification, while IVT-based methods, used in CEL-seq and MARS-Seq, offer linear amplification [27]. Both approaches can introduce amplification biases, necessitating the use of UMIs for accurate quantification.

• Library Preparation and Sequencing: Amplified cDNA is fragmented and processed into sequencing libraries with the addition of platform-specific adapters. Libraries are then sequenced using high-throughput sequencing platforms, typically generating millions of reads per cell.

The following diagram illustrates the complete scRNA-seq workflow, from sample preparation to data analysis:

Figure 1: Comprehensive scRNA-seq Workflow for Endometrial Research

Special Considerations for Endometrial Tissue

When working with proliferative phase endometrial tissues, several specific considerations apply. The endometrium undergoes cyclic remodeling, making precise timing of sample collection critical for comparative studies. Additionally, the presence of rare progenitor populations necessitates processing sufficient cells to ensure these populations are adequately represented in the final dataset [29]. For tissues that are difficult to dissociate or when working with archived frozen samples, single-nucleus RNA sequencing (snRNA-seq) provides an alternative approach that minimizes artificial transcriptional stress responses, though it primarily captures nuclear transcripts and might miss important biological processes related to mRNA processing and metabolism [27].

Analytical Frameworks for Deconvoluting Heterogeneity

Data Preprocessing and Normalization

The initial analysis of scRNA-seq data involves rigorous quality control to remove low-quality cells, typically identified by low unique gene counts, high mitochondrial read percentage, or low library size. Normalization is then performed to address technical variations in sequencing depth across cells. Traditional approaches like counts per 10,000 (CP10K) assume constant transcriptome size across all cells, but recent advancements have highlighted the importance of accounting for biological variations in transcriptome size across different cell types [30]. Methods like ReDeconv's Count based on Linearized Transcriptome Size (CLTS) incorporate transcriptome size into scRNA-seq normalization, correcting differentially expressed genes typically misidentified by standard CP10K normalization [30].

Cell Type Identification and Classification

Once normalized, scRNA-seq data undergoes dimensionality reduction (typically using principal component analysis) followed by clustering to group cells with similar expression profiles. Cell type identity is then assigned to each cluster based on the expression of known marker genes. In endometrial studies, this approach has identified diverse cell types, including epithelial cells, stromal cells, endothelial cells, immune cells, and rare progenitor populations [29] [31].

Table 1: Major Cell Types Identified in Proliferative Phase Endometrium via scRNA-seq

Cell Type	Proportion in Healthy Endometrium	Key Marker Genes	Functional Significance
Fibroblasts	Most abundant (~36.8%) [31]	COL1A1, COL1A2, DCN, LUM, PDGFRA [31]	Tissue structure, extracellular matrix production
Secretory Epithelial Cells	~22.4% [31]	PAX8, MUC1, WFDC2, GABRP, TFF3, KRT18 [31]	Gland formation, secretory function
T Cells	~11.8% [31]	CD2, CD3D, TRAC, TRBC2 [31]	Immune surveillance and regulation
Endothelial Cells	~7.7% [31]	CDH5, CLDN5, PECAM1, VWF, KDR [31]	Vasculature formation, nutrient transport
Macrophages	~3.9% [31]	LYZ, CD14, C1QC, MRC1, CD68 [31]	Immune function, tissue remodeling
Perivascular CD9+ SUSD2+ Cells	Rare population [29]	CD9, SUSD2 [29]	Putative progenitor stem cells with roles in endometrial regeneration

Detecting Rare Cell Populations

Identifying rare cell populations requires specific analytical strategies to ensure these populations are not obscured by more abundant cell types. Approaches include over-clustering (using higher resolution parameters), focused analysis on subpopulations, and incorporating known markers for rare populations. In the endometrium, these methods have been instrumental in identifying rare progenitor cells, such as perivascular CD9+ SUSD2+ cells, which exhibit stem cell properties and play crucial roles in endometrial regeneration and repair [29].

Applications in Proliferative Phase Endometrium Research

Characterizing Cellular Heterogeneity in Normal Endometrium

ScRNA-seq has revealed remarkable cellular diversity within the proliferative phase endometrium. Studies have identified numerous distinct cell types and subtypes, each with unique transcriptional signatures and functional specializations. Fibroblasts, the most abundant cell type in endometrial tissues, display significant heterogeneity, with scRNA-seq analysis revealing at least five distinct subclusters with unique gene expression profiles and potential functional specializations [31]. Similarly, endothelial cells can be categorized into arterial, venous, capillary, and proliferating subtypes, each contributing differently to vascular function and regulation [31].

Identifying Rare Progenitor Populations

The identification of rare progenitor cell populations represents one of the most significant contributions of scRNA-seq to endometrial biology. Research using scRNA-seq has revealed that perivascular CD9+ SUSD2+ cells function as putative progenitor stem cells based on pseudotime trajectory analysis and enriched functions in ossification, stem cell development, and wound healing [29]. These cells exhibit a specific perivascular expression pattern across different menstrual cycle phases and demonstrate functional properties critical for endometrial regeneration and repair.

Investigating Pathological Conditions

ScRNA-seq has provided unprecedented insights into endometrial pathologies by revealing alterations in cellular composition and transcriptional programs. In conditions like thin endometrium (TE), scRNA-seq has identified significant changes in cell function, manifesting as increased fibrosis and attenuated cell cycle and adipogenic differentiation [29]. Cell-cell communication network analysis has further underscored aberrant crosstalk among specific cell types in TE, implicating crucial pathways such as collagen over-deposition around perivascular CD9+ SUSD2+ cells, indicating a disrupted response to endometrial repair [29].

Similarly, in intrauterine adhesions (IUAs), scRNA-seq has revealed alterations in fibroblast subpopulations, with specific fibroblast subclusters showing significant expansion in IUA tissues compared to healthy controls [31]. These pathological fibroblast subclusters exhibit distinct gene expression profiles involved in processes such as response to reactive oxygen species and regulation of mitotic DNA damage checkpoints [31].

Advanced Analytical Techniques

Trajectory Inference and Pseudotemporal Ordering

Trajectory inference methods, such as Monocle, allow researchers to reconstruct cellular dynamics and transitions by ordering cells along pseudotemporal trajectories based on transcriptional similarity [31]. Applied to endometrial fibroblasts, this approach has revealed developmental trajectories from one subcluster to another, providing insights into fibroblast differentiation and specialization during endometrial regeneration and repair [31].

Cell-Cell Communication Analysis

Tools like CellChat enable the systematic analysis of cell-cell communication networks by leveraging known ligand-receptor interactions [29]. In endometrial research, this approach has identified disrupted communication pathways in pathological conditions like thin endometrium, particularly highlighting aberrant signaling related to extracellular matrix remodeling and vascular function [29].

Integration with Spatial Transcriptomics

While scRNA-seq provides detailed information about cellular heterogeneity, it loses the spatial context of cells within tissues. Spatial transcriptomics technologies address this limitation by mapping gene expression within tissue sections. Integrated approaches combining scRNA-seq with spatial transcriptomics have been powerfully applied in endometriosis research, revealing hierarchical microenvironment organization and niche interactions that sustain lesion growth [32]. These integrated methods preserve spatial information while maintaining single-cell resolution, offering comprehensive insights into tissue organization and cellular interactions.

The following diagram illustrates the key signaling pathways identified through scRNA-seq analysis in proliferative phase endometrium:

Figure 2: Key Signaling Pathways in Proliferative Phase Endometrium

Research Reagent Solutions

Table 2: Essential Research Reagents for Endometrial scRNA-seq Studies

Reagent/Category	Specific Examples	Function/Application	Technical Considerations
Cell Isolation Kits	Fluorescence-activated cell sorting (FACS) reagents, Magnetic-activated cell sorting (MACS) kits	Isolation of specific cell populations from endometrial tissue	CD9 and SUSD2 antibodies for progenitor cell isolation [29]
Single-Cell Platforms	10x Genomics Chromium, Smart-seq2, Drop-seq	Single-cell capture, barcoding, and library preparation	10x Genomics suitable for high-throughput studies [27]
Library Preparation Kits	10x Genomics Library Kit, SMARTer Ultra Low RNA Kit	Conversion of RNA to cDNA, amplification, and library construction	Incorporation of UMIs for accurate quantification [27]
Bioinformatics Tools	Seurat, Scanpy, Monocle, CellChat	Data processing, normalization, clustering, trajectory inference	Seurat version 5.0.1 used in endometrial studies [29]
Spatial Transcriptomics	10x Visium, Slide-seq	Spatial mapping of gene expression in endometrial tissue sections	Integration with scRNA-seq for spatial context [32]

Methodological Considerations and Limitations

Despite its powerful capabilities, scRNA-seq presents several methodological challenges that researchers must address. Technical artifacts, including batch effects, amplification biases, and dropout events (where lowly expressed genes are not detected), can complicate data interpretation [27]. The dissociation process itself can induce artificial transcriptional stress responses, potentially altering the transcriptional profiles of sensitive cell types [27]. Computational challenges include appropriate normalization to account for variations in transcriptome size across cell types [30] and effective integration of datasets from different samples or conditions.

For endometrial research specifically, careful consideration must be given to the timing of sample collection relative to the menstrual cycle, as transcriptional profiles vary significantly throughout the different phases. The cellular composition of endometrial tissues also varies between individuals, requiring adequate sample sizes to distinguish biological variation from technical artifacts. When studying rare populations, strategies to enrich for these cells before scRNA-seq may be necessary to ensure sufficient representation for robust analysis.

Single-cell RNA sequencing has revolutionized our ability to deconvolute cellular heterogeneity and identify rare populations in the proliferative phase endometrium. By providing high-resolution transcriptional profiles of individual cells, this technology has uncovered previously unappreciated diversity in endometrial cell types, identified rare progenitor populations with critical roles in tissue regeneration, and revealed altered cellular states and interactions in pathological conditions. The continued refinement of scRNA-seq technologies and analytical methods, along with integration with complementary approaches like spatial transcriptomics, promises to further enhance our understanding of endometrial biology and pathology, ultimately contributing to improved diagnostics and therapeutics for endometrial disorders.

Spatial transcriptomics (ST) represents a revolutionary suite of technologies that enable comprehensive gene expression profiling while preserving the crucial spatial localization information within intact tissue specimens. These methodologies have transformed our understanding of complex tissue biology by revealing how transcriptional programs are orchestrated within their native structural contexts [33]. In the specific field of endometrial research, particularly concerning the proliferative phase and implantation window, ST provides unprecedented insights into the precise cellular niches and molecular interactions that govern endometrial receptivity and function [9] [34]. The transcriptional landscape of the proliferative phase endometrium is characterized by dynamic, spatially-organized gene expression patterns that establish the structural and functional framework necessary for potential embryo implantation.

Traditional bulk RNA sequencing and even single-cell RNA sequencing approaches, while valuable, fundamentally disrupt native tissue architecture, thereby losing critical spatial information about cellular interactions and microenvironmental influences [9]. Spatial transcriptomics overcomes this limitation by mapping gene expression data directly onto histological sections, enabling researchers to decipher how cellular function is influenced by physical location within the endometrial tissue [35] [33]. This technical advancement is particularly crucial for understanding complex physiological processes such as endometrial regeneration during the proliferative phase, stromal-epithelial interactions, and the establishment of receptivity during the implantation window [34] [36].

Technical Foundations of Spatial Transcriptomics

Core Technological Platforms

Spatial transcriptomics technologies primarily fall into two methodological categories: sequencing-based approaches and imaging-based approaches. Sequencing-based methods, such as 10x Genomics Visium [9] [33], utilize spatially-barcoded oligonucleotides on a surface to capture mRNA molecules from tissue sections, followed by high-throughput sequencing to reconstruct gene expression patterns with spatial coordinates. Imaging-based approaches, including MERFISH [33], seqFISH [33], and the Xenium platform [34], employ in situ hybridization with fluorescently-labeled probes to detect hundreds to thousands of transcripts directly in fixed tissues through sequential imaging rounds.

The 10x Visium platform, prominently used in recent endometrial studies [9], features capture areas measuring 6.5 × 6.5 mm, each containing approximately 5,000 spots equipped with spatial barcodes. Each spot has a diameter of 55 μm and centers are spaced 100 μm apart, capturing mRNA from multiple cells per spot. In contrast, higher-resolution platforms like Xenium [34] and MERFISH [33] achieve subcellular resolution, detecting individual mRNA molecules within intact tissue architecture. These technological differences directly influence experimental design decisions, with sequencing-based approaches offering whole-transcriptome coverage and imaging-based methods providing superior spatial resolution at the cost of more limited gene panel sizes.

Experimental Workflow for Endometrial Research

The standard experimental workflow for spatial transcriptomics in endometrial studies involves multiple critical stages, each requiring rigorous optimization to ensure data quality and biological relevance:

• Tissue Collection and Preparation: Endometrial biopsies are collected during specific menstrual cycle phases, typically the mid-luteal phase (LH+7) for implantation window studies [9] [36]. Tissues are rapidly frozen in isopentane pre-chilled with liquid nitrogen and stored at -80°C to preserve RNA integrity. Optimal cutting temperature (OCT) compound-embedded tissues are cryosectioned at thicknesses of 5-16 μm, with sections placed onto specific spatial transcriptomics slides.

• Quality Control and RNA Assessment: RNA quality is rigorously assessed using RNA Integrity Number (RIN), with a minimum threshold of RIN > 7.0 recommended to minimize degradation artifacts [9]. Tissue optimization experiments determine optimal permeabilization time to balance mRNA capture efficiency and tissue morphology preservation.

• Library Preparation and Sequencing: For 10x Visium protocols [9], tissue sections are fixed, stained with hematoxylin and eosin (H&E) for histological reference, permeabilized to release mRNA, and subjected to reverse transcription using barcoded primers. Libraries are constructed following platform-specific protocols and sequenced on high-throughput platforms such as Illumina NovaSeq 6000 with PE150 configuration.

• Validation and Integration: Protein-level validation through immunohistochemistry or immunofluorescence on adjacent sections is crucial for correlating transcriptional patterns with protein localization [36]. Integration with single-cell RNA sequencing data enables more refined cell type identification and deconvolution of spot-level data [9].

Table 1: Key Experimental Parameters for Spatial Transcriptomics in Endometrial Studies

Parameter	10x Visium Specification	Xenium Platform	Quality Threshold
Spatial Resolution	55 μm spot diameter, 100 μm center-center spacing	Subcellular (≤1 μm)	N/A
Tissue Section Thickness	5-16 μm	5-10 μm	Uniform thickness critical
RNA Integrity Number	>7.0 [9]	>7.0	Minimum 500 genes/spot
Sequencing Depth	~300 million read pairs/sample [9]	Varies by gene panel	>90% sequencing saturation
Mitochondrial Gene Percentage	<20% [9]	<20%	Exclude spots above threshold

Analytical Frameworks and Computational Methods

Data Processing and Quality Control

The computational analysis of spatial transcriptomics data begins with raw sequencing data processing and rigorous quality control. The Space Ranger pipeline (version 2.0.0) is commonly used for 10x Visium data to align sequences to reference genomes (GRCh38 for human endometrial studies), detect tissue sections, and align fiducial markers [9]. Following alignment, spot-level filtering excludes low-quality measurements based on thresholds for detected genes (>500 genes/spot) and mitochondrial gene percentage (<20%) [9].

Data normalization addresses technical variability between spots using methods like SCTransform in Seurat (version 4.3.0) [9]. For integration across multiple samples, harmony-based batch correction effectively mitigates technical variations while preserving biological signals [9]. Principal component analysis (PCA) utilizing the top 30 principal components typically provides sufficient dimensionality reduction for subsequent clustering analyses.

Table 2: Spatial Transcriptomics Data Quality Metrics from Endometrial Study [9]

Quality Metric	Reported Values	Acceptance Criteria
Total High-Quality Spots	10,131 across 8 samples	Gene count >500, MT% <20%
Median Genes per Spot	3,156	Minimum 2,000 recommended
Median UMI Counts per Spot	6,860	Minimum 4,000 recommended
Sequencing Saturation	>90%	>80% required
Reads Mapped to Genome	>90%	>80% required
Q30 Score for Barcode/UMI	>90%	>85% required

Spatial Domain Identification and Cellular Niche Characterization

A fundamental analytical task in endometrial spatial transcriptomics is identifying spatial domains—histologically and functionally distinct regions characterized by similar gene expression patterns. Computational methods for spatial domain detection have evolved from non-spatial clustering approaches (Louvain, SCANPY) to sophisticated spatial algorithms that integrate gene expression with spatial coordinates [35].

The SR-DGN (Spatially Regularized Deep Graph Networks) framework represents a recent advancement that employs graph attention networks (GAT) to adaptively aggregate gene expression information from neighboring spots while maintaining spatial consistency [35]. This method incorporates spatial regularization constraints that ensure spatially neighboring spots remain close in the embedded latent space, while spatially distant spots are separated, even when exhibiting similar expression profiles [35]. Additionally, SR-DGN utilizes cross-entropy loss to model gene dropout events, effectively handling technical zeros common in spatial transcriptomics data [35].

In endometrial applications, these approaches have successfully identified seven distinct cellular niches with specific characteristics in human endometrial tissues from both normal individuals and patients with repeated implantation failure (RIF) [9]. Integration with public single-cell RNA sequencing data (GSE183837) enables deconvolution of spot-level data to estimate cellular compositions, revealing unciliated epithelial cells as dominant components in mid-luteal phase endometrial samples [9].

Integration with Single-Cell and Histological Data

The true power of spatial transcriptomics emerges through integration with complementary data modalities. Computational deconvolution methods, such as CARD (conditional autoregressive-based deconvolution) [9], leverage single-cell RNA sequencing references to estimate cell type proportions within each spatial spot. This approach is particularly valuable in heterogeneous tissues like the endometrium, where multiple cell types coexist in defined architectural relationships.

For endometrial studies, integration with histological features from H&E staining enables correlation of transcriptional patterns with morphological landmarks. Advanced methods further incorporate protein expression data from immunohistochemistry or immunofluorescence on serial sections, allowing multidimensional characterization of tissue organization [36]. Digital alignment of adjacent serial sections stained for different markers (e.g., p16 for senescent cells, CD68 for macrophages) enables quantitative spatial analysis, including nearest-neighbor calculations between different cell populations [36].

In the context of proliferative phase endometrium research, these integrated approaches have revealed precise spatial distributions of senescent cells and their proximity to immune subsets, with macrophages and monocytes localizing closest to senescent cells (45 ± 20 μm and 45 ± 25 μm, respectively), while T-helper and NK cells positioned at greater distances (102 ± 42 μm and 53 ± 23 μm, respectively) [36]. Such spatial relationships likely play crucial roles in endometrial remodeling and receptivity establishment.

Applications in Endometrial Biology and Pathology

Characterizing the Proliferative Phase Endometrium

Spatial transcriptomics has provided unprecedented insights into the spatial organization of cellular niches during the proliferative phase of the menstrual cycle. Endometrial regeneration following menstruation involves precisely coordinated proliferation and differentiation events across epithelial, stromal, and vascular compartments. ST analyses have identified distinct transcriptional zones within the functionalis layer, characterized by graded expression patterns of Wnt signaling components, growth factors, and extracellular matrix remodeling enzymes [34].

The basalts layer demonstrates unique spatial signatures marked by progenitor cell populations (highlighted by MME and THY1 expression) [34] that give rise to the renewing functionalis layer. Epithelial glandular structures show spatially-restricted expression of genes involved in secretory function preparation (MUC1) [34], even during the proliferative phase, indicating early molecular preparation for potential implantation. Fibroblast subpopulations exhibit zonal distribution patterns, with distinct transcriptional programs between periglandular, stromal, and vascular niches [34].

Insights into Endometrial Receptivity and Implantation Failure

The transition from proliferative to secretory phase culminates in the brief implantation window, during which the endometrium acquires receptivity to embryo attachment. Spatial transcriptomics of mid-luteal phase endometrium has revealed intricate spatial coordination of gene expression patterns that define the receptive state [9]. Comparative analyses between normal individuals and patients with repeated implantation failure (RIF) have identified spatially-dysregulated genes and pathways potentially contributing to infertility [9].

In RIF patients, specific spatial domains show abnormal expression of genes involved in immune response, extracellular matrix organization, and epithelial-stromal crosstalk [9]. These alterations manifest as disrupted spatial gradients of key receptivity factors and aberrant cellular niche organizations. Particularly, the spatial distribution of senescent cells (p16-positive) and their relationship with immune populations appears crucial for normal receptivity, with RIF associated with altered spatial relationships between senescent cells and specific immune subsets like uNK cells and macrophages [36].

The growing complexity of spatial transcriptomics data has driven development of specialized computational tools and resources. SRT-Server represents the first comprehensive webserver for spatial transcriptomics analysis, providing user-friendly access to multiple analytical modules without requiring programming expertise [33]. This platform supports various analytical tasks including quality control, spatially variable gene detection, cell type deconvolution, spatial domain identification, differential expression analysis, and cell-cell communication inference [33].

For endometrial-specific applications, integrated analytical pipelines typically combine several computational approaches:

• Spatially Variable Gene Detection: Methods like SpatialDE, SPARK, and BOOST-GP identify genes with significant spatial expression patterns beyond random distribution [33].

• Cell-Cell Communication Inference: Tools such as CellChat and COMMOT leverage ligand-receptor databases to infer communication probabilities between spatially-proximal cell types [33].

• Spatial Trajectory Analysis: PAGA and other pseudotemporal ordering methods reconstruct differentiation or activation trajectories across spatial locations [33].

• Multi-omics Integration: Computational frameworks for integrating spatial transcriptomics with spatial proteomics, epigenomics, and single-cell datasets provide comprehensive views of endometrial tissue organization [34].

Table 3: Essential Research Reagents and Computational Tools for Endometrial Spatial Transcriptomics

Resource Category	Specific Tools/Reagents	Application in Endometrial Research
Experimental Platforms	10x Visium [9], Xenium [34], MERFISH [33]	Spatial transcriptomics profiling at various resolutions
Computational Tools	SRT-Server [33], SR-DGN [35], Seurat [9], STAGATE [35]	Data analysis, spatial domain identification, visualization
Cell Type Markers	p16 (senescent cells) [36], CD markers (immune cells) [36], MUC1/EPCAM (epithelial) [34]	Cell type identification and validation
Reference Datasets	GSE183837 (scRNA-seq) [9], GSE287278 (ST) [9]	Data integration and deconvolution benchmarks
Spatial Analysis Software	HALO Image Analysis [36], Space Ranger [9]	Image processing, cell segmentation, quantification

Future Directions and Technical Considerations

The rapidly evolving field of spatial transcriptomics continues to address several technical challenges while expanding applications in endometrial biology. Current limitations include spatial resolution constraints in sequencing-based approaches, RNA capture efficiency variations, and computational requirements for analyzing large-scale datasets. Emerging technologies are pushing toward single-cell and subcellular resolution while expanding multimodal capabilities to simultaneously profile gene expression, protein abundance, and chromatin accessibility in spatial context.

For proliferative phase endometrium research, future applications may include:

• Temporal-Spatial Dynamics: Mapping transcriptional changes across the entire menstrual cycle to understand zonal regeneration and differentiation.

• Embryo-Endometrium Interface: Characterizing the spatial dialogue between implanting embryos and receptive endometrium at single-cell resolution.

• Pathological Spatial Alterations: Identifying spatially-disrupted pathways in endometriosis, adenomyosis, and other endometrial disorders.

• Therapeutic Development: Leveraging spatial insights to develop targeted interventions for endometrial pathologies and infertility.

The integration of spatial transcriptomics with other omics technologies and computational modeling will continue to transform our understanding of endometrial biology, ultimately advancing diagnostic capabilities and therapeutic strategies for endometrial disorders and implantation failure.

The transcriptional landscape of the proliferative phase endometrium represents a complex, dynamic system essential for female reproductive health. Traditional gene-level expression analyses have provided foundational knowledge but fail to capture the full regulatory complexity governing endometrial function. Transcript isoform-level changes and RNA splicing variations represent a critical layer of regulation that occurs beyond gene-level expression, significantly expanding the functional diversity of the genome and contributing to the precise molecular control of endometrial development and function. Recent advances demonstrate that splicing quantitative trait loci (sQTLs)—genetic variations that influence RNA splicing patterns—serve as key regulators in endometrial tissue, with profound implications for understanding endometrial physiology and pathology. This technical guide examines the critical importance of investigating transcript isoforms and RNA splicing mechanisms within the context of proliferative phase endometrium research, providing researchers with comprehensive methodological frameworks and analytical approaches to advance this emerging field.

Technical Foundations: RNA Splicing Mechanisms and Regulatory Networks

Fundamental Splicing Processes and Types

RNA splicing is an essential eukaryotic gene regulation mechanism involving the removal of non-coding introns and ligation of coding exons to generate mature mRNA. Two fundamental biochemical processes govern this mechanism: (1) branching, where the 5' end of the intron connects to the branch site adenosine, and (2) ligation, where the 3'-OH group of the 5' exon connects to the 3' splicing site [37]. These coordinated events are facilitated by the spliceosome, a multi-megadalton complex comprising five small nuclear ribonucleoproteins (U1, U2, U4, U5, and U6) and numerous protein splicing factors that collectively identify splicing sites and execute cutting and connecting reactions [37].

RNA splicing manifests in two primary forms with distinct biological implications:

• Constitutive splicing (CS): Follows the GT-AG splicing site rule to produce consistent mRNA transcripts from a specific gene, maintaining proteomic stability for essential cellular functions [37].
• Alternative splicing (AS): Generates multiple distinct mature mRNA variants from a single pre-mRNA molecule through various patterns including exon skipping (ES), alternative 5' splice sites (A5SS), alternative 3' splice sites (A3SS), intron retention (IR), and mutually exclusive exons (MXE) [37]. Notably, approximately 90% of human genes undergo AS under normal physiological conditions, dramatically expanding functional genomic diversity [37].

The following diagram illustrates the core splicing processes and major alternative splicing types:

Multi-Layered Regulation of Splicing Networks

RNA splicing is governed by a complex regulatory network involving multiple molecular players that ensure precise spatiotemporal control:

• Splicing Factors (SFs): RNA-binding proteins including serine/arginine-rich (SR) proteins and heterogeneous nuclear ribonucleoproteins (hnRNPs) that recognize specific splicing enhancer or silencer elements to facilitate or repress spliceosome assembly. For example, hnRNP H and F trigger HRAS exon 5 splicing by binding to splicing enhancer sites in introns, promoting prostate cancer cell proliferation [37].

• Oncogenic Signaling Pathways: Key cellular signaling cascades directly influence splicing decisions through phosphorylation of splicing factors. The RAS/RAF/ERK pathway activates Sam68, increasing exon inclusion in CD44 mRNA and enhancing tumor invasiveness [37]. The PI3K/AKT pathway directly phosphorylates SRSF1, mediating exclusion of exons 3-6 in the casp9 gene to produce the anti-apoptotic casp-9b isoform [37].

• Epigenetic Modifications: Chromatin structure and histone modifications influence splicing outcomes by affecting transcription elongation rates and recruitment of splicing factors. DNA methylation patterns and histone acetylation states create chromatin environments that either facilitate or hinder access to splicing regulatory elements [38] [37].

• Environmental Factors: Cellular stressors, metabolic changes, and external stimuli can alter splicing patterns through activation of stress-responsive kinases and other signaling molecules that modify splicing factor activity [37].

The integrated function of these regulatory layers enables tissue-specific and condition-dependent splicing programs essential for normal physiological function, with dysregulation contributing to disease states including endometriosis and endometrial cancer.

Experimental Frameworks for Splicing Analysis in Endometrial Research

Transcriptomic Profiling Methodologies

Comprehensive analysis of transcript isoforms and splicing events requires specialized experimental approaches that extend beyond standard RNA-sequencing:

• Bulk RNA-Sequencing with Deep Coverage: Standard RNA-seq protocols must be optimized for splicing analysis through deeper sequencing (typically >50 million reads per sample) and longer read lengths (150bp paired-end recommended) to adequately cover splice junctions and detect low-abundance isoforms. For endometrial tissue analysis, careful consideration of menstrual cycle timing is essential, with phase confirmation through histological dating or hormonal measurements [39] [6].

• Single-Cell RNA-Sequencing (scRNA-seq): High-resolution cellular transcriptomics enables the identification of cell-type-specific splicing patterns within the complex cellular architecture of endometrial tissue. Recent studies have successfully applied droplet-based scRNA-seq (10X Chromium platform) to profile over 220,000 endometrial cells across the window of implantation, revealing distinct epithelial and stromal subpopulations with unique splicing signatures [8].

• Long-Read Sequencing Technologies: Pacific Biosciences (PacBio) Iso-Seq and Oxford Nanopore Technologies direct RNA sequencing provide full-length transcript information without assembly, allowing for comprehensive isoform characterization and detection of complex splicing patterns that may be missed by short-read approaches.

• Targeted Splicing Assays: For validation and high-throughput screening, targeted approaches including Nanostring nCounter and RT-PCR panels specifically designed for endometrial splicing events enable cost-effective analysis of candidate isoforms across large sample cohorts.

Computational and Statistical Approaches for Splicing Quantification

Accurate identification and quantification of splicing events requires specialized bioinformatic tools:

• Splicing Event Detection: Software packages such as rMATS, LeafCutter, and SUPPA2 effectively identify and quantify alternative splicing events from RNA-seq data. LeafCutter's intron-centric approach is particularly valuable for sQTL mapping as it does not require pre-annotation of transcript structures [39].

• Differential Splicing Analysis: Multiple complementary analytical frameworks provide robust detection of splicing changes:

  • Differential Transcript Usage (DTU): Identifies genes with significant changes in the relative abundance of specific transcript isoforms between conditions.
  • Differential Splicing (DS): Detects alterations in specific splicing events (exon skipping, intron retention, etc.) through metrics such as Percent Spliced In (PSI) [39].

• sQTL Mapping: Genetic variants influencing splicing patterns are identified through sQTL analysis, which associates genotype data with splicing quantitative phenotypes (e.g., PSI values or intron excision ratios). Standardized pipelines such as FastQTL and TensorQTL enable efficient sQTL mapping in large cohorts, with appropriate corrections for multiple testing and confounding factors [39].

Table 1: Key Analytical Frameworks for Splicing Quantification

Analysis Type	Key Metrics	Software Tools	Biological Interpretation
Differential Gene Expression (DGE)	Fold change, FPKM/TPM	DESeq2, edgeR, limma	Overall gene expression changes
Differential Transcript Usage (DTU)	Transcript proportion, Isoform frequency	DEXSeq, sleuth, IsoformSwitchAnalyzeR	Shifts in dominant transcript isoforms
Differential Splicing (DS)	Percent Spliced In (PSI), Junction counts	rMATS, LeafCutter, SUPPA2	Alterations in specific splicing events
sQTL Mapping	Effect size (β), P-value	FastQTL, TensorQTL, Matrix eQTL	Genetic regulation of splicing patterns

Key Findings: Splicing Dynamics in Proliferative Phase Endometrium

Menstrual Cycle-Associated Splicing Transitions

Comprehensive transcriptomic profiling of endometrial tissue across the menstrual cycle has revealed extensive splicing dynamics that exhibit distinct phase-specific patterns:

• Phase-Specific Splicing Transitions: Analysis of 206 endometrial samples revealed that the most pronounced transcriptomic changes occur between the mid-proliferative (MP) and early secretory (ES) phases, followed by ES to mid-secretory (MS) transitions [39]. Notably, differential transcript usage (DTU) analysis demonstrated minimal cross-phase overlap, suggesting that alternative transcript usage confers strong phase specificity in endometrial regulation [39].

• Splicing-Specific Changes Beyond Gene Expression: Comparative analysis of different transcriptomic levels revealed that a significant proportion of genes with splicing changes escape detection by conventional gene-level analysis. Specifically, in the MP versus MS phase comparison, 24.5% of DTU genes and 27.0% of DS genes showed no significant differential gene expression, indicating these represent splicing-specific regulatory events [39].

• Functional Enrichment of Splicing-Regulated Genes: Pathway analysis of genes identified exclusively through transcript isoform-level and splicing analyses revealed significant enrichment in biologically relevant processes including hormone regulation, cell growth pathways, and extracellular matrix organization, highlighting the functional importance of splicing regulation in endometrial tissue remodeling [39].

Table 2: Splicing Changes Across Menstrual Cycle Transitions

Phase Comparison	DGE Genes	DTE Genes	DTU Genes	DS Genes	Splicing-Specific Genes
MP vs. ES	8,452	8,712	1,845	2,528	612 (24.2%)
ES vs. MS	9,824	9,935	2,103	2,867	743 (25.9%)
MS vs. LS	7,635	7,892	1,724	2,316	594 (25.6%)
MP vs. MS	11,912	11,930	2,347	3,205	865 (27.0%)

Genetic Regulation of Endometrial Splicing (sQTLs)

The integration of genotype data with transcriptomic profiles has revealed extensive genetic control over splicing patterns in endometrial tissue:

• Extensive sQTL Landscape: Mapping of splicing quantitative trait loci in endometrial tissue identified 3,296 significant sQTLs, with the majority (67.5%) of genes with sQTLs showing no corresponding effects at the gene expression level (eQTLs) [39]. This demonstrates that genetic influences on splicing represent a largely independent layer of transcriptional regulation.

• Endometriosis Risk Genes via Splicing Mechanisms: Integration of sQTL data with endometriosis genome-wide association studies (GWAS) identified two genes—GREB1 and WASHC3—with significant associations to endometriosis risk mediated through genetically regulated splicing events [39]. This provides a mechanistic link between non-coding genetic risk variants and disease pathogenesis through splicing alteration.

• Cell-Type-Specific Splicing Regulation: Emerging evidence from single-cell studies suggests that genetic effects on splicing may exhibit cell-type specificity within the heterogeneous endometrial tissue environment, though larger-scale single-cell sQTL studies are needed to fully characterize these patterns [8].

The following diagram illustrates the integration of sQTL mapping with GWAS to identify functional mechanisms for disease-associated genetic variants:

Signaling Pathways Integrating Splicing Regulation in Endometrium

Hormonal Regulation of Splicing Networks

The endometrial proliferative phase is characterized by estrogen-dominated signaling that prepares the tissue for potential implantation, with growing evidence suggesting direct involvement of hormonal pathways in splicing regulation:

• Estrogen Receptor Signaling: Estrogen receptor alpha (ERα) activation influences the expression and activity of multiple splicing factors through both transcriptional and post-translational mechanisms. In breast cancer models, ERα-mediated signaling alters the splicing of genes including ZNF217, which also demonstrates splicing alterations in endometriosis [39].

• Progesterone Receptor Isoforms: The progesterone receptor gene (PGR) generates functionally distinct isoforms (PRA and PRB) through alternative splicing, with differential expression across menstrual cycle phases and pathological states [40]. Progesterone signaling further influences splicing patterns through downstream kinases that phosphorylate splicing factors.

• Chromatin Accessibility and Splicing Integration: Hormonal signaling influences chromatin architecture through recruitment of chromatin remodeling complexes, creating accessible regions that potentially affect splicing factor binding and splice site selection. In endometrial cells, estradiol priming exposes progestin-dependent PR binding sites in regions with pre-existing open chromatin [40].

Splicing-Centric View of Endometrial Pathways

Recent findings position RNA splicing as an integral component of core endometrial signaling pathways:

• MAPK/ERK and Splicing Factor Phosphorylation: The MAPK/ERK pathway directly phosphorylates splicing factors including Sam68, which is elevated in endometrial cancer cell lines and clinical samples and promotes cell proliferation through mechanisms potentially involving altered splicing of growth regulatory genes [37].

• PI3K/AKT Signaling and Splicing Control: AKT-mediated phosphorylation of SRSF1 influences alternative splicing of apoptotic genes including caspase-9, shifting the balance toward anti-apoptotic isoforms. Additionally, AKT activation promotes nuclear translocation of SRPK1, which hyperphosphorylates SR proteins and alters splicing patterns of angiogenesis-related genes including VEGFA [37].

• Integration with Chromatin Remodeling: Splicing regulation intersects with chromatin states through mechanisms such as the interaction between splicing factors and chromatin regulators including ARID1A, which is mutated in endometriosis and influences invasive behavior through AP-1-mediated gene expression [38].

The Scientist's Toolkit: Essential Research Reagents and Materials

Table 3: Essential Research Reagents for Endometrial Splicing Studies

Reagent Category	Specific Examples	Application Notes	Functional Role
RNA Extraction Kits	miRNeasy Mini Kit (Qiagen), TRIzol-based methods	Include DNase treatment; preserve RNA integrity (RIN >8)	High-quality RNA recovery preserving labile transcripts
RNA-Seq Library Prep	TruSeq Stranded mRNA, SMARTer Stranded RNA-Seq	Ribosomal RNA depletion preferred over poly-A selection	Comprehensive transcriptome coverage including non-polyadenylated isoforms
Single-Cell Platforms	10X Chromium, Parse Biosciences	Cell viability >90%; rapid processing after tissue dissociation	Single-cell resolution of splicing heterogeneity
sQTL Mapping Tools	FastQTL, TensorQTL, PLINK	Genotype imputation; appropriate population stratification control	Genetic association analysis with splicing phenotypes
Splicing Detection	rMATS, LeafCutter, SUPPA2	Parameter optimization for endometrial-specific transcripts	Quantification of alternative splicing events
Validation Reagents	Nanostring nCounter, TaqMan splice assays	Design junction-spanning probes for specific isoforms	Experimental confirmation of computational predictions

The integration of transcript isoform-level analyses and sQTL mapping represents a paradigm shift in our understanding of endometrial biology, moving beyond gene-centric views to embrace the complexity of transcriptional regulation. The proliferative phase endometrium exhibits dynamic splicing transitions that contribute substantially to its functional maturation, with genetic variation influencing individual splicing landscapes and potentially contributing to disease susceptibility. Future research directions should include comprehensive single-cell sQTL mapping in endometrial cell subtypes, functional characterization of endometriosis-associated splicing variants in GREB1 and WASHC3, and development of therapeutic approaches targeting pathological splicing events. The methodological frameworks and analytical approaches outlined in this technical guide provide researchers with essential tools to advance this emerging frontier in endometrial research.

The human endometrium exhibits remarkable cellular dynamism during the proliferative phase, a period of extensive tissue regeneration and growth driven by estrogen. Understanding the transcriptional landscape of this phase is crucial for elucidating the fundamental biology of endometrial renewal and the molecular origins of associated disorders. Traditional bulk transcriptomic approaches have begun to characterize this phase [1], but they mask cellular heterogeneity. The integration of advanced computational tools with single-cell RNA sequencing (scRNA-seq) now enables the deconstruction of this complex tissue at unprecedented resolution. This technical guide details the application of three core computational methodologies—pseudotime analysis, RNA velocity, and cell-cell communication inference—within the specific context of proliferative phase endometrial research, providing a framework for uncovering the cellular programs governing endometrial proliferation and their dysregulation in disease.

Core Computational Methodologies

Pseudotime Analysis: Reconstructing Cellular Trajectories

Concept and Application: Pseudotime analysis is a computational technique that orders individual cells along a hypothetical continuum of a dynamic process, such as differentiation or cellular activation, based on their transcriptomic similarities. In proliferative phase endometrium research, this is instrumental for modeling the developmental trajectories of epithelial stem/progenitor cells or the transition of stromal fibroblasts into specialized subtypes.

Experimental Protocol and Workflow:

• Data Input: Begin with a pre-processed and annotated scRNA-seq dataset (e.g., a Seurat object) where cell types have been identified. The analysis is typically focused on a subset of cells, such as all epithelial cells or all stromal fibroblasts.
• Tool Selection: Employ a dedicated trajectory inference package. Monocle 2 is widely used, as demonstrated in studies of endometrial fibroblasts [41].
• Feature Selection: Identify genes that are differentially expressed across the cell subset. These genes will serve as the basis for ordering the cells.
• Dimensionality Reduction: Use a nonlinear dimensionality reduction algorithm, such as DDRTree in Monocle, to project cells into a lower-dimensional space where the trajectory can be constructed.
• Order Cells: The tool will then place cells along the inferred trajectory, assigning each a "pseudotime" value, usually starting from a user-defined root state (e.g., a putative progenitor state).

Key Findings in Endometrial Research: A seminal application involved profiling ~55,000 single cells from ectopic, eutopic (from women with endometriosis), and normal endometrium. Pseudotime analysis of fibroblasts revealed a continuum of cell states with two distinct trajectories branching from a common origin (State 1, primarily composed of normal and eutopic endometrial fibroblasts). This analysis suggested that eutopic fibroblasts from patients with endometriosis can differentiate into ectopic lesion fibroblasts, uncovering a potential developmental trajectory for the disease [41]. The following diagram illustrates a generalized workflow for applying these core computational tools to endometrial scRNA-seq data.

RNA Velocity: Predicting Cell Fate Decisions

Concept and Application: RNA velocity quantifies the time derivative of a cell's gene expression state by distinguishing between unspliced (nascent) and spliced (mature) mRNA transcripts, which are captured in standard scRNA-seq protocols. It predicts the future state of individual cells, providing direct insight into the dynamics of cellular transitions. This is particularly powerful for studying the rapid tissue remodeling during the proliferative phase.

Experimental Protocol and Workflow:

• Data Preparation: Use the velocyto.py command-line tool to generate counts of spliced and unspliced transcripts for each cell, starting from the aligned BAM files obtained from your scRNA-seq pipeline (e.g., Cell Ranger).
• Tool Selection: Perform the analysis in Python using the scVelo package, which offers dynamic modeling of RNA velocity.
• Preprocessing: Load the spliced/unspliced matrices and the corresponding cell embeddings (e.g., UMAP from your Seurat analysis). Preprocess the data by filtering and normalizing.
• Modeling: The scv.tl.recover_dynamics() function fits a dynamic model to the data, which accounts for transcription, splicing, and degradation rates for each gene. This is considered more robust than the simpler steady-state model.
• Visualization: Project the velocity vectors onto an existing embedding (e.g., UMAP) using scv.pl.velocity_embedding_stream() to create a flow field that shows the predicted directions of cellular evolution.

Key Findings in Endometrial Research: In a high-resolution atlas of the window of implantation, RNA velocity analysis of endometrial epithelial cells was pivotal. The vector stream of RNA velocity demonstrated that a identified luminal epithelial population, which expresses markers like LGR5 and EDG7, exhibits high differentiation potential and a trajectory toward glandular epithelial cells [8]. This provided strong computational evidence for the dynamic relationship and potential lineage hierarchy between luminal and glandular epithelial compartments during endometrial differentiation. The table below summarizes the key tools and their primary functions.

Table 1: Core Computational Tools for scRNA-seq Analysis in Endometrial Research

Methodology	Key Tools & Resources	Primary Function	Example Application in Endometrium
Pseudotime Analysis	Monocle 2, PAGA	Reconstructs developmental trajectories and orders cells along a pseudotemporal axis	Modeling fibroblast differentiation in endometriosis [41]
RNA Velocity	scVelo, Velocyto	Predicts future cell states from unspliced/spliced mRNA ratio	Revealing luminal-to-glandular epithelial cell fate [8]
Cell-Cell Communication Inference	CellChat, NicheNet, CellPhoneDB	Infers and analyzes ligand-receptor interactions between cell types	Identifying MIF-(CD74+CD44) & WNT5A signaling in disease [42] [32]
Ligand-Receptor Databases	CellPhoneDB, OmniPath, LIANA+	Provides curated lists of ligand-receptor pairs for CCC analysis	Foundational resource for all CCC studies [43]

Cell-Cell Communication Inference: Decoding Intercellular Signaling

Concept and Application: Cell-cell communication (CCC) inference methods use the expression of ligand and receptor genes to systematically map the potential signaling networks between different cell types in a tissue. For the proliferative endometrium, this reveals how epithelial-stromal-immune crosstalk coordinates regeneration.

Experimental Protocol and Workflow:

• Data Input: A pre-processed, annotated scRNA-seq dataset with cell type labels.
• Tool Selection: Choose a CCC tool based on your needs. CellChat is user-friendly and provides extensive visualization and pattern recognition, while NicheNet can also predict downstream signaling and target genes. The field contains nearly 100 different tools, so selection is critical [43].
• Ligand-Receptor Resource: The tool references a curated database of ligand-receptor (LR) interactions. Commonly used resources include CellPhoneDB and OmniPath, which account for protein complexes. The choice of database is a trade-off between comprehensiveness and risk of false positives [43].
• Statistical Inference: The tool calculates communication probabilities for each LR pair and each pair of cell types, using statistical or network-based methods.
• Visualization and Analysis: Use the tool's built-in functions to visualize networks, identify dominant signaling pathways, and perform differential analysis between conditions (e.g., healthy vs. diseased).

Key Findings in Endometrial Research: CCC analysis has uncovered critical pathogenic signaling hubs. In endometrioid endometrial cancer, a robust communication via the MIF-(CD74+CD44) ligand-receptor pair was identified between a specific macrophage subtype (M2_like2) and a malignant epithelial subpopulation (SOX9+LGR5-), with the transcription factor NFKB2 mediating this pro-tumorigenic effect [42]. In endometriosis, WNT5A signaling was shown to mediate interactions between ectopic endometrial stromal cells and distinct ovarian stromal cells, promoting a fibrotic and inflammatory microenvironment conducive to lesion growth [32]. The following diagram conceptualizes a specific CCC pathway discovered in endometrial research.

Table 2: Research Reagent Solutions for Computational Transcriptomics

Reagent / Resource	Type	Function in Analysis
10X Genomics Chromium	Wet-bench Kit	Generates barcoded single-cell RNA-seq libraries (used in [41] [8])
CellRanger	Software Suite	Processes raw sequencing data, performs alignment, and generates feature-barcode matrices
Seurat R Package	Software Toolbox	Comprehensive toolkit for scRNA-seq data QC, normalization, clustering, and annotation
CellPhoneDB / OmniPath	Curated Database	Provides evidence-based ligand-receptor complexes for communication inference [43]
Human GRCh38/hg38	Reference Genome	Genomic reference for aligning sequencing reads from human endometrial samples [42]

Integrated Analysis: A Path Toward Mechanistic Insights

The true power of these computational tools is realized when they are integrated. For instance, RNA velocity might predict that a specific stromal subpopulation gives rise to decidualized cells, pseudotime analysis can order this transition and identify key regulator genes, and CCC inference can then reveal which ligands from epithelial or immune cells drive this differentiation program. This integrated approach was used to characterize the two-stage decidualization process of stromal cells and the concurrent gradual transition of luminal epithelial cells across the window of implantation [8]. Furthermore, the creation of the Human Endometrial Cell Atlas (HECA)—integrating data from 63 women—exemplifies the large-scale collaborative efforts needed to build a definitive reference for mapping new data and contextualizing findings across the menstrual cycle, including the dynamic proliferative phase [44]. By applying these computational toolkits, researchers can move beyond descriptive cataloging to generate testable hypotheses about the molecular mechanisms controlling endometrial proliferation, ultimately advancing diagnostics and therapeutics for endometrial disorders.

The transcriptional landscape of the proliferative phase endometrium, characterized by rapid estrogen-driven cellular growth and differentiation, presents a complex and dynamic system for genomic study. A multi-omics approach that strategically integrates bulk RNA-seq, single-cell RNA-seq (scRNA-seq), and spatial transcriptomics is essential to fully deconstruct this complexity. Such integration moves beyond the limitations of individual technologies, enabling the resolution of cellular heterogeneity, spatial organization, and tissue-level gene expression programs that define endometrial receptivity and function. This technical guide provides a comprehensive framework for the effective design and execution of integrated multi-omics studies, with specific methodologies and analytical workflows tailored to endometrial biology.

The human endometrium undergoes precisely orchestrated molecular and cellular changes across the menstrual cycle. Transcriptome-wide analyses have historically compared distinct phases, such as secretory versus proliferative endometrium, to identify markers of endometrial receptivity [1]. However, the proliferative phase itself is not a monolithic stage but involves critical transitions, such as the shift from the mid-proliferative (MP) to the late proliferative (LP) peri-ovulatory phase, which are essential for preparing the tissue for subsequent implantation [1]. Bulk RNA-seq of whole-tissue endometrium has identified thousands of differentially expressed genes (DEGs) across these phases, but it obscures critical cell-type-specific signals and spatial distributions [1].

The integration of scRNA-seq and spatial transcriptomics is therefore transformative, allowing researchers to:

• Decellularize bulk RNA-seq signatures into their constituent cell-type-specific expressions.
• Map distinct cell subpopulations, such as epithelial, stromal, and immune cells, to their precise tissue locations.
• Uncover novel cell states and communication networks that drive endometrial proliferation and differentiation.

This guide details the protocols and data integration strategies to achieve these objectives, providing a roadmap for advancing research into the proliferative phase endometrium.

Experimental Design and Data Acquisition

A successful multi-omics study requires careful planning, from sample collection through to data generation, ensuring that the datasets are ultimately compatible for integration.

Sample Collection and Preparation

Key Consideration: For studies of the cycling endometrium, precise histological dating of biopsy specimens is paramount. The proliferative phase should be subdivided, for example, into mid-proliferative (MP) and late proliferative (LP) phases, to capture critical transitional biology [1].

• Protocol: Endometrial Tissue Biopsy Processing for Multi-Omics
  • Collection: Obtain endometrial biopsies under an approved ethical protocol. Immediately divide the tissue into three aliquots.
  • Bulk RNA-seq Sample: Preserve one aliquot in RNAlater or similar RNA stabilization reagent for bulk RNA-seq.
  • scRNA-seq Sample: Place a second aliquot into a cold, sterile transport medium suitable for viable cell dissociation. Process as soon as possible to maximize cell viability.
  • Spatial Transcriptomics Sample: Embed the third aliquot in Optimal Cutting Temperature (OCT) compound and snap-freeze in liquid nitrogen-cooled isopentane, or preserve in formalin and embed in paraffin (FFPE), following standard protocols for spatial transcriptomics platforms.

Data Generation with Complementary Technologies

Each technology provides a unique and essential layer of information, as summarized in Table 1.

Table 1: Overview of Core Transcriptomic Technologies

Technology	Resolution	Key Output	Primary Strength	Key Limitation
Bulk RNA-seq	Tissue-level	Average gene expression for all cells in a sample	Cost-effective for large cohorts; ideal for identifying overall DEGs [1]	Obscures cellular heterogeneity and spatial information
Single-cell RNA-seq (scRNA-seq)	Single-cell level	Gene expression matrix for thousands of individual cells	Identifies novel cell (sub)types and rare populations; infers cell trajectories [45]	Loss of native tissue architecture and spatial context
Spatial Transcriptomics	Spot-based (multi-cellular)	Gene expression data mapped to 2D coordinates on a tissue section	Retains spatial localization; enables identification of spatially distinct "ecotypes" or niches [45]	Lower resolution than scRNA-seq (each spot contains multiple cells)

Computational Data Integration Strategies

After generating high-quality data from each platform, the next challenge is their computational integration. The following workflow outlines the primary strategies.

Strategy 1: Deconvolution of Bulk RNA-seq using scRNA-seq

This strategy leverages scRNA-seq to estimate the proportional composition of cell types within a bulk tissue sample.

• Protocol: Reference-based Deconvolution
  • Generate a Reference Profile: From your scRNA-seq data, calculate the average gene expression profile for each distinct cell type (e.g., stromal fibroblasts, luminal epithelial, ciliated epithelial, immune cells) identified through clustering and annotation.
  • Prepare Bulk Data: Normalize and transform your bulk RNA-seq data (e.g., to TPM or CPM) to be compatible with the reference profile.
  • Run Deconvolution Algorithm: Use computational tools like RCTD (Reference-based Cell-type Deconvolution) or CIBERSORTx with the scRNA-seq-derived reference profile to estimate cell type proportions in each bulk sample [45].
  • Validation: Correlate the deconvoluted proportions with histopathological assessments or flow cytometry data if available.

Strategy 2: Mapping scRNA-seq to Spatial Transcriptomics

This strategy anchors scRNA-seq data to spatial data to predict the location of cell (sub)types within the tissue architecture.

• Protocol: Spatial Mapping of Cell Types
  • Data Preprocessing: Ensure both scRNA-seq and spatial transcriptomics datasets are normalized and that gene overlaps are maximized.
  • Cell Type Transfer: Employ a tool like RCTD to deconvolve the spatial transcriptomics spots [45]. The algorithm uses the scRNA-seq data as a reference to predict the cellular composition of each multi-cellular spot on the spatial slide.
  • Visualization and Analysis: Visualize the predicted cell type abundances on the spatial map. This reveals the anatomical positioning of cell types, such as the enrichment of specific Schwann cell subtypes in central versus peripheral tumor regions, a finding analogous to potential epithelial-stromal compartmentalization in the endometrium [45].
  • Identify Spatial Ecotypes: Use the cell type abundance maps to identify recurrent, spatially coherent multicellular communities, or "spatial ecotypes" [45]. This can reveal functional niches, such as a "proliferative niche" involving cycling epithelial cells, specific fibroblasts, and immune cells.

Strategy 3: Integrated Analysis of Dynamic Processes

This strategy combines all three data types to understand temporal-spatial dynamics, such as across the menstrual cycle.

• Protocol: Trajectory Inference with Spatial Validation
  • Define Trajectories from scRNA-seq: Using pseudotime analysis tools (e.g., Monocle3, PAGA) on scRNA-seq data from multiple time points (MP, LP, ES), model the differentiation trajectories of key cell lineages, such as the transition from a proliferative to a secretory stromal fibroblast.
  • Link Trajectories to Bulk Data: Identify the key genes that define the trajectory and confirm their coordinated expression in bulk RNA-seq time-series data.
  • Spatial Validation: Project the trajectory-inferred cell states back onto the spatial transcriptomics data using the mapping strategy in 3.2. This allows you to visualize whether early and late states in a differentiation process occupy distinct spatial locations within the tissue.

The Scientist's Toolkit: Essential Research Reagents and Computational Tools

Successful execution of a multi-omics project relies on a suite of wet-lab and computational resources.

Table 2: Research Reagent Solutions and Computational Tools

Category	Item / Tool	Specific Function / Application
Wet-Lab Reagents	RNAlater / RNA Stabilization Reagent	Preserves RNA integrity in bulk tissue samples prior to extraction [46]
	Cold Transport Medium (e.g., Hibernate)	Maintains cell viability for fresh tissue dissociation for scRNA-seq
	OCT Compound / FFPE Kit	Embedding medium for preserving tissue architecture for spatial transcriptomics
	Cell Dissociation Kit (e.g., collagenase-based)	Liberates individual viable cells from endometrial tissue for scRNA-seq
Computational Tools	R Package "sva" / ComBat Algorithm	Removes technical batch effects when integrating datasets from different cohorts or platforms [46]
	"Seurat" or "Scanpy"	Comprehensive toolkits for scRNA-seq analysis, including clustering, annotation, and integration with spatial data
	"ConsensusClusterPlus"	Performs consensus clustering to identify molecular subtypes, e.g., based on PTM signatures [46]
	RCTD (SpatialDWLS)	Deconvolves spatial transcriptomics data using an scRNA-seq reference to map cell types [45]
	"WGCNA"	Identifies co-expressed gene modules in bulk data that correlate with specific sample traits or cell type abundances [46]
	"Cell2location"	A Bayesian method for spatially mapping cell types with high resolution.

Application in Proliferative Phase Endometrium Research

To illustrate the power of integration, consider this hypothetical analysis of the MP-to-LP transition. A bulk RNA-seq analysis would identify DEGs like histone-encoding genes from the HIST cluster on chromosome 6, which show increased activity during the LP phase [1]. scRNA-seq would reveal which specific cell types (e.g., epithelial versus stromal) drive this HIST cluster upregulation. Finally, spatial transcriptomics would confirm whether these HIST-high cells are uniformly distributed or organized into specific proliferative niches.

The following diagram conceptualizes the analytical workflow for discovering a proliferative-phase-specific cellular niche.

Strategic data integration is the cornerstone of modern genomic research into complex tissues like the proliferative phase endometrium. By moving beyond single-technology analyses, researchers can construct a high-fidelity, spatially resolved map of cellular interactions and transcriptional programs that underlie endometrial function and failure. The methodologies outlined in this guide provide a actionable roadmap for designing and executing such integrative studies, paving the way for novel diagnostics and therapeutic interventions in endometrial disorders and infertility.

Diagnosing Transcriptomic Aberrations: From Thin Endometrium to Implantation Failure

Thin endometrium (TE), typically defined as an endometrial thickness of ≤7 mm during the proliferative phase, is a significant cause of impaired endometrial receptivity, leading to reduced pregnancy rates and poor reproductive outcomes [47] [48] [23]. While clinical factors are recognized, the underlying molecular mechanisms remain poorly understood. Emerging research places increasing emphasis on the transcriptional landscape of the proliferative phase endometrium, revealing that immune dysregulation and altered gene expression are critical contributors to TE pathogenesis [47] [48]. This whitepaper synthesizes recent transcriptomic and single-cell RNA sequencing (scRNA-seq) evidence, highlighting the specific immune-related gene signatures and dysregulated cytotoxic responses that characterize TE. This perspective is framed within a broader thesis that precise mapping of the proliferative phase transcriptional landscape is fundamental to understanding endometrial pathology and developing targeted interventions.

Key Immune-Related Findings in Thin Endometrium

Integrated analyses of bulk and single-cell RNA sequencing data have consistently identified a distinct immune signature in TE, characterized by the upregulation of cytotoxic genes and altered immune cell communication.

Table 1: Key Dysregulated Genes and Pathways in Thin Endometrium

Component	Finding	Significance
Differentially Expressed Genes (DEGs)	57 DEGs identified in bulk RNA-seq [47] [48]	Highlights transcriptomic divergence of TE from normal endometrium.
Key Upregulated Genes	CORO1A, GNLY, GZMA [47] [48] [23]	Functionally related to cytotoxic immune responses; validated by qPCR.
Enriched Biological Processes	Leukocyte degranulation, NK cell-mediated cytotoxicity [47] [48]	Indicates aberrant activation of immune effector functions.
Cellular Composition	Increased immune cell infiltration; altered stromal/epithelial gene expression [47] [48]	Suggests a pervasive immune component in the TE microenvironment.
Putative Progenitor Cells	Perivascular CD9+ SUSD2+ cells show dysregulated function [49]	Implicates impaired endometrial regeneration and repair in TE.

A pivotal study employing bulk RNA sequencing of endometrial tissues from TE patients and controls revealed 57 differentially expressed genes (DEGs) [47] [48]. Gene Ontology enrichment analysis demonstrated significant involvement of immune activation processes, notably leukocyte degranulation and natural killer (NK) cell-mediated cytotoxicity [47] [48]. This points toward an aberrantly active immune environment in TE. Further integration with public scRNA-seq data confirmed increased immune cell infiltration and altered gene expression within stromal and epithelial compartments [47] [48]. Notably, the genes CORO1A, GNLY, and GZMA were significantly upregulated in both datasets, a finding validated by quantitative PCR [47] [48] [23]. These genes are functionally implicated in cytotoxic immune responses, suggesting a key role for immune cell-mediated activity in TE pathogenesis.

Beyond the immune compartment, dysregulation of specific stromal progenitor cells has been observed. ScRNA-seq analysis has identified perivascular CD9+ SUSD2+ cells as putative endometrial progenitor cells [49]. In TE, these cells exhibit functional shifts toward a pro-fibrotic phenotype and attenuated adipogenic differentiation, with cell-cell communication networks indicating aberrant collagen deposition around them [49]. This implies a disrupted regenerative response in TE, where the extracellular matrix is not properly remodeled.

Table 2: Clinical and Sample Information from Key Studies

Study Focus	TE Patients (n)	Control Patients (n)	TE Definition	Key Analytical Methods
Imm-related Gene Signatures [47] [48] [23]	3	3	<7 mm	Bulk RNA-seq, scRNA-seq integration, qPCR validation
Perivascular CD9+ SUSD2+ Cells [49]	10	27	<7 mm at mid-luteal phase	scRNA-seq, Flow Cytometry, Colony-Forming Assays, Immunofluorescence

Detailed Experimental Protocols

To ensure reproducibility and provide a technical reference for researchers, this section outlines the core methodologies used in the cited studies.

Bulk RNA Sequencing and Analysis

Sample Collection and RNA Extraction:

• Endometrial tissues were collected during the proliferative phase of the natural menstrual cycle from patients with TE (endometrial thickness <7 mm) and controls (endometrial thickness ≥8 mm) [47] [48] [23].
• Participants were under 35 years old, with regular menstrual cycles, and excluded for conditions like PCOS, endometriosis, or other systemic/endocrine disorders [48] [23].
• Total RNA was extracted from snap-frozen tissues using RNA-easy isolation reagent. RNA quality was assessed with tools such as NanoDrop and Agilent Bioanalyzer [48] [23].

Library Construction and Sequencing:

• Strand-specific RNA-seq libraries were prepared following ribosomal RNA (rRNA) depletion. Library quality control was performed via Agilent 2100 Bioanalyzer and qRT-PCR [48] [23].
• High-throughput sequencing was conducted on the BGISEQ platform, generating approximately 6 Gb of data per sample [48] [23].

Bioinformatic Analysis:

• Raw reads were quality-controlled (FastQC, Trim Galore, Cutadapt) and aligned to a reference genome (e.g., STAR) [48].
• Gene-level quantification was performed (StringTie, RSEM) and normalized using FPKM/TPM metrics [48].
• Differential expression analysis was carried out with the DESeq2 package in R, defining DEGs as having an adjusted p-value (FDR) < 0.05 and a fold change > 1.5 [48].
• Functional enrichment analysis (Gene Ontology) was performed using the clusterProfiler package [48].

Single-Cell RNA Sequencing (scRNA-seq) Analysis

Data Preprocessing and Quality Control:

• Publicly available scRNA-seq data (e.g., NCBI SRA accession PRJNA730360) was processed using the Seurat package in R [48] [49].
• Cells were filtered based on quality metrics: typically, cells with fewer than 200-1,000 detected genes or high mitochondrial read percentages were excluded [50] [49].
• Data normalization was performed using the "LogNormalize" method with a scale factor of 10,000 [49].

Cell Clustering and Annotation:

• Principal component analysis (PCA) was performed on highly variable genes. Graph-based clustering (e.g., Louvain algorithm) was conducted on the principal components [50] [49].
• Cell types were annotated using reference-based annotation (e.g., SingleR package) and marker gene enrichment (e.g., "AddModuleScore" in Seurat) [50].
• Differential expression between clusters or conditions was identified using the "FindMarkers" or "FindAllMarkers" functions [49].

Advanced Analyses:

• Cell-cell communication networks were inferred using tools like CellChat to identify dysregulated signaling pathways [49].
• RNA velocity analysis was performed with the scVelo package to explore cellular dynamics and state transitions [49].
• Gene set functional scores were calculated using AUCell to assess pathway activity across cell types [50].

Figure 1: Experimental workflow for transcriptomic profiling of thin endometrium, integrating bulk and single-cell RNA sequencing approaches.

Table 3: Key Research Reagent Solutions for Endometrial Transcriptomics

Reagent / Resource	Function / Application	Example Vendor / Source
RNA-easy Isolation Reagent	Total RNA extraction from endometrial tissues	Vazyme [48] [23]
Nanostring nCounter GX Human Immunology V2	Targeted immune and inflammation transcriptomic profiling	Nanostring [51]
Seurat R Package	Comprehensive scRNA-seq data analysis (QC, normalization, clustering, DE)	CRAN/Bioconductor [50] [48] [49]
DESeq2 R Package	Differential expression analysis from bulk RNA-seq count data	Bioconductor [48]
CellChat R Package	Inference and analysis of cell-cell communication networks	GitHub [49]
scVelo Python Package	RNA velocity analysis to model cellular dynamics	GitHub [49]
Human Primary Cell Atlas Data	Reference dataset for automated cell type annotation (SingleR)	Bioconductor [50]
BGISEQ Platform	High-throughput sequencing for transcriptomic libraries	BGI [48] [23]

Pathway Visualization and Logical Framework

The molecular pathogenesis of TE can be conceptualized as a self-reinforcing cycle of immune dysregulation and impaired tissue repair, driven by specific transcriptional changes.

Figure 2: Proposed pathogenic pathway in thin endometrium, integrating cytotoxic immune activation and progenitor cell dysfunction.

The evidence unequivocally demonstrates that Thin Endometrium is characterized by a distinct immune-related gene signature, prominently featuring the upregulation of cytotoxic genes like CORO1A, GNLY, and GZMA. This immune dysregulation, observed alongside functional impairments in perivascular CD9+ SUSD2+ progenitor cells, disrupts the delicate balance required for endometrial regeneration and receptivity. These findings, emerging from the detailed transcriptional landscape of the proliferative phase, provide a new pathophysiological framework for understanding TE.

For researchers and drug development professionals, these insights reveal promising diagnostic biomarkers and therapeutic targets. Future work should focus on functional validation of these genes and pathways, the development of organoid or microphysiological systems to model the immune-stromal interactions in TE, and translational studies to assess the efficacy of immunomodulatory or regenerative strategies for treating this challenging condition.

Recurrent implantation failure (RIF) presents a significant challenge in assisted reproductive technology, affecting approximately 10-15% of couples undergoing treatment. Emerging research has illuminated two central pathophysiological mechanisms: displaced windows of implantation (WOI) and hyper-inflammatory microenvironments. This whitepaper synthesizes current understanding of how transcriptional dysregulation in the endometrium, particularly during the proliferative phase, contributes to these phenomena. Advanced transcriptomic profiling has revealed distinct molecular subtypes of RIF, characterized by immune activation and metabolic disturbances. Single-cell RNA sequencing of over 220,000 endometrial cells has further uncovered aberrant cellular dynamics and communication networks in RIF endometria. This comprehensive analysis integrates multi-omics data to elucidate the complex interplay between transcriptional landscapes, immune dysfunction, and endometrial receptivity, offering insights for targeted therapeutic interventions and personalized treatment approaches in reproductive medicine.

The human endometrium undergoes precisely orchestrated cyclic changes under hormonal regulation to achieve receptivity—a transient period known as the window of implantation (WOI) when the endometrium becomes conducive to embryo attachment and invasion. In the proliferative phase, estrogen-driven cellular proliferation rebuilds the endometrial lining following menstruation, establishing the foundation for subsequent differentiation during the secretory phase [52] [18]. The transcriptional programs activated during the proliferative phase are crucial for establishing this foundation, and disruptions in these early events may propagate through the cycle, ultimately compromising receptivity.

Recurrent implantation failure (RIF) is clinically defined as the failure to achieve a clinical pregnancy after multiple transfers of good-quality embryos, with varying criteria across studies but typically involving at least three unsuccessful cycles with high-quality embryos in women under 40 years of age [53] [54] [55]. While embryonic factors contribute to RIF, growing evidence emphasizes the critical role of endometrial dysfunction, particularly displaced WOI and improper inflammatory milieus, as major pathogenic drivers [8] [56] [57].

This technical review examines the molecular underpinnings of RIF through the lens of transcriptional dysregulation, focusing on how proliferative phase programming establishes trajectories that culminate in defective receptivity. We integrate findings from bulk and single-cell transcriptomic studies to elucidate the cellular and molecular networks disrupted in RIF, with particular emphasis on immune activation pathways and their implications for diagnostic and therapeutic innovation.

Molecular Taxonomy of RIF: Transcriptional Subtypes and Clinical Implications

Comprehensive transcriptomic profiling has revealed that RIF is not a monolithic entity but rather encompasses distinct molecular subtypes with characteristic pathogenic mechanisms. Integrated analysis of multiple endometrial transcriptome datasets has enabled the stratification of RIF into reproducible subtypes, each with unique transcriptional signatures and potential therapeutic implications.

Table 1: Molecular Subtypes of Recurrent Implantation Failure

Subtype	Key Characteristics	Dysregulated Pathways	Potential Targeted Interventions
Immune-Driven (RIF-I)	Enhanced immune activation, inflammatory microenvironment	IL-17 signaling, TNF signaling, chemokine activity	Sirolimus, immunomodulation
Metabolic-Driven (RIF-M)	Altered energy metabolism, circadian disruption	Oxidative phosphorylation, fatty acid metabolism, steroid hormone biosynthesis	Prostaglandins, metabolic modulation

The immune-driven subtype (RIF-I) demonstrates significant enrichment of inflammatory pathways, including IL-17 signaling, TNF signaling, and chemokine activity [56] [57]. This subtype exhibits increased infiltration of effector immune cells and elevated pro-inflammatory cytokines, creating a hostile microenvironment for embryo implantation. Notably, the T-bet/GATA3 expression ratio is significantly elevated in RIF-I, indicating a shift toward pro-inflammatory T-helper cell polarization [56].

In contrast, the metabolic-driven subtype (RIF-M) is characterized by pervasive dysregulation of metabolic pathways, including oxidative phosphorylation, fatty acid metabolism, and steroid hormone biosynthesis [56]. This subtype also demonstrates altered expression of circadian clock genes, particularly PER1, suggesting disruption of the temporal coordination essential for endometrial receptivity. The metabolic alterations in RIF-M may reflect compromised cellular energy production and steroid hormone responsiveness necessary for optimal endometrial function.

A machine learning classifier (MetaRIF) developed to distinguish these subtypes has demonstrated high predictive accuracy (AUC: 0.94 and 0.85 in validation cohorts), outperforming previous models and offering a potential tool for personalized treatment approaches [56]. This classification system represents a significant advance toward precision medicine in reproductive medicine, enabling targeted interventions based on underlying pathophysiology.

Single-Cell Dissection of Endometrial Dynamics Across the Implantation Window

High-resolution single-cell transcriptomic profiling has transformed our understanding of endometrial cellular composition and dynamics across the window of implantation. A time-series atlas generated from over 220,000 endometrial cells from fertile women across five time points (LH+3 to LH+11) has revealed intricate cellular transitions and communication networks essential for receptivity [8].

Table 2: Cellular Dynamics During the Window of Implantation

Cell Type	Dynamic Processes During WOI	Key Regulatory Features	Alterations in RIF
Luminal Epithelial Cells	Gradual transition with time-varying receptivity gene expression	Expression of LGR4, FGFR2, ERBB4; differentiation potential toward glandular cells	Dysregulated epithelial receptivity gene sets; stratified deficiency patterns
Stromal Cells	Two-stage decidualization process	Sequential activation of decidualization markers; distinct early and late phases	Disrupted decidualization progression; aberrant stromal-immune crosstalk
Immune Cells	Coordinated recruitment and functional modulation	uNK cells promoting angiogenesis through VEGF, PlGF; macrophage polarization	Hyper-inflammatory microenvironment; altered uNK function and recruitment

The analysis uncovered a two-stage decidualization process in stromal cells, with distinct transcriptional programs characterizing early and late decidualization phases [8]. This phased differentiation appears disrupted in RIF, with aberrant expression of decidualization markers and impaired stromal-immune communication.

Luminal epithelial cells undergo a gradual transitional process across the WOI, characterized by time-varying expression of receptivity genes [8]. These cells exhibit both luminal and glandular characteristics and demonstrate differentiation potential toward glandular cells, as evidenced by RNA velocity trajectory analysis. In RIF, this epithelial transition is disrupted, with stratification into distinct classes of receptivity deficiencies.

Notably, the RIF endometrium displays a hyper-inflammatory microenvironment, particularly affecting epithelial-stromal-immune interactions [8]. This inflammatory state likely disrupts the precise cellular communication networks necessary for embryo acceptance, creating a hostile environment for implantation.

Methodological Framework: Experimental Protocols for Endometrial Transcriptomics

Integrated Multi-Cohort Transcriptomic Analysis

To overcome limitations of individual studies and identify robust RIF signatures, researchers have developed protocols for integrating multiple endometrial transcriptome datasets:

• Dataset Curation and Harmonization: Collect microarray expression datasets from public repositories (e.g., GEO), applying strict inclusion criteria for secretory-phase endometrial samples from precisely timed cycles [56] [57]. Apply batch effect correction using established algorithms (e.g., ComBat, surrogate variable analysis) to remove technical variability while preserving biological signals.

• Differential Expression Analysis: Identify consistently dysregulated genes across datasets using meta-analysis approaches (e.g., random-effects models) with stringent significance thresholds (FDR < 0.05) [56] [57]. Validate findings in independent cohorts to ensure reproducibility.

• Network and Pathway Analysis: Construct protein-protein interaction networks and perform weighted gene co-expression network analysis (WGCNA) to identify functionally related gene modules [57]. Conduct pathway enrichment analysis (GSEA) to elucidate biological processes disrupted in RIF.

Single-Cell RNA Sequencing Workflow

For high-resolution cellular profiling, single-cell RNA sequencing provides unparalleled insights into endometrial heterogeneity:

• Sample Processing and Quality Control: Collect endometrial biopsies via pipelle aspiration during precisely timed WOI (LH+7). Dissociate tissue enzymatically, isolate single cells, and capture using 10X Chromium system [8]. Perform rigorous quality control to remove low-quality cells and doublets.

• Cell Type Identification and Annotation: Cluster cells based on transcriptional similarity using graph-based methods. Annotate cell types using well-established marker genes: epithelial cells (EPCAM, KRTT1), stromal cells (PDGFRA, DECORIN), endothelial cells (PECAM1, VWF), and immune subsets (PTPRC, NK cell-specific markers) [8].

• Trajectory Inference and RNA Velocity: Reconstruct cellular differentiation trajectories using pseudotime analysis and RNA velocity to model dynamic transcriptional changes across the WOI [8]. Identify transitional cell states and directionality of cellular processes.

Functional Validation Approaches

To establish causal relationships between identified genes and RIF pathogenesis, implement functional validation:

• Gene Knockdown Studies: Select hub genes identified through network analysis (e.g., ENTPD3) for functional validation. Design siRNA constructs and transfert primary endometrial epithelial cells. Assess functional outcomes including epithelial-mesenchymal transition, cytokine secretion, and adhesion capacity [57].

• Immunohistochemical Validation: Validate protein-level expression of subtype-specific markers (e.g., T-bet/GATA3 ratio for RIF-I) in independent patient cohorts [56]. Correlate protein expression with clinical outcomes and transcriptional subtypes.

The Scientist's Toolkit: Essential Research Reagents and Platforms

Table 3: Key Research Reagents and Platforms for Endometrial Receptivity Research

Category	Specific Tools	Application	Key Features
Sequencing Platforms	10X Chromium Single Cell Solution	Single-cell transcriptomics	Cellular heterogeneity resolution, high cell throughput
	Illumina TAC-seq (beREADY test)	Targeted endometrial receptivity assessment	Quantification of 68 receptivity biomarkers, 4 housekeepers
Bioinformatics Tools	StemVAE algorithm	Temporal modeling of transcriptomic dynamics	Predictive modeling of WOI progression, pattern discovery
	MetaRIF classifier	RIF subtype identification	Machine learning-based stratification (AUC: 0.94)
Cell Culture Models	Endometrial organoids	3D modeling of endometrial physiology	Recapitulates glandular architecture, hormone responsiveness
	Primary endometrial epithelial cells	Functional validation studies	Primary cell source for mechanistic investigations
Immunological Assays	CD138 immunostaining	Chronic endometritis diagnosis	Plasma cell detection in endometrial stroma
	Multiplex cytokine panels	Inflammatory microenvironment profiling	Simultaneous quantification of multiple cytokines

Signaling Pathways and Molecular Networks in RIF Pathogenesis

Transcriptomic analyses have identified several key signaling pathways consistently disrupted in RIF, highlighting the complex interplay between immune activation, metabolic regulation, and endometrial receptivity.

The IL-17 and TNF signaling pathways emerge as consistently upregulated in RIF, particularly in the immune-driven subtype [56] [57]. These pathways drive pro-inflammatory cytokine production (including TNF-α, IL-1β, IL-6) and recruit immune cells, creating a hostile endometrial microenvironment. Concurrently, oxidative phosphorylation and fatty acid metabolism pathways are dysregulated in the metabolic subtype, compromising cellular energy production essential for decidualization and implantation [56].

At the cellular level, epithelial-mesenchymal transition (EMT) processes are disrupted in RIF, with functional studies demonstrating that knockdown of hub gene ENTPD3 promotes EMT and increases pro-inflammatory cytokines [57]. This suggests that proper EMT regulation is crucial for establishing receptivity, and its dysregulation contributes to RIF pathogenesis through both structural and inflammatory mechanisms.

The circadian clock gene PER1 shows altered expression in RIF-M, suggesting that temporal disruption of endometrial programming may represent an underappreciated aspect of implantation failure [56]. This finding highlights the importance of precisely coordinated molecular events across the menstrual cycle for achieving receptivity.

The transcriptional landscape of the proliferative phase endometrium establishes critical foundations for subsequent receptivity, and disruptions in this early programming contribute significantly to RIF pathogenesis through displaced WOI and hyper-inflammatory microenvironments. Single-cell transcriptomics has revealed the remarkable cellular heterogeneity and dynamic transitions essential for receptivity, while integrated multi-omics approaches have delineated distinct RIF subtypes with characteristic molecular signatures.

Future research directions should focus on several key areas: First, developing refined classification systems that integrate transcriptional subtyping with clinical parameters to enable truly personalized treatment approaches. Second, elucidating the temporal progression of transcriptional dysregulation from proliferative through secretory phases to identify critical intervention points. Third, advancing 3D endometrial models (organoids, assembloids) that recapitulate the complex cellular interactions of the native endometrium for mechanistic studies and drug screening.

The emerging paradigm of RIF as a heterogeneous disorder with distinct molecular subtypes promises to transform clinical management through precision medicine approaches. By aligning therapeutic strategies with underlying pathophysiology—whether targeting immune dysregulation, metabolic disturbances, or inflammatory pathways—we can anticipate improved outcomes for patients experiencing this challenging condition.

The proliferative phase of the endometrium, characterized by rapid estrogen-driven cellular growth and differentiation, represents a critical window in the menstrual cycle where precise molecular regulation determines subsequent reproductive success. Traditional transcriptomic studies have largely relied on gene-level expression analysis, which quantifies the total expression of genes by aggregating all transcript isoforms. However, this approach fundamentally obscures a crucial layer of biological complexity: alternative splicing, the process by which a single gene can generate multiple structurally and functionally distinct protein isoforms. In the context of proliferative phase endometrium research, this oversight is particularly significant, as the dynamic tissue remodeling and differentiation processes likely require precise spatiotemporal regulation of isoform expression [1] [39].

Growing evidence indicates that isoform-level dysregulation serves as a molecular substrate for various disease states, even when bulk gene expression appears normal. This technical guide explores how splicing defects contribute to disease pathogenesis through mechanisms invisible to conventional gene-level analysis, with specific emphasis on the endometrial proliferative phase environment. We present quantitative evidence, methodological frameworks, and analytical tools to empower researchers in detecting and characterizing these previously overlooked regulatory defects, ultimately advancing both diagnostic capabilities and therapeutic development in reproductive medicine and beyond [58] [39].

The Molecular Basis of Splicing Defects

Pre-mRNA Splicing Mechanics and Regulatory Elements

Pre-mRNA splicing is an essential biochemical process where introns are removed and exons are joined to form mature mRNA molecules. This process occurs in two coordinated steps: first, an internal adenosine (the branchpoint) makes a nucleophilic attack on the 5' end of the intron, cleaving the upstream exon from the intron and generating an intron lariat intermediate; second, the end of the upstream exon attacks the 3' end of the intron, joining the two exons and releasing the intron lariat [58].

The precision of this process is governed by an extensive network of cis and trans regulatory elements:

• Core splice sites: 5' and 3' splice site dinucleotides (GT/AG, GC/AG, or AT/AC) that flank each intron
• Branchpoint sequence: Typically located 18-40 nucleotides upstream of the 3' splice site
• Polypyrimidine tract: A pyrimidine-rich region adjacent to the 3' splice site
• Splicing enhancer/silencer elements: Auxiliary sequences within exons and introns that enhance or inhibit splicing through interactions with RNA-binding proteins (RBPs)

These elements collectively constitute the "splicing code" that determines exon inclusion levels, alternative splice site selection, and ultimately, proteomic diversity [58].

Alternative Splicing Variants and Their Functional Consequences

Alternative splicing generates remarkable transcriptomic diversity through several distinct mechanisms:

Table 1: Major Types of Alternative Splicing Events

Splicing Type	Description	Functional Impact
Skipped Exon (SE)	An exon is either included or skipped in the final transcript	Can remove entire protein domains, affecting function and interactions
Alternative 5' Splice Site (A5SS)	Selection of different 5' splice sites within an exon	Alters the N-terminal boundary of exons, potentially changing coding potential
Alternative 3' Splice Site (A3SS)	Selection of different 3' splice sites within an exon	Alters the C-terminal boundary of exons, potentially changing coding potential
Mutually Exclusive Exons (MXE)	One of two exons is selected, but never both together	Swaps functionally distinct protein domains
Intron Retention (RI)	An intron remains in the mature mRNA	Often introduces premature termination codons, leading to nonsense-mediated decay

These splicing variations can profoundly impact protein function by altering enzymatic activity, subcellular localization, protein-protein interactions, and stability. In the context of the proliferative phase endometrium, where precise hormonal regulation drives tissue remodeling, subtle changes in splicing patterns could significantly impact cellular proliferation, differentiation, and receptivity—without necessarily altering overall gene expression levels [59] [39].

Quantitative Evidence: Isoform-Level versus Gene-Level Analysis

Diagnostic Gaps in Rare Disease and Psychiatric Disorders

The limitation of gene-centric analysis is particularly evident in rare genetic diseases and complex psychiatric disorders. It is estimated that 15-30% of disease-causing variants disrupt splicing, with the majority falling outside canonical splice sites and thus frequently missed by standard diagnostic workflows [58] [60]. A comprehensive analysis of post-mortem brain samples from individuals with autism spectrum disorder (ASD), schizophrenia, and bipolar disorder revealed striking disparities between analytical approaches [61].

Table 2: Transcriptomic Alterations in Psychiatric Disorders

Analysis Level	ASD	Schizophrenia	Bipolar Disorder	Key Findings
Differential Gene Expression (DGE)	1,611 genes	4,821 genes	1,119 genes	Substantial cross-disorder overlap; moderate effect sizes
Differential Transcript Expression (DTE)	767 isoforms	3,803 isoforms	248 isoforms	Greater disease specificity; larger effect sizes
Isoform-Only DE Genes	294 genes	811 genes	60 genes	Predominantly downregulated; enriched in neuronal functions

Notably, isoform-level changes exhibited significantly larger effect sizes compared to gene-level changes (mean |log2FC| 0.25 vs. 0.14, P<2×10⁻¹⁶), particularly for protein-coding biotypes. These isoform-specific changes showed greater disease specificity and were more reflective of the neuronal and synaptic dysfunction characteristic of each disorder [61].

Endometrial-Specific Splicing Dynamics Across the Menstrual Cycle

In endometrial research, studies have demonstrated that transcript isoform-level and splicing-specific analyses capture dynamic changes across the menstrual cycle that are invisible to gene-level analysis. A comprehensive analysis of 206 endometrial samples revealed that comparing mid-proliferative (MP) to mid-secretory (MS) phases identified significant changes in 11,912 genes at the DGE level, but also detected an additional 865 genes (27.0%) with differential splicing (DS) changes and 576 genes (24.5%) with differential transcript usage (DTU) that showed no significant change at the gene expression level [39].

These splicing-specific changes were particularly pronounced during the transition from the proliferative to secretory phases, suggesting that alternative splicing represents a crucial regulatory mechanism in endometrial transformation. Pathway analysis revealed that genes identified only through isoform-level and splicing analyses were enriched in biologically relevant processes including hormone regulation and cell growth—both critical to endometrial function and preparation for implantation [39].

Methodological Framework: Detecting Splicing Defects in Transcriptomic Data

Experimental Design and RNA Sequencing Considerations

Robust detection of splicing defects requires careful experimental design and appropriate sequencing strategies:

• Sequencing Depth: Deeper sequencing (typically ≥50 million paired-end reads per sample) improves detection of low-abundance isoforms and splicing events
• Read Length: Longer reads (≥100 bp) facilitate more accurate mapping across splice junctions
• Library Preparation: Protocols that preserve strand information (stranded RNA-seq) enhance splice junction detection accuracy
• Replication: Biological replicates (recommended n≥3 per condition) are essential for statistical power in differential splicing analysis
• Sample Quality: RNA integrity number (RIN) ≥7.0 is critical for accurate splicing quantification, as degraded RNA produces biased splicing measurements

These parameters are particularly important when studying endometrial tissues, where RNA quality can vary significantly across cycle phases and patient cohorts [39] [60].

Computational Tools for Splicing Analysis: A Comparative Evaluation

Several computational tools have been developed specifically for detecting alternative splicing events from RNA-seq data. A systematic evaluation using simulated RNA-seq data revealed significant performance differences:

Table 3: Performance Comparison of Splicing Detection Tools

Tool	AUC	Sensitivity	Specificity	Strengths	Limitations
AS-Quant	0.84	0.64	0.98	Excellent for SE, MXE, A3SS events; integrated visualization	Lower performance on A5SS
SUPPA2	0.80	0.44	0.97	Fast, uses transcript quantification	Performance depends on input quantification accuracy
diffSplice	0.74	0.05	0.79	-	Very low sensitivity
rMATS	0.65	0.22	0.49	Good for SE detection	High false positive rate
FRASER	-	-	-	Detects IR events; controls for confounders	Complex implementation

AS-Quant demonstrated particularly strong performance for detecting skipped exon (SE), mutually exclusive exon (MXE), and alternative 3' splice site (A3SS) events, with AUC scores approaching 1.0 in simulation studies. The tool also provides integrated visualization capabilities, enabling researchers to generate short-read coverage plots for specific splicing events [59].

FRASER represents a methodological advance through its ability to capture not only alternative splicing but also intron retention events, which typically doubles the number of detected aberrant events compared to methods focusing solely on alternative splicing. Additionally, FRASER automatically controls for widespread latent confounders (e.g., batch effects, RNA quality) that can substantially affect sensitivity [60].

Diagram 1: Splicing Analysis Workflow. This pipeline outlines the key steps in detecting and validating splicing events from RNA-seq data.

Table 4: Essential Research Reagents for Splicing Analysis

Reagent/Resource	Function	Application Notes
TriZol/RNAstable	RNA preservation and extraction	Maintain RNA integrity; critical for accurate splicing quantification
RiboZero Gold	Ribosomal RNA depletion	Enhances coverage of non-polyadenylated transcripts and novel isoforms
- Strand-specific RNA-seq kits	Library preparation	Preserves strand information for accurate junction mapping
Flux Simulator	In silico RNA-seq simulation	Benchmarking tool for evaluating splicing detection performance
Salmon/kallisto	Pseudoalignment and transcript quantification	Rapid isoform-level quantification from RNA-seq data
Vials Visualization	Visual analysis of alternative splicing	Enables exploratory analysis of isoform abundance across sample groups

These tools and reagents form a comprehensive pipeline for investigating splicing defects, from experimental wet-lab procedures to computational analysis and visualization [59] [60] [62].

Case Studies: Splicing Defects in Endometrial Pathology

Endometriosis and Splicing QTLs

A compelling example of isoform-level dysregulation comes from endometriosis research, where conventional gene expression analysis has consistently failed to identify robust differentially expressed genes between affected and unaffected women. However, when investigators applied transcript-level and splicing-specific analyses to 206 endometrial samples, they identified 18 genes with significant evidence of isoform-level dysregulation associated with endometriosis [39].

Notably, the gene ZNF217—functionally related to hormone regulation and estrogen receptor α-mediated signaling—showed a differentially spliced intron cluster with decreased exon 4 skipping (ΔPSI = -6.4%) in endometriosis patients. This specific splicing alteration would have been completely missed by gene-level analysis, which showed no significant expression differences for ZNF217 between cases and controls [39].

Through integration of genotype data, the study also identified 3,296 splicing quantitative trait loci (sQTLs) in endometrium, with the majority of affected genes (67.5%) not discovered in gene-level eQTL analysis. This splicing-specific genetic regulation highlights the molecular mechanisms potentially linking genetic risk variants to endometriosis pathogenesis [39].

Recurrent Implantation Failure and Splicing Dysregulation

In recurrent implantation failure (RIF), precise molecular regulation of the window of implantation is critical. Single-cell transcriptomic profiling of luteal-phase endometrium has revealed that displaced WOI and dysregulated epithelium in a hyper-inflammatory microenvironment characterize RIF endometria. While traditional analysis focused on gene-level expression, isoform-level alterations in key regulatory genes likely contribute to the functional deficiencies observed in RIF patients [8].

Time-series single-cell analysis across the window of implantation (LH+3 to LH+11) has enabled researchers to delineate the gradual transitional process of luminal epithelial cells and identify a time-varying gene set regulating epithelial receptivity. Subtle alterations in the splicing patterns of these receptivity regulators could fundamentally impact endometrial function without manifesting as bulk gene expression changes [8].

Diagram 2: Splicing Defects in Endometrial Pathogenesis. This pathway illustrates how genetic variants lead to disease through splicing dysregulation.

Implications for Diagnostic and Therapeutic Development

Bridging the Diagnostic Gap

The integration of splicing-level analysis into diagnostic workflows represents a promising avenue for addressing the significant diagnostic gap in rare diseases and complex disorders. Currently, standard clinical variant interpretation focuses predominantly on protein-coding regions and canonical splice sites, overlooking the substantial portion of pathogenic variants that disrupt splicing regulation through more subtle mechanisms [58].

For endometrial disorders specifically, incorporating transcript-level and splicing analyses could significantly improve molecular diagnosis and patient stratification. The discovery that the mid-secretory phase shows the most pronounced endometriosis-specific splicing differences suggests potential biomarkers for this notoriously challenging-to-diagnose condition [39]. Similarly, in recurrent implantation failure, isoform-level signatures could provide more accurate prognostic indicators than conventional histological dating alone.

Therapeutic Opportunities and Splicing-Targeted Interventions

The identification of disease-relevant splicing defects opens several therapeutic avenues:

• Antisense oligonucleotides (ASOs) that modulate splicing patterns by blocking or enhancing specific splice sites
• Small molecules that target specific splicing factors or regulatory complexes
• Gene-specific approaches that correct pathological splicing defects

In endometrial cancer, systematic analysis of alternative splicing patterns has revealed 2,324 splicing events associated with overall survival, with an 11-marker prognostic AS model demonstrating high performance for risk stratification. Splicing network analysis further identified eight candidate splicing factors that could serve as therapeutic targets, highlighting the clinical potential of splicing-focused approaches in gynecological malignancies [63].

For non-malignant endometrial conditions like endometriosis and implantation failure, the identification of master splicing regulators that control networks of functionally coordinated splicing events could reveal entirely new therapeutic targets. This approach is particularly promising given the limited treatment options currently available for these common and debilitating conditions.

The evidence overwhelmingly supports the critical importance of isoform-level analysis for comprehensively understanding disease mechanisms, particularly in dynamic tissues like the proliferative phase endometrium. Splicing defects represent a pervasive yet underappreciated molecular mechanism underlying various pathological states, one that frequently eludes detection by conventional gene-level analysis.

Future research directions should prioritize:

• Development of more sensitive and specific algorithms for detecting subtle splicing alterations
• Creation of comprehensive tissue-specific splicing maps, including detailed characterization of endometrial splicing across the menstrual cycle
• Investigation of the functional consequences of disease-associated splicing variants through genome engineering approaches
• Exploration of splicing-based biomarkers for early detection, diagnosis, and monitoring of endometrial disorders
• Development of splicing-modulating therapeutics targeted to specific gynecological conditions

As sequencing technologies continue to advance and analytical methods become more sophisticated, incorporating isoform-level analysis into standard research practice will undoubtedly yield novel insights into endometrial biology and pathology, ultimately advancing both diagnostic capabilities and therapeutic options for patients with reproductive disorders.

Fibroblast Heterogeneity and Dysfunction in Intrauterine Adhesions (IUA)

The human endometrium exhibits a remarkable capacity for cyclic regeneration and scarless repair, processes that are critically dependent on its stromal fibroblast population. Historically viewed as a homogeneous structural component, fibroblasts are now recognized as highly heterogeneous and dynamic sentinel cells that direct tissue homeostasis, inflammation, and wound healing [64] [65]. Within the context of the proliferative phase endometrium, this heterogeneity enables the precise coordination of regenerative processes necessary for successful reproduction. However, in Intrauterine Adhesions (IUA), also known as Asherman's syndrome, this sophisticated system becomes dysregulated, leading to pathological fibrosis instead of regeneration [66] [67].

The emerging single-cell transcriptomic landscape of the proliferative endometrium has revealed an unexpected complexity in stromal cell populations, with distinct fibroblast subpopulations occupying specific functional niches [31] [68]. When endometrial injury occurs—typically following procedures like dilation and curettage—the normally balanced interplay between these fibroblast subsets is disrupted, initiating a cascade of molecular events that drive excessive extracellular matrix (ECM) deposition and adhesion formation [66] [69]. Understanding the transcriptional programs that govern both normal endometrial regeneration and pathological fibrotic responses in IUA provides crucial insights for developing targeted therapeutic strategies to restore uterine function and fertility.

Single-Cell Transcriptional Landscape of Endometrial Fibroblasts

Identification of Fibroblast Subpopulations in Healthy and IUA Endometrium

Recent advances in single-cell RNA sequencing (scRNA-seq) have revolutionized our understanding of endometrial cellular architecture, particularly the heterogeneity of stromal fibroblasts. A comprehensive scRNA-seq analysis of 55,308 primary human endometrial cells from both healthy controls and IUA patients identified fibroblasts as the most abundant cellular component in endometrial tissues, defined by classic markers including LUM, DCN, COL1A1, COL1A2, and PDGFRA [31]. Unsupervised clustering of these fibroblasts revealed five distinct subclusters with unique gene expression signatures and functional potentials.

Table 1: Fibroblast Subclusters in Human Endometrium

Subcluster	Key Marker Genes	Distribution in IUA vs. Healthy	Potential Functional Specialization
Subcluster 1	IGFBP5, IL17RB, SLC26A7	Significantly reduced in IUA	Regulatory functions
Subcluster 2	WIF1, ZCCHC12, LRRTM1	Significantly reduced in IUA	Wnt modulation, matrix organization
Subcluster 3	FOSB, ZFP36, ATF3	Enriched in IUA	Stress response, pro-fibrotic signaling
Subcluster 4	CLSPN, FAM111B, MCM10	Significantly reduced in IUA	Proliferative capacity
Subcluster 5	ADAMDEC1, PLA2G2A, RPS4Y1	Enriched in IUA	Immune modulation, matrix remodeling

Of particular pathological significance is Subcluster 3, which demonstrates marked enrichment in IUA tissues and exhibits a characteristic gene expression profile featuring immediate early genes such as FOSB, ZFP36, and ATF3 [31]. These genes are associated with cellular stress responses and are rapidly induced following various stimuli, suggesting this subpopulation may represent an activated fibroblast state in the pro-fibrotic endometrial microenvironment.

Pseudotemporal Dynamics and Lineage Relationships

The application of computational trajectory inference tools like Monocle to endometrial fibroblast transcriptomes has enabled the reconstruction of their potential differentiation pathways. Analysis reveals a uniform developmental progression from Subcluster 1 through Subcluster 5, with Subclusters 2 and 3 from healthy endometrium positioned early in the differentiation trajectory [31]. In IUA, this normal differentiation continuum appears disrupted, with aberrant accumulation of cells in pro-fibrotic trajectories and depletion of regenerative subsets. Transcription factor regulatory network analysis through SCENIC has further identified distinct regulon activities across subclusters, with Subcluster 3 exhibiting enrichment of KLF4, KLF10, BHLHE40, and MYC—factors implicated in fibrotic responses across multiple tissues [31].

Molecular Mechanisms of Fibroblast Dysfunction in IUA Pathogenesis

Key Signaling Pathways Driving Fibrotic Transformation

The transition from physiological regeneration to pathological fibrosis in IUA involves the dysregulation of multiple interconnected signaling pathways that drive fibroblast activation and myofibroblast differentiation.

TGF-β/Smad Signaling: The TGF-β pathway serves as a master regulator of IUA pathogenesis [66] [67]. Upon endometrial injury, elevated TGF-β levels activate canonical Smad-dependent signaling and non-canonical pathways, promoting the transdifferentiation of both resident fibroblasts and specialized endometrial mesenchymal stem/stromal cells (eMSCs) into myofibroblasts. These activated cells are characterized by elevated α-smooth muscle actin (α-SMA) expression and excessive production of ECM components, particularly type I collagen [66] [67]. The autocrine perpetuation of TGF-β signaling creates a self-sustaining fibrotic cascade even after the initial injury has resolved.

Hippo/Wnt/TGF-β Cross-Talk: Emerging evidence indicates significant cross-talk between Hippo, Wnt, and TGF-β signaling pathways in IUA pathogenesis [69]. In physiological conditions, the Hippo pathway inhibits the nuclear translocation of transcriptional co-activators TAZ and YAP. Following endometrial injury, this inhibitory mechanism is disrupted, leading to TAZ accumulation and subsequent interaction with both Wnt and TGF-β signaling components. This synergistic interaction drives the expression of pro-fibrotic target genes and further amplifies the fibrotic response [69].

Figure 1: Signaling Pathway Cross-Talk in IUA Pathogenesis. The diagram illustrates how endometrial injury activates multiple interconnected pro-fibrotic signaling pathways that drive disease progression.

Dysregulated Cellular Processes in IUA Fibroblasts

Autophagy Impairment: Autophagy, a conserved intracellular degradation process, is significantly disrupted in IUA fibroblasts [66]. Under normal conditions, autophagy maintains cellular homeostasis by removing damaged organelles and proteins. In IUA, however, autophagic activity is markedly reduced, leading to accumulation of pro-fibrotic mediators and exacerbated ECM deposition. This impairment occurs through multiple mechanisms, including hyperactivation of the PI3K/AKT/mTOR pathway (a potent autophagy inhibitor) and dysregulation of WNT/β-catenin signaling [66]. The loss of DKK1, a WNT inhibitor, further reduces autophagic activity and promotes myofibroblast differentiation [66].

Inflammatory Activation: Persistent inflammation serves as a critical driver of IUA progression [66]. Following endometrial injury, excessive activation of immune cells—particularly macrophages—and sustained release of pro-inflammatory cytokines (TNF-α, IL-6) create a microenvironment that perpetuates fibrotic signaling. In IUA, the normal cyclical inflammation characteristic of endometrial repair is replaced by chronic inflammation that disrupts tissue homeostasis and promotes irreversible fibrosis [66]. This inflammatory milieu further induces specialized forms of cell death such as ferroptosis, which exacerbates tissue damage and sustains fibrosis initiation [66].

Experimental Models and Methodologies for IUA Research

Isolation and Characterization of Human Endometrial Fibroblasts

Tissue Collection and Processing: Endometrial biopsies should be obtained during the proliferative phase (cycle day 7) from both healthy controls and IUA patients, using Pipelle aspirators or during hysteroscopic procedures [31] [68]. Tissues must be immediately processed—washed in phosphate-buffered saline (PBS) and minced into approximately 2mm³ fragments. For single-cell suspension preparation, tissues undergo sequential enzymatic digestion using Dispase II (0.5 U/mL) at 4°C overnight followed by Collagenase III (150 U/mL) with DNAse (139 U/mL) at 37°C for 45 minutes with agitation [68]. The resulting cell suspension is filtered through 70μm strainers, treated with red blood cell lysis buffer, and viability assessed using automated cell counters.

Fibroblast Separation and Culture: For functional subset isolation, the Thy-1 (CD90) surface marker provides a reliable discrimination method [64]. Magnetic bead separation or fluorescence-activated cell sorting (FACS) using anti-Thy-1 antibodies (e.g., clone F15-421-5) enables purification of Thy-1⁺ and Thy-1⁻ fibroblast subsets. Cells are cultured in RPMI 1640 or DMEM-F12 media supplemented with 10% fetal bovine serum (FBS), non-essential amino acids, and gentamicin [64]. Fibroblast identity should be confirmed through positive staining for vimentin and negative staining for cytokeratin (epithelial cells), α-SMA (myofibroblasts/smooth muscle cells), CD34 (endothelial cells), and CD45 (hematopoietic cells) [64].

Figure 2: Experimental Workflow for Endometrial Fibroblast Isolation and Characterization. The diagram outlines key steps from tissue collection through functional analysis.

Functional Characterization of Fibroblast Subsets

Myofibroblast Differentiation Assay: To evaluate the fibrotic potential of endometrial fibroblast subsets, cells are seeded in 24-well plates (2×10⁴ cells/well) and treated with recombinant TGF-β1 (10 ng/mL) for 4 days in low-serum media (DMEM/F12 with 2% FBS) [67]. Myofibroblast differentiation is quantified through immunofluorescence analysis of α-SMA expression and measurement of fluorescence intensity using ImageJ software. This assay is particularly relevant for IUA research as eMSCs from IUA patients demonstrate enhanced myofibroblast differentiation potential compared to those from healthy controls [67].

Cytokine Production Profiling: Fibroblast subpopulations exhibit distinct inflammatory secretomes. After stimulation with IL-1β (10 ng/mL) or IFN-γ (10 ng/mL), cytokine production can be quantified using ELISA or multiplex immunoassays [64]. Thy-1⁺ fibroblasts uniquely produce MCP-1 following IL-1β stimulation and upregulate CD40 surface expression in response to IL-1β or IFN-γ treatment [64]. CD40 engagement further induces IL-6, IL-8, and MCP-1 production specifically in the Thy-1⁺ subset, highlighting their specialized role in inflammatory signaling.

The Scientist's Toolkit: Essential Research Reagents

Table 2: Key Research Reagents for Endometrial Fibroblast Studies

Reagent/Category	Specific Examples	Application/Function
Cell Isolation Enzymes	Collagenase III, Dispase II, DNAse	Tissue dissociation and single-cell suspension preparation
Cell Culture Media	RPMI 1640, DMEM-F12	Fibroblast expansion and maintenance
Supplemental Factors	Fetal Bovine Serum (FBS), Non-essential amino acids, Gentamicin	Culture media supplementation
Fibroblast Markers	Vimentin, COL1A1, DCN, LUM, PDGFRA	Fibroblast identification and validation
Exclusion Markers	Cytokeratin, CD34, CD45, α-SMA	Exclusion of non-fibroblast populations
Subset Separation	Anti-Thy-1 (CD90) antibody	Isolation of fibroblast subpopulations
Activation Stimuli	Recombinant TGF-β1, IL-1β, IFN-γ	Induction of pro-fibrotic and inflammatory responses
Analysis Antibodies	Anti-α-SMA, Anti-CD40	Assessment of activation and differentiation states

Therapeutic Implications and Future Directions

The delineation of fibroblast heterogeneity in IUA opens promising avenues for targeted therapeutic interventions. Current standard treatments like transcervical resection of adhesions (TCRA) provide only anatomical restoration but fail to address the underlying cellular dysfunction, resulting in recurrence rates up to 62.5% [66]. Novel approaches leveraging the molecular understanding of fibroblast biology are urgently needed.

Stem Cell and Exosome-Based Therapies: Mesenchymal stem cell (MSC) transplantation has demonstrated potential in endometrial repair due to multipotent differentiation capabilities and immunomodulatory functions [66] [69]. However, challenges including low post-transplant survival and potential tumorigenic risks have limited clinical application. Exosomes—nanoscale extracellular vesicles—have emerged as a promising cell-free alternative [66]. These vesicles carry bioactive cargo (proteins, miRNAs, lipids) that modulate fibrosis, inflammation, and epithelial-mesenchymal transition without the risks of cell-based therapies. When combined with biomaterial scaffolds like hyaluronic acid hydrogels, exosomes enable sustained local delivery and significantly enhance therapeutic efficacy [66].

Targeting Fibroblast Subsets and Signaling Pathways: The identification of specific pro-fibrotic fibroblast subsets (e.g., Subcluster 3) and their characteristic signaling pathways provides opportunities for precision interventions. Small molecule inhibitors targeting the TGF-β pathway, SHH signaling (e.g., GANT61), or autophagy modulators represent promising pharmaceutical approaches [66] [67]. Additionally, targeting the mechanical properties of the fibrotic niche through biomaterials that reduce tissue stiffness may help reverse myofibroblast activation and promote regenerative responses.

Future research should prioritize the comprehensive mapping of fibroblast lineage relationships in the endometrium and the development of subset-specific targeting strategies. Integration of multi-omics approaches—including single-cell epigenomics and spatial transcriptomics—will further elucidate the molecular networks governing fibroblast heterogeneity in both physiological and pathological states. Such advances will ultimately enable the design of novel therapeutics that specifically modulate dysfunctional fibroblast subpopulations while preserving regenerative capacity, thereby restoring endometrial function and fertility in IUA patients.

The endometrium, the inner lining of the uterus, undergoes dramatic cyclic changes in preparation for embryo implantation. The proliferative phase, governed predominantly by estrogen, is characterized by rapid cellular proliferation and regeneration. A precise molecular orchestration defines this phase, and its transcriptional landscape sets the stage for the subsequent window of implantation (WOI). Disruptions in this intricate transcriptional program can lead to a spectrum of reproductive disorders, including repeated implantation failure (RIF), endometriosis, recurrent miscarriage (RM), and adenomyosis, ultimately contributing to infertility [9] [70] [71]. The identification and validation of transcriptomic biomarkers from this landscape are therefore paramount for developing diagnostic tools that can objectively assess endometrial health and receptivity, paving the way for personalized therapeutic interventions in assisted reproduction.

Key Transcriptomic Biomarkers in Endometrial Disorders

Advanced transcriptomic technologies, including bulk RNA sequencing (RNA-seq), single-cell RNA sequencing (scRNA-seq), and spatial transcriptomics (ST), have revolutionized the identification of diagnostic biomarkers. These biomarkers can be categorized into differentially expressed genes (DEGs), gene signatures representative of specific biological processes, and cellular composition changes.

Table 1: Key Transcriptomic Biomarkers and Their Diagnostic Associations

Disorder	Identified Biomarkers / Signatures	Proposed Diagnostic Utility	Technology Used
Repeated Implantation Failure (RIF)	175-gene signature (rsERT); 7 distinct cellular niches (Niche 1-7) with specific spatial gene expression [72] [9]	Predict Window of Implantation (WOI); Classify endometrial receptivity status for personalized embryo transfer [72]	RNA-seq; 10x Visium Spatial Transcriptomics [9] [72]
Adenomyosis	382 suggestive DEGs; Altered interferon (IFN) signaling pathways (e.g., "Expression of IFN-induced genes") [71]	Identify altered endometrial receptivity; Understand mechanisms of impaired uterine receptivity [71]	RNA-seq [71]
Thin Endometrium (TE)	Upregulation of immune-related genes (CORO1A, GNLY, GZMA); Signatures of leukocyte degranulation and NK cell cytotoxicity [23]	Differentiate TE from normal endometrium based on immune dysregulation; Potential therapeutic targets [23]	Bulk RNA-seq; scRNA-seq integration [23]
Endometriosis & Recurrent Miscarriage	Endothelial-Mesenchymal Transition (EndMT) hub genes (FGF2, ITGB1, VIM, NR4A1, MAPK1, SMAD1) [70]	Uncover shared pathogenic mechanisms; Diagnostic biomarkers for vascular dysfunction and immune dysregulation [70]	Microarray analysis; Integrative bioinformatics [70]

Experimental Protocols for Biomarker Discovery and Validation

The translation of transcriptomic findings into robust diagnostics relies on a series of rigorous and standardized experimental protocols.

Sample Collection and Preparation

Endometrial biopsies are typically collected during a specific phase of the menstrual cycle, often timed using the luteinizing hormone (LH) surge (e.g., LH+7) to target the window of implantation [9] [71]. stringent patient inclusion and exclusion criteria are critical. For example, studies often enroll women aged ≤35-42 years with regular menstrual cycles and without uterine pathologies, endocrine, or autoimmune diseases [9] [71] [23]. Upon collection, tissues are either snap-frozen in liquid nitrogen for RNA extraction or prepared for specialized assays like spatial transcriptomics, which involves rapid freezing in isopentane and cryosectioning [9].

RNA Sequencing and Data Generation

For bulk RNA-seq, total RNA is extracted, and ribosomal RNA is removed to enrich for mRNA. Libraries are constructed from fragmented mRNA and sequenced on platforms such as Illumina NovaSeq 6000 or BGISEQ, generating millions of reads per sample [71] [23]. For spatial transcriptomics using the 10x Visium platform, tissue sections are placed on spatially barcoded spots. After permeabilization, mRNA is captured, reverse-transcribed into cDNA, and sequenced, allowing gene expression data to be mapped back to its original tissue location [9].

Bioinformatics and Data Analysis

• Quality Control and Preprocessing: Raw sequencing data undergo quality checks for metrics like sequencing saturation (>90%), Q30 scores (>90%), and alignment rates (>90% mapped to the genome) [9]. For scRNA-seq data, cells are filtered based on detected gene counts, UMI counts, and mitochondrial gene percentage [9] [23].
• Differential Expression Analysis: Using tools like the Limma R package or Seurat, differentially expressed genes (DEGs) are identified between case and control groups, often with a significance threshold of p < 0.05 [70] [71].
• Functional Enrichment Analysis: DEGs are analyzed with tools like clusterProfiler to identify overrepresented Gene Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, providing biological context [70] [71].
• Data Integration: Bulk RNA-seq data can be deconvoluted using scRNA-seq reference datasets with computational tools like CARD to infer changes in cellular composition [9]. This helps determine if gene expression changes are due to shifts in cell type abundance or intrinsic changes within specific cell populations.

The following diagram illustrates the core computational workflow for biomarker identification from raw sequencing data.

Pathway Analysis and Functional Insights

Functional enrichment analysis of identified biomarkers reveals the underlying biological processes disturbed in endometrial disorders. Key pathways frequently implicated include:

• Immune and Inflammatory Responses: Studies on Thin Endometrium show significant enrichment in processes like "leukocyte degranulation" and "natural killer (NK) cell-mediated cytotoxicity," highlighting a role for immune dysregulation [23].
• Interferon Signaling: In adenomyosis, "Expression of IFN-induced genes" is a prominently altered pathway, suggesting a crucial role for interferon signaling in the pathology of impaired uterine receptivity [71].
• Vascular Remodeling and Endothelial-Mesenchymal Transition (EndMT): Integrative analysis of endometriosis and recurrent miscarriage has identified shared dysregulation in EndMT, a process critical for vascular remodeling and immune regulation, with hub genes like FGF2 and MAPK1 [70].
• Extracellular Matrix Organization: This pathway has been identified as a key player in adenomyosis, potentially affecting the tissue architecture necessary for embryo implantation [71].

Table 2: Key Research Reagents and Platforms for Endometrial Transcriptomics

Reagent / Platform	Specific Example / Vendor	Function in Research
Spatial Transcriptomics Platform	10x Visium Spatial Tissue Optimization Slide [9]	Captures genome-wide mRNA expression data while retaining spatial location information within a tissue section.
RNA Isolation Reagent	RNA-easy isolation reagent (Vazyme) [23]	Extracts high-quality total RNA from endometrial tissue samples for downstream sequencing.
Sequencing Platform	Illumina NovaSeq 6000 [9] [71]	High-throughput sequencing platform for generating bulk or spatial RNA-seq data.
Bioinformatics Software	Seurat R package (v4.3.0.1) [9]	A comprehensive toolkit for single-cell and spatial transcriptomics data analysis, including QC, clustering, and DEG analysis.
Data Deconvolution Tool	CARD package (v1.1) [9]	Deconvolutes spatial transcriptomics data to estimate cell type proportions in each spot using a reference scRNA-seq dataset.
Functional Analysis Tool	clusterProfiler R package (v4.10.0) [70]	Performs functional enrichment analysis (GO, KEGG) to interpret the biological meaning of gene lists.

Validation and Clinical Translation

The journey from a transcriptomic finding to a clinically validated diagnostic test requires meticulous validation and the development of a robust, often simplified, assay format.

Analytical and Clinical Validation

Candidate biomarkers identified from discovery-phase RNA-seq are typically validated using independent techniques such as quantitative PCR (qPCR) on a separate cohort of patient samples [23]. For a test to be clinically applicable, its analytical performance—including accuracy, reproducibility, and reliability—must be demonstrated. For instance, the RNA-Seq-based Endometrial Receptivity Test (rsERT) reported an average accuracy of 98.4% using tenfold cross-validation [72].

Development of Diagnostic Assays

The final clinical diagnostic tool often involves translating a complex gene signature into a manageable panel. The rsERT, for example, was refined from a broader transcriptomic analysis into a panel of 175 biomarker genes [72]. Similarly, other tests like the Endometrial Receptivity Array (ERA) utilize microarray technology to assess a fixed gene set [72]. The ultimate goal is to create a classifier that can accurately assign an endometrial sample to a specific diagnostic category, such as "receptive" or "non-receptive."

Assessing Clinical Utility

The most critical step is demonstrating that the use of the diagnostic test improves patient outcomes. This is often evaluated through prospective, though not always randomized, controlled trials. In the case of RIF, a study showed that personalized embryo transfer (pET) guided by the rsERT resulted in a significantly higher intrauterine pregnancy rate (50.0%) compared to conventional transfer (23.7%) when transferring day-3 embryos [72]. The following diagram outlines the key stages in this translational pipeline.

The transcriptional landscape of the proliferative phase endometrium provides a foundational blueprint for endometrial function. The integration of advanced transcriptomic technologies and bioinformatic analyses has dramatically accelerated the discovery of diagnostic biomarkers for a range of endometrial disorders. By following rigorous experimental and validation protocols, these transcriptomic findings are being successfully translated into clinical diagnostics that offer objective assessment and personalized treatment strategies, ultimately improving outcomes for patients facing infertility. Future efforts will focus on refining these biomarkers, reducing the cost and complexity of testing, and further demonstrating their value in large-scale randomized controlled trials.

Validating Discoveries and Placing the Proliferative Phase in a Broader Biological Context

The human endometrium is a complex, dynamic tissue that lines the uterine cavity and undergoes dramatic cyclical changes in structure and function during each menstrual cycle. This tissue consists of multiple cell types, including luminal and glandular epithelial cells, endometrial stromal cells, vascular cells, and immune cells [73] [2]. The endometrium is unique in its capacity for monthly regeneration, generating up to 10mm of new mucosa with each cycle [73] [2]. During the proliferative phase, the endometrium undergoes rapid cellular proliferation and tissue regeneration under the influence of estrogen, preparing the tissue for potential embryo implantation [73]. Understanding the genetic regulation of transcription in this phase provides critical insights into endometrial function, fertility, and the pathogenesis of reproductive disorders.

Gene expression in the endometrium is dominated by events across the menstrual cycle and is influenced by hormonal regulation, changing cellular composition, and genetic variation between individuals [73] [2]. The proliferative phase specifically is characterized by healing and cell proliferation [73], with upregulated genes having roles related to cell proliferation, differentiation, tissue remodelling, immunomodulation, and angiogenesis [73]. Recent evidence demonstrates that expression of many genes is influenced by genetic variation between individuals, with genetic factors accounting for a substantial portion of transcriptional variation in endometrial tissue [73] [74] [2].

Fundamental Concepts of eQTLs in Endometrial Biology

Definition and Classification of eQTLs

Expression Quantitative Trait Loci (eQTLs) are specific regions of the genome containing genetic variants that influence the expression levels of mRNA transcripts. These regulatory elements can function through various mechanisms including altering promoters, transcription factor binding sites, enhancers, regulatory ncRNAs, RNA splicing, and UTRs (important for post-translational regulation) [73] [2]. eQTLs are classified based on their genomic position relative to their target genes:

• cis-eQTLs: Genetic variants located nearby the gene they regulate, typically within 1 Mb of the gene's transcription start site [73] [74].
• trans-eQTLs: Genetic variants that regulate distant genes, often on different chromosomes, frequently through intermediary mechanisms [74] [75].

The standard analytical approach for eQTL mapping involves testing for associations between genetic variants and expression levels of mRNA transcripts, with significance thresholds adjusted for multiple testing [74].

Technical Considerations for Endometrial eQTL Studies

Endometrial eQTL studies present unique methodological challenges due to the tissue's dynamic nature and cellular complexity. The menstrual cycle involves continuous cellular proliferation, differentiation, and structural remodelling in response to circulating steroid hormones [73] [2]. These changes in cellular function and composition reflect the changing roles of this dynamic tissue and introduce substantial technical variability that must be accounted for in experimental design.

Key considerations include:

• Sample timing: Precise histological dating of endometrial samples to specific menstrual cycle phases [74] [75]
• Cellular heterogeneity: The endometrium consists of multiple cell types with distinct transcriptional profiles [73]
• Hormonal influences: Fluctuating levels of estrogen and progesterone dramatically affect gene expression [73] [2]
• Genetic ancestry: Population-specific genetic effects require careful consideration of ancestry in study design [74]

Quantitative Landscape of Endometrial eQTLs

Table 1: Summary of Key Endometrial eQTL Studies

Study	Sample Size	Technology	cis-eQTLs	trans-eQTLs	Novel Findings
Fung et al. (2017) [76]	123 women	Microarray (Illumina Human HT-12 v4.0)	18,595 associations (198 unique genes)	Not reported	First demonstration of strong genetic effects on endometrial gene expression; cycle stage-specific eQTLs
Mortlock et al. (2020) [74]	206 women	RNA-sequencing	444 sentinel cis-eQTLs	30 trans-eQTLs	327 novel cis-eQTLs; 85% shared with other tissues
Powell et al. (2018) [75]	229 women	Microarray	45,923 cis-eQTLs (417 unique genes)	2,968 trans-eQTLs (82 unique genes)	eQTLs in endometriosis risk regions; dynamic expression changes across cycle

Table 2: Tissue Specificity of Endometrial eQTLs

Tissue Comparison	eQTL Sharing	Biological Implications
Reproductive tissues (uterus, ovary)	High correlation	Shared genetic regulation of gene expression in biologically similar tissues [74]
Digestive tissues (salivary gland, stomach)	High correlation	Unexpected shared regulation with endodermal-derived tissues [74]
Blood/immune tissues	Moderate correlation	Highlights importance of tissue-specific studies for reproductive traits [74]
Endometrium-specific eQTLs	~15% of all eQTLs	Potential key regulators of endometrial-specific biology and pathology [74]

Methodological Framework for Endometrial eQTL Mapping

Sample Collection and Preparation

The foundational step in endometrial eQTL studies involves careful patient recruitment and sample collection. In representative studies, women of European ancestry and reproductive age were recruited from clinical settings [74]. Endometrial tissue samples are typically obtained by curettage during investigative laparoscopic surgery [74]. Critical methodological considerations include:

• Histological assessment: An experienced pathologist categorizes samples into specific menstrual cycle stages (menstrual, early-proliferative, mid-proliferative, late-proliferative, early-secretory, mid-secretory, late-secretory) based on standardized criteria [74] [75].
• Exclusion criteria: Samples from women with hormonal treatment, abnormal histopathology, or ambiguous disease status are typically excluded [74].
• Sample preservation: Fresh tissue is stored in RNAlater at -80°C for subsequent RNA extraction to preserve RNA integrity [74].
• Blood collection: Whole blood samples are collected for DNA isolation and genotyping [74].

Genotyping and RNA Sequencing

Modern eQTL studies employ high-throughput technologies for both genotyping and transcriptome characterization:

• Genotyping: DNA samples are genotyped using platforms such as Illumina HumanCoreExome chips, followed by imputation to increase variant density using reference panels [74] [76].
• RNA sequencing: Total RNA is extracted from endometrial tissues and sequenced using RNA-seq technologies, which provides a broader dynamic range than microarray platforms [74]. The transition from microarrays to RNA-seq has enabled detection of approximately 30% more genes [74].
• Quality control: Rigorous QC measures include assessment of RNA integrity, alignment rates, and batch effects [74] [75].

Statistical Analysis and eQTL Mapping

The core analytical workflow for eQTL discovery involves:

• Expression quantification: Generation of normalized expression values (e.g., TPM, FPKM) for each gene [77].
• Covariate adjustment: Inclusion of technical covariates (batch effects, RNA quality) and biological covariates (menstrual cycle stage, cellular composition) to account for confounding factors [74] [75].
• Association testing: Performing linear regression between each genetic variant and expression value, typically using a linear model framework that accounts for population structure [74].
• Multiple testing correction: Applying false discovery rate (FDR) controls to account for the millions of tests performed, with study-wide significance thresholds typically ranging from P < 1×10⁻⁷ to P < 2.57×10⁻⁹ for cis-eQTLs [74] [76].

Figure 1: Endometrial eQTL Mapping Workflow

Signaling Pathways in Endometrial Gene Regulation

The endometrium is regulated by complex signaling pathways that respond to hormonal cues and genetic variation. Key pathways identified through eQTL studies include:

Hormone Response Pathways

The estrogen and progesterone signaling pathways dominate endometrial regulation during the proliferative phase [73] [2]. These pathways involve:

• Estrogen receptor (ESR1): Regulates endometrial epithelial proliferation, promotes stromal cell differentiation, and is critical for endometrial receptivity through induction of cytokines, IGF1 signaling, Wnt/β-catenin signaling, FGF signaling, ERK-MAPK signaling and PGR signaling [73] [2].
• Progesterone receptor (PGR): Plays an important role regulating cell differentiation and proliferation through extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK) and Protein Kinase B (AKT) pathways, with target genes (e.g., IHH, HOXA10, IGFBP1, STAT3, FOXO1, SOX17) required for successful implantation and decidualization [73] [2].

Proliferation and Differentiation Pathways

During the proliferative phase, several critical pathways drive endometrial growth and remodeling:

• ERK/MAPK signaling: Mediates cellular responses to growth factors and hormones [73] [2].
• Wnt/β-catenin signaling: Involved in tissue patterning and cell fate determination [73] [2].
• Epithelial-Mesenchymal Transition (EMT): Pathway enrichment analysis has identified EMT as a significantly enriched pathway for genes with variable expression across the menstrual cycle [75].

Figure 2: Key Signaling Pathways in Proliferative Endometrium

Research Reagents and Experimental Tools

Table 3: Essential Research Reagents for Endometrial eQTL Studies

Reagent/Tool	Specifications	Application	Key Considerations
RNA Stabilization	RNAlater (Life Technologies)	Tissue preservation for RNA integrity	Critical for surgical samples; immediate immersion recommended
Genotyping Array	Illumina HumanCoreExome	Genome-wide variant detection	Provides coverage of common and exonic variants; requires imputation
RNA Sequencing	Total RNA-seq, paired-end	Transcriptome quantification	Preferred over microarrays for dynamic range and novel transcript detection
Histological Staining	Hematoxylin and Eosin	Menstrual cycle dating	Gold standard for cycle phase determination by pathologist
eQTL Mapping Software	FastQTL, Matrix eQTL	Association testing	Efficient for large-scale genotype-expression correlation analyses
Functional Annotation	FUMA, VEP	Functional characterization of identified eQTLs	Determines regulatory potential and tissue specificity

Integration with Disease Mechanisms and Therapeutic Applications

Endometrial eQTL studies have provided crucial insights into the pathogenesis of reproductive disorders by connecting genetic risk variants with their functional target genes:

Endometriosis

eQTL analyses have identified potential target genes for endometriosis risk loci [74] [78] [79]. Key findings include:

• Tissue-enriched heritability: Genes surrounding endometriosis risk loci show significant enrichment in reproductive tissues [74].
• Candidate genes: Transcriptome-wide association studies indicate that gene expression at 39 loci is associated with endometriosis, including five known endometriosis risk loci [74].
• Multi-tissue regulation: Endometriosis-associated variants function as eQTLs across multiple relevant tissues including uterus, ovary, vagina, and gastrointestinal tissues [78] [79].

Endometrial Cancer

Large-scale eQTL studies have identified susceptibility loci for endometrial carcinoma with functional implications:

• Risk loci: Recent GWAS meta-analyses identified five additional risk loci (3p25.2, 3q25.2, 6q22.31, 12q21.2, and 17q24.2) for endometrial cancer [80].
• Tumor suppressors: Gene-based analyses supported findings for NAV3 (12q21.2) as a tumor suppressor in endometrial cells, where downregulation accelerated cell division and wound healing capacity [80].
• Prognostic models: Integration of eQTL data with Mendelian randomization has enabled development of prognostic models for endometrial carcinoma with potential clinical utility [81].

Reproductive Failure

Implantation failure and infertility have been linked to endometrial gene regulation through:

• Receptivity-associated genes (RAGs): Genes with consistent patterns of differential expression during the receptive phase have been classified as RAGs and play roles in structural and functional modifications required for successful embryo implantation [73] [2].
• Diagnostic tools: The endometrial receptivity array (ERA) utilizes transcriptomic signatures to diagnose receptivity in women with recurrent implantation failure [73] [2].

The integration of eQTL data with functional genomic approaches continues to advance our understanding of endometrial biology and pathology, providing insights for developing targeted therapeutic interventions for reproductive disorders.

Splicing quantitative trait loci (sQTLs) represent a critical class of genetic variants that influence alternative splicing, a fundamental process in eukaryotic mRNA biogenesis that enables a single gene to produce multiple protein isoforms with distinct functions [82]. In the context of endometrial research, understanding sQTLs provides crucial insights into the molecular mechanisms underlying endometrial tissue dynamics and pathological conditions such as endometriosis. The endometrium undergoes extensive cyclical remodeling throughout the menstrual cycle, with the proliferative phase representing a period of rapid tissue growth and regeneration in response to estrogen stimulation [1]. Recent transcriptomic analyses have revealed that the proliferative phase, particularly the late proliferative (peri-ovulatory) period, demonstrates significant transcriptomic and functional changes that may critically impact the achievement of subsequent mid-secretory endometrial receptivity [1]. Investigating genetic variants that regulate splicing patterns specifically during this phase offers unprecedented opportunities to understand how constitutive genetic differences influence endometrial biology and contribute to disease pathogenesis.

Fundamental Concepts of Splicing QTLs

Definition and Biological Significance

Splicing QTLs are genetic variants that correlate with variations in alternative splicing patterns across individuals in a population. These variants typically reside in regulatory regions that influence splice site selection, including splice sites themselves, branch points, polypyrimidine tracts, and enhancer or silencer elements recognized by RNA-binding proteins [82]. Unlike expression QTLs (eQTLs) that affect overall gene expression levels, sQTLs specifically alter the relative abundances of different transcript isoforms from the same gene, potentially changing protein function without necessarily affecting total mRNA output [82]. This regulatory layer is particularly important in tissues with dynamic functional requirements like the endometrium, where rapid tissue remodeling necessitates precise control of isoform expression.

Methodological Approaches for sQTL Mapping

sQTL mapping leverages RNA sequencing data from multiple individuals with corresponding genotype information to identify statistical associations between genetic variants and splicing patterns. The sQTLseekeR2 pipeline represents an advanced methodological approach that treats splicing as a multivariate phenotype, testing associations between genetic variants and vectors of AS phenotypes such as transcript isoform relative abundances or intron excision ratios [82]. This multivariate approach accounts for the strongly correlated structure of AS measurements, where at constant gene expression levels, increased abundance of one isoform necessarily corresponds to decreased abundance of others. The method employs the Hellinger distance to estimate variability in isoform abundances across observations and Anderson's non-parametric method to assess association significance [82]. For enhanced reproducibility and efficiency, this statistical framework can be embedded in computational workflows such as sqtlseeker2-nf, which enables portable, highly parallel sQTL mapping through containerization technologies [82].

Table 1: Key Software Tools for sQTL Analysis

Tool Name	Primary Function	Input Requirements	Output Visualizations
sQTLseekeR2	Multivariate sQTL mapping	RNA-seq data, genotype information, transcript annotations	Statistical associations, effect sizes
LeafCutter	Intron excision quantification	RNA-seq BAM files	Splicing clusters, junction counts
SplicePlot	sQTL visualization	BAM files, VCF genotypes, GTF annotations	Hive plots, structure plots, Sashimi plots

Endometrial Splicing Dynamics Across the Menstrual Cycle

Transcriptomic Landscape of the Proliferative Phase

Comprehensive transcriptome analysis of the endometrium across the entire menstrual cycle has revealed pronounced phase-specific gene expression patterns, with the late proliferative phase representing an essential transition point from proliferative to secretory phase [1]. Temporal transcriptome analysis encompassing five time points (mid-proliferative, late proliferative, early secretory, mid-secretory, and late secretory phases) has identified 5,082 significantly differentially expressed genes (DEGs) across the menstrual cycle [1]. The late proliferative phase demonstrates particularly significant transcriptomic and functional changes that prepare the endometrium for the potential implantation of a fertilized egg. As an example of coordinated gene activity, histone-encoding genes within the HIST cluster on chromosome 6 show increased activity during the late proliferative phase followed by decline during the mid-secretory phase [1]. These findings establish the proliferative phase as a critical period in endometrial maturation rather than merely a period of estrogen-driven growth.

Splicing-Specific Regulation in Endometrial Tissue

A recent large-scale study of endometrial transcriptomics (n=206) has identified substantial RNA splicing and transcript isoform-level changes across the menstrual cycle and in endometriosis that were not apparent in conventional gene-level analyses [4]. These transcriptomic differences were most pronounced in the mid-secretory (receptive) phase in endometriosis samples, suggesting that aberrant splicing regulation during the window of implantation may contribute to endometrial dysfunction in this condition [4]. By integrating genotype data, researchers demonstrated evidence of cis-genetic effects on splicing in endometrium, identifying 3,296 splicing quantitative trait loci (sQTLs) [4]. Notably, the majority of genes with sQTLs (67.5%) were not discovered in gene-level eQTL analysis, highlighting the specificity and additional regulatory information captured by splicing-focused approaches [4].

Table 2: Endometrial Splicing Changes Across Menstrual Cycle Phases

Menstrual Cycle Phase	Key Splicing Characteristics	Associated Genetic Factors	Relevance to Endometriosis
Mid-Proliferative (MP)	Baseline splicing patterns	Constitutional sQTLs	Potential predisposition markers
Late Proliferative (LP)	Transition-associated splicing	Cell cycle-related sQTLs	May influence tissue remodeling capacity
Early Secretory (ES)	Differentiation-initiated splicing	Hormone-responsive sQTLs	Potential early dysfunction indicators
Mid-Secretory (MS)	Receptivity-associated splicing	Implantation-related sQTLs	Strongest association with endometriosis
Late Secretory (LS)	Regression-associated splicing	Apoptosis-related sQTLs	Limited research to date

Integration of sQTLs with Endometriosis Genetics

Genetic Regulation of Splicing in Endometriosis Pathogenesis

The integration of sQTL mapping with endometriosis genome-wide association study (GWAS) data has enabled the identification of specific genes through which genetic risk variants potentially mediate disease susceptibility via splicing alterations. A landmark study analyzing endometrial tissue identified two genes—GREB1 and WASHC3—that were significantly associated with endometriosis risk through genetically regulated splicing events [4]. GREB1 (Growth Regulating Estrogen Receptor Binding 1) is an estrogen-regulated gene involved in hormone-responsive tissue growth, while WASHC3 functions in the WASH complex regulating endosomal trafficking. The discovery that endometriosis-associated genetic variants affect the splicing patterns of these genes provides mechanistic insight into how non-coding risk variants may influence protein function and contribute to disease pathogenesis through isoform-specific effects.

Tissue-Specific Regulatory Patterns

The regulatory impact of endometriosis-associated genetic variants demonstrates considerable tissue specificity, as revealed by integrative analyses combining GWAS data with expression QTL information from multiple relevant tissues [83]. Comparing eQTL effects across six physiologically relevant tissues (peripheral blood, sigmoid colon, ileum, ovary, uterus, and vagina) has shown distinct regulatory profiles: immune and epithelial signaling genes predominate in colon, ileum, and peripheral blood, while reproductive tissues show enrichment for genes involved in hormonal response, tissue remodeling, and adhesion [83]. This tissue-specific pattern suggests that endometriosis risk variants may exert their effects through different molecular pathways depending on the tissue context, with splicing alterations in reproductive tissues potentially affecting processes more directly related to endometrial function and implantation.

Experimental Framework for Endometrial sQTL Studies

Core Methodological Workflow

sQTL Analysis Workflow: From Sample to Validation

Key Research Reagents and Experimental Materials

Table 3: Essential Research Reagents for Endometrial sQTL Studies

Reagent/Resource	Specification	Experimental Function
Endometrial Biopsies	Precisely timed to menstrual phase (MP, LP, ES, MS, LS)	Provides tissue-specific RNA source for splicing analysis
RNA Stabilization Reagents	RNAlater or similar	Preserves RNA integrity during sample processing
RNA Sequencing Kits	Poly-A selection or rRNA depletion	Library preparation for transcriptome sequencing
Genotyping Arrays	Illumina Global Screening Array or similar	Genome-wide variant identification
sQTL Mapping Software	sQTLseekeR2, LeafCutter	Statistical identification of splicing-associated variants
Visualization Tools	SplicePlot	Generation of hive plots, structure plots, Sashimi plots

Detailed sQTL Mapping Protocol

The sQTL mapping process begins with quality-controlled RNA sequencing data from endometrial samples precisely timed to menstrual cycle phase. Isoform-level quantification is performed using tools such as Salmon or kallisto, which estimate transcript abundances from RNA-seq data. For sQTLseekeR2 analysis, the input consists of a matrix of transcript relative abundances, where the abundance of each transcript is expressed as a proportion of the total expression of its parent gene [82]. Genotype data are typically filtered to include variants with minor allele frequency >5% within a cis-window defined as the gene body plus 5kb upstream and downstream of transcriptional start and end sites. The core statistical test in sQTLseekeR2 employs a multivariate approach that calculates the Hellinger distance between the vectors of relative isoform abundances across genotype groups, followed by Anderson's permutation-based method to assess significance [82]. Multiple testing correction is performed using an empirical approach that characterizes the distribution of p-values expected under the null hypothesis for each gene. The output includes sQTL-gene pairs with associated p-values and effect sizes, with the effect size (MD) representing the absolute maximum difference in adjusted transcript relative expression between genotype groups [82].

Visualization and Interpretation of sQTL Results

Advanced Visualization Techniques

Effective visualization of sQTL effects requires specialized tools that can represent genotype-dependent splicing patterns across multiple individuals. SplicePlot is a dedicated utility that generates three primary visualization types: hive plots, structure plots, and modified Sashimi plots [84]. Hive plots use a radial layout where each axis represents a splice junction with fixed donor or acceptor sites, individuals are represented by curved paths color-coded by genotype, and radial distances correspond to splicing ratios [84]. Structure plots display stacked bars for each individual, with bar height representing splicing ratios and color indicating specific junctions, while individuals are grouped by genotype to facilitate comparison [84]. Modified Sashimi plots extend the conventional Sashimi plot to compare average read depth and junction-spanning reads across genotype groups, illustrating how sQTLs affect both splicing patterns and transcript abundance [84].

sQTL Mechanism to Disease Risk Pathway

Functional Interpretation of Endometrial sQTLs

The biological interpretation of endometrial sQTLs involves multiple analytical steps to prioritize functionally relevant variants and understand their mechanistic consequences. Integration with epigenetic annotations such as histone modification marks and DNase I hypersensitivity sites can help determine whether sQTL variants reside in regulatory regions. For coding genes affected by sQTLs, protein domain analysis determines whether alternative splicing affects functional protein regions, potentially altering protein function or interaction networks. Pathway enrichment analysis of genes with strong sQTL effects in endometrial tissue has revealed overrepresentation of genes involved in RNA processing, cellular transport, immune response, and mitochondrial functions [82]. Interestingly, this suggests possible splicing autoregulation mechanisms, whereas genes without detectable sQTLs tend to be enriched in developmental and signaling functions [82]. For endometriosis-specific investigations, integration with GWAS signals through colocalization analysis determines whether the same underlying genetic variant influences both splicing and disease risk, providing evidence for potential causal mechanisms.

Implications for Diagnostic and Therapeutic Development

The identification of endometriosis-associated sQTLs opens promising avenues for diagnostic and therapeutic innovation. From a diagnostic perspective, sQTL profiles could potentially stratify endometriosis risk or identify molecular subtypes with distinct clinical presentations and treatment responses. The discovery that specific sQTLs operate in a menstrual cycle phase-dependent manner suggests that diagnostic approaches may need to account for temporal regulation of splicing events [4] [1]. Therapeutically, genes identified through sQTL analyses represent novel targets for precision medicine approaches in endometriosis. Particularly promising are cases where sQTLs affect genes encoding druggable proteins or where the splicing itself could be targeted using antisense oligonucleotides or small molecule splicing modulators. The tissue-specific nature of many sQTL effects [83] offers the potential for developing treatments with reduced off-target effects, while the identification of core sQTLs shared across tissues [82] might enable broader therapeutic interventions. As our understanding of endometrial splicing regulation advances, these genetic insights may transform the management of endometriosis and other endometrial disorders through more personalized and mechanism-based approaches.

The human endometrium undergoes profound, cyclic remodeling to support embryo implantation and pregnancy. This process is governed by tightly regulated transcriptomic programs activated in response to ovarian hormones. The proliferative phase, driven by estrogen, focuses on tissue regeneration and growth, while the secretory phase, under the influence of progesterone, enables endometrial receptivity and preparation for implantation [1]. Understanding the distinct and transitional molecular landscapes of these phases is crucial for elucidating the mechanisms behind endometrial-factor infertility and developing targeted therapeutic interventions. This review synthesizes recent transcriptomic studies to provide a comparative analysis of the proliferative and secretory phase molecular programs, framing them within the broader context of endometrial tissue dynamics and their implications for reproductive health.

Transcriptomic Landscapes Across the Menstrual Cycle

Phase-Specific Gene Expression Profiles

Advanced transcriptomic analyses, including RNA-exome sequencing and single-cell RNA sequencing (scRNA-seq), have delineated the dynamic gene expression patterns that characterize the endometrial cycle. A study centered on the proliferative phase examined five precise time points: mid-proliferative (MP), late proliferative (LP) or peri-ovulatory, early secretory (ES), mid-secretory (MS), and late secretory (LS) phases [1]. This design enabled a detailed view of the transitions, particularly highlighting the LP phase as a critical transition point.

The study identified 5,082 differentially expressed genes (DEGs) across the cycle compared to the MP reference point [1]. Most of these DEGs are phase-specific, underscoring the unique functional demands of each stage. For instance, the late proliferative phase exhibits significant upregulation of genes involved in cell cycle regulation and histone synthesis, such as those within the HIST cluster on chromosome 6 [1] [85]. In contrast, the mid-secretory phase, which encompasses the window of implantation (WOI), shows a distinct signature geared toward receptivity, immune modulation, and embryo support.

Table 1: Key Differentially Expressed Genes (DEGs) Across Menstrual Cycle Phases

Gene Name	Phase Comparison	Log2 Fold Change	Function / Note
CYP26A1	MS vs. MP	8.42	Retinoic acid metabolism, implicated in receptivity [1]
MT1H	MS vs. MP	8.13	Metallothionein, potential role in immune modulation [1]
PLA2G4F	MS vs. MP	8.06	Phospholipase, involved in lipid signaling [1]
IGFN1	MS vs. MP	-7.35	Cell adhesion, significantly downregulated [1]
HIST genes	LP vs. MP	Increased	Coordinated upregulation of histone cluster activity [1]
RNA5-8SN3	LP vs. MP	7.61	Example of upregulated non-coding RNA in LP [1]

Functional Enrichment and Biological Pathways

Gene Ontology (GO) and hallmark pathway enrichment analyses of the phase-specific DEGs reveal the shifting biological priorities of the endometrium.

• Proliferative Phase: The MP and LP phases are characterized by enrichments in pathways related to cell proliferation, DNA replication, and chromatin organization. The high activity of histone-encoding genes supports the rapid cellular division and tissue growth required post-menstruation [1].
• Secretory Phase: The transition into the ES and MS phases shows a marked shift towards pathways governing response to steroids, lipid metabolism, immune response, and extracellular matrix organization [1] [8]. The MS phase, in particular, is defined by the establishment of a receptive environment, which includes the process of decidualization and the fine-tuning of immune cell populations to accept the semi-allogeneic embryo.

Single-Cell Resolution of Endometrial Dynamics

Single-cell transcriptomics has revolutionized our understanding by uncovering the cell-type-specific contributions to the phase transitions, moving beyond the limitations of bulk tissue analysis.

Cellular Heterogeneity and Subpopulation Dynamics

scRNA-seq of human endometrium has identified at least eight major cell types: unciliated epithelial, ciliated epithelial, stromal, endothelial, natural killer (NK)/T cells, myeloid cells, B cells, and mast cells [8]. Further clustering within these types reveals extensive heterogeneity, with distinct subpopulations emerging across the cycle.

• Epithelial Cells: Subpopulations include luminal, glandular, secretory, and proliferative cells. A key finding is that luminal epithelial cells exhibit high differentiation potential and can give rise to glandular cells, a process visualized through RNA velocity trajectory analysis [8].
• Stromal Cells: The decidualization process in the secretory phase is not monolithic. Time-series scRNA-seq has uncovered a two-stage decidualization process in stromal cells, indicating a more complex and graduated maturation than previously appreciated [8].
• Immune Cells: Uterine Dendritic Cells (uDCs) have been mapped into seven subtypes, including a newly identified tissue-resident progenitor DC population that gives rise to implantation-relevant DCs. These subtypes play stage-specific roles in antigen presentation and immune tolerance during the WOI [13].

Temporal Dynamics Across the Window of Implantation (WOI)

High-resolution temporal mapping from LH+3 to LH+11 has delineated the precise transcriptomic shifts that define the WOI. This involves a gradual transition of luminal epithelial cells and the coordinated two-stage decidualization of stromal cells [8]. A time-varying gene set regulating epithelial receptivity has been identified, providing a more dynamic model of how the endometrium prepares for embryo attachment.

Figure 1: Transcriptomic and Cellular Dynamics Across the Endometrial Cycle. The diagram illustrates the key phase transitions, dominant biological processes, and cell-specific differentiation pathways from the proliferative to the secretory phase.

Dysregulation in Pathological States

Aberrations in the carefully orchestrated transcriptomic programs of the proliferative and secretory phases are linked to reproductive disorders and implantation failure.

Recurrent Implantation Failure (RIF)

In RIF, the endometrium displays significant molecular deficiencies. Studies have identified:

• Displaced WOI: A proportion of RIF patients exhibit a temporally displaced window of implantation, meaning the receptive transcriptomic signature occurs outside the expected timeframe [8].
• Epithelial Dysfunction: RIF endometria can be stratified into classes based on deficiencies in the time-varying epithelial receptivity gene set [8].
• Hyper-inflammatory Microenvironment: A prominent feature in RIF is a dysfunctional, hyper-inflammatory state in endometrial epithelial cells, which is likely hostile to embryo implantation [8].
• Spatial Alterations: Spatial transcriptomics of RIF versus control endometria in the mid-luteal phase has identified seven distinct cellular niches with altered compositions and gene expression, particularly affecting epithelial domains [9].

Endometriosis

A meta-analysis of transcriptome data from 125 women revealed that the eutopic endometrium of women with endometriosis has a subtly different gene expression profile during the mid-secretory phase compared to controls [86]. While no single molecule was drastically altered after stringent correction, pathway analysis detected dysregulation in immune response, chemotaxis, and locomotion pathways, specifically highlighting molecules like C4BPA, MAOA, and PAEP [86].

Thin Endometrium (TE)

scRNA-seq of TE during the proliferative phase reveals a fundamental failure in regenerative programming. Key findings include:

• Attenuated Cell Cycle: TE-associated cells show reduced expression of genes involved in cell proliferation [29].
• Increased Fibrosis: There is a signature of elevated collagen deposition and extracellular matrix (ECM) dysregulation [29].
• Dysfunctional Progenitor Cells: A specific subpopulation of perivascular CD9+ SUSD2+ cells, identified as putative endometrial progenitor cells, displays altered function and participates in aberrant cell-cell communication networks, failing to support normal tissue regeneration [29].

Table 2: Transcriptomic Dysregulation in Endometrial Pathologies

Pathology	Key Transcriptomic Findings	Main Affected Pathways/Cell Types
Recurrent Implantation Failure (RIF)	Displaced WOI; Deficient epithelial receptivity gene sets; Hyper-inflammatory epithelium [8]; Altered spatial niches [9]	Immune response; Epithelial-stromal crosstalk
Endometriosis	Subtle but distinct MS phase profile; Dysregulated immune and defence pathways [86]	Chemotaxis; Locomotion; C4BPA, MAOA, PAEP
Thin Endometrium (TE)	Attenuated cell cycle; Increased fibrosis; Dysfunctional perivascular CD9+ SUSD2+ progenitor cells [29]	Collagen/ECM deposition; Stem cell development; Wound healing

Experimental Methodologies and Protocols

Sample Collection and Preparation

For transcriptomic studies, endometrial biopsies are typically collected under hysteroscopic guidance or using a Pipelle catheter. Precise cycle dating is critical and is achieved through a combination of:

• Serial serum LH measurement to identify the LH surge (denoted as LH+0) [8] [9].
• Transvaginal ultrasound and urinary LH dipstick testing [9].
• Histological dating according to the Noyes criteria [85].

For single-cell and spatial analyses, fresh tissue is immediately processed. For spatial transcriptomics, tissues are rapidly frozen in isopentane pre-chilled with liquid nitrogen and sectioned for placement on 10x Visium slides [9].

Single-Cell RNA Sequencing Workflow

The standard scRNA-seq protocol involves:

• Tissue Dissociation: Enzymatic dispersion of the endometrial biopsy into a single-cell suspension [29] [8].
• Cell Capture and Barcoding: Using the 10X Chromium system to capture individual cells and barcode transcripts [8].
• Library Preparation and Sequencing: Reverse transcription, cDNA amplification, and library construction followed by sequencing on platforms like Illumina NovaSeq [8] [9].
• Data Preprocessing: Using tools like CellRanger for alignment and Seurat for quality control. Cells with low gene counts (<500-1,000 genes) or high mitochondrial gene percentage (>20%) are filtered out [29] [9].
• Downstream Analysis: This includes normalization, clustering, differential expression analysis, and advanced analyses such as RNA velocity, trajectory inference, and cell-cell communication mapping using tools like scVelo and CellChat [29] [8].

Data Integration and Deconvolution

Integration of scRNA-seq with spatial transcriptomics data is performed using deconvolution algorithms like CARD (conditional autoregressive-based deconvolution). This estimates the cell type proportions for each spot in the spatial data, allowing for the mapping of transcriptional signatures to their precise tissue location [9].

Figure 2: Experimental Workflow for Endometrial Transcriptomics. The diagram outlines the key steps from patient sample collection to data analysis for both single-cell and spatial transcriptomic profiling.

Table 3: Essential Research Reagents and Tools for Endometrial Transcriptomics

Reagent / Tool	Function / Application	Example Use in Context
10X Genomics Chromium	Single-cell RNA sequencing platform for high-throughput cell barcoding and capture.	Profiling cellular heterogeneity in endometrial biopsies [8].
10X Visium Spatial Slide	Spatial transcriptomics platform for capturing gene expression data within tissue morphology.	Mapping gene expression niches in RIF and control endometrium [9].
Seurat R Package	Comprehensive toolkit for single-cell genomics data analysis, including QC, clustering, and visualization.	Primary software for analyzing scRNA-seq data from endometrial cells [29] [8] [9].
scVelo Python Package	RNA velocity analysis to model cellular dynamics and predict future cell states.	Tracing the differentiation trajectory of luminal epithelial cells [8].
CARD Software	Deconvolution tool for spatial transcriptomics to infer cell type composition at each spatial spot.	Integrating scRNA-seq data with ST data to resolve cellular niches [9].
Enzymatic Dissociation Mix	Collagenase-based enzymes for breaking down tissue into a single-cell suspension.	Preparing endometrial biopsies for scRNA-seq [29] [8].
Anti-CD9 & Anti-SUSD2 Antibodies	Cell surface markers for isolating a putative population of endometrial progenitor cells via FACS.	Isulating and studying perivascular CD9+ SUSD2+ cells in thin endometrium [29].

The comparative analysis of proliferative and secretory phase transcriptomic programs reveals an exquisitely complex and dynamic system. The proliferative phase is not merely a period of growth but involves a precise preparatory transcriptomic cascade, culminating in the critical late proliferative transition. The secretory phase is characterized by a finely-tuned, multi-stage differentiation process across diverse cell types to achieve receptivity. The emergence of single-cell and spatial transcriptomics has been pivotal in uncovering the cellular heterogeneity, temporal trajectories, and spatial niches underlying these phases. Dysregulation of these programs—whether a displaced WOI in RIF, a hyper-inflammatory state, altered immune pathways in endometriosis, or a failure of progenitor cell function in thin endometrium—highlights their importance in reproductive success. Future research leveraging these advanced technologies will continue to decode the molecular dialogue of the endometrium, paving the way for novel diagnostics and targeted therapies for endometrial-factor infertility.

The transcriptional landscape of the proliferative phase endometrium represents a dynamic and complex system crucial for female reproductive function. Understanding the genetic regulation of this tissue requires moving beyond isolated analysis to a comprehensive cross-tissue framework. Genetic effects on gene expression are often tissue-specific, yet many regulatory elements operate across multiple tissues, creating a complex regulatory architecture that can only be decoded through comparative approaches [76]. Cross-tissue validation has emerged as a powerful paradigm for distinguishing true biological signals from false positives, identifying tissue-shared versus tissue-specific regulatory mechanisms, and uncovering novel pathogenic pathways for endometrial disorders.

For researchers investigating the proliferative phase endometrium, cross-tissue approaches provide essential biological context. By comparing endometrial expression quantitative trait loci (eQTLs) with those from other reproductive tissues (ovary, fallopian tube) and non-reproductive tissues (blood, liver, brain), we can determine which regulatory elements are unique to endometrial function versus those that represent systemic regulatory patterns. This review provides a comprehensive technical guide to methodologies, analytical frameworks, and practical applications for cross-tissue validation of genetic effects, with specific emphasis on implications for proliferative phase endometrial research.

Fundamental Methodologies for Cross-Tissue Analysis

Transcriptome-Wide Association Study (TWAS) Frameworks

TWAS has become a cornerstone methodology for integrating genotype and gene expression data to identify gene-trait associations. Two principal approaches enable cross-tissue investigation:

• Single-Tissue TWAS: Methods such as FUSION utilize expression prediction models built from individual tissues, testing associations between predicted gene expression and traits separately for each tissue [87] [88]. This approach preserves tissue-specific signals but may lack power for detecting shared genetic effects across tissues.

• Cross-Tissue TWAS: Methods including UTMOST and MTWAS employ penalized multivariate regression and aggregation strategies to leverage shared genetic effects across multiple tissues simultaneously [89] [87] [88]. UTMOST applies a group-lasso penalty to identify eQTLs shared across tissues while preserving robust tissue-specific effects, substantially enhancing statistical power for detecting cross-tissue regulatory mechanisms [88].

The recently developed MTWAS framework introduces a three-step approach that significantly advances cross-tissue analysis: (1) non-parametric imputation of missing expression values across tissues; (2) identification of cross-tissue eQTLs (ct-eQTLs) through principal component analysis of multi-tissue expression matrices; and (3) detection of tissue-specific eQTLs (ts-eQTLs) after accounting for ct-eQTL effects [89]. This approach has demonstrated 47.4% average improvement in prediction accuracy compared to single-tissue methods across 47 GTEx tissues, with particularly dramatic improvements in tissues with smaller sample sizes [89].

Advanced Cross-Tissue Network Analyses

Beyond TWAS, novel methods are emerging to decode complex interactions between tissues:

CrossWGCNA extends the Weighted Gene Co-expression Network Analysis to identify highly interacting genes across tissues, cell types, or organs [90]. The pipeline involves: (1) data pre-processing of subject-matched transcriptomic data from two tissues; (2) adjacency calculation with corrections for shared genetic background; (3) degree calculation for intra- and inter-tissue connectivity; (4) topological overlap measurement; and (5) clustering of genes with high inter-tissue connectivity [90]. This method is particularly valuable for studying epithelium-stroma interactions in endometrial tissue and immune-endometrial crosstalk.

Regulatory network integration combines TWAS with Mendelian randomization and colocalization analyses to establish causal relationships between gene expression across tissues and disease endpoints. For endometriosis, this approach has identified six novel susceptibility genes (CISD2, EFRB, GREB1, IMMT, SULT1E1, and UBE2D3) whose expression across multiple tissues demonstrates causal relationships with disease risk [88].

Table 1: Key Computational Methods for Cross-Tissue Analysis

Method	Primary Function	Advantages	Applications in Endometrial Research
MTWAS [89]	Partitioning cross-tissue and tissue-specific genetic effects	Non-parametric imputation for missing data; superior prediction accuracy	Identifying endometrial-specific eQTLs shared with other reproductive tissues
UTMOST [87] [88]	Cross-tissue TWAS with group regularization	Identifies shared eQTL effects while preserving tissue-specificity	Discovering endometriosis risk genes across multiple tissues
FUSION [87] [88]	Single-tissue TWAS	Tissue-specific association testing; well-established framework	Validating endometrial-specific expression-trait associations
CrossWGCNA [90]	Inter-tissue co-expression networks	Unsupervised identification of highly interacting genes	Studying endometrial-stromal communication and immune interactions
MAGMA [87] [88]	Gene-set analysis of GWAS data	Functional annotation and pathway enrichment	Testing tissue-specific enrichment of endometrial risk genes

Experimental Validation Approaches

Computational predictions require experimental validation through multiple complementary approaches:

• Spatial transcriptomics using platforms like 10x Visium enables precise mapping of gene expression patterns within endometrial tissue architecture, preserving spatial context that is crucial for understanding functional compartmentalization [9]. Integration with single-cell RNA sequencing data through deconvolution algorithms (CARD) further resolves cellular heterogeneity within spatial spots [9].

• Single-cell RNA sequencing of endometrial tissues across menstrual cycle phases has redefined the transcriptional dynamics of endometrial remodeling, revealing four major transcriptomic phases that correlate with but refine traditional histological staging [91]. These datasets provide essential references for validating cell-type-specific cross-tissue effects.

• Organoid models of endometrial epithelium closely replicate the cellular, transcriptomic and functional characteristics of native tissue, providing a physiologically relevant experimental system for functional validation of cross-tissue genetic discoveries [91].

Technical Protocols for Cross-Tissue Validation

Protocol 1: Implementing MTWAS for Endometrial Research

The MTWAS framework offers a robust approach for cross-tissue analysis specifically optimized for scenarios with limited sample sizes in individual tissues - a common challenge in endometrial research [89].

Step 1: Multi-Tissue Expression Data Preprocessing

• Collect genotype and expression data from endometrium and reference tissues (GTEx v8 provides 54 tissues from 838 individuals)
• Perform quality control: exclude tissues with sample size <100; filter genes based on expression variance
• Impute missing expression values using non-parametric imputation that leverages correlations between tissues [89]

Step 2: Identify Cross-Tissue eQTLs (ct-eQTLs)

• Extract principal components (PCs) from imputed sample-by-tissue expression matrix
• Regress each significant PC against cis-SNPs (default: 1Mb upstream/downstream of TSS)
• Select ct-eQTLs using stepwise procedure based on Extended Bayesian Information Criterion (EBIC) [89]

Step 3: Identify Tissue-Specific eQTLs (ts-eQTLs)

• For each tissue, regress tissue-specific expression against cis-SNPs conditional on ct-eQTLs
• Apply SODA algorithm with EBIC minimization to select ts-eQTLs [89]
• Estimate effects of ct-eQTLs and ts-eQTLs using weighted least squares

Step 4: Association Testing with Endometrial Traits

• For trait of interest, derive MTWAS statistics using estimated eQTL effects, GWAS summary statistics, and reference LD matrix
• Perform association tests in tissue-specific manner to retain tissue specificity [89]

Figure 1: MTWAS Workflow for Cross-Tissue Genetic Analysis

Protocol 2: Cross-Tissue Co-expression Analysis with CrossWGCNA

For investigating coordinated gene expression between endometrium and other tissues, CrossWGCNA provides an unsupervised approach to identify highly interacting genes [90].

Step 1: Data Preparation

• Obtain subject-matched transcriptomic data from endometrium and target tissue(s)
• Filter genes based on expression variance across samples (top 5000-8000 most variable genes recommended)
• Combine expression matrices row-wise, appending "tiss1" and "tiss2" to gene identifiers to distinguish tissue origin [90]

Step 2: Adjacency Calculation

• Compute Spearman correlations between all gene pairs across tissues
• Apply self-loop correction: set correlations between same gene in different tissues to zero
• Optional: subtract average correlation within each tissue to remove shared genetic background effects
• Calculate signed adjacency: sij = 0.5 + 0.5*rij, then aij = (sij)^β with soft threshold β=6 [90]

Step 3: Network Analysis

• Compute intra-tissue and inter-tissue connectivity degrees for each gene
• Calculate topological overlap measure (TOM) to identify modules of highly interconnected genes
• Perform hierarchical clustering to identify gene modules with high cross-tissue connectivity [90]

Step 4: Biological Interpretation

• Annotate cross-tissue modules with gene ontology and pathway enrichment
• Validate top candidate genes using spatial transcriptomics or functional assays
• Integrate with TWAS results to prioritize candidate genes for experimental follow-up

Table 2: Essential Research Resources for Cross-Tissue Endometrial Studies

Resource Category	Specific Resources	Key Applications	Technical Considerations
Expression Datasets	GTEx v8 (54 tissues, 838 donors) [87] [88]	Primary resource for cross-tissue eQTL discovery	Predominantly European ancestry; limited endometrial samples
	EndometDB (115 patients, 53 controls) [92]	Endometrium-specific expression reference	Includes endometriosis lesions; clinical metadata
	Spatial transcriptomics of endometrium [9]	Spatial validation of cross-tissue findings	10x Visium platform; 10,131 high-quality spots
Analysis Tools	MTWAS software [89]	Primary cross-tissue analysis	Implements non-parametric imputation for missing data
	UTMOST [87] [88]	Cross-tissue TWAS	Group-lasso regularization for shared effects
	CrossWGCNA R package [90]	Cross-tissue network analysis	Requires matched samples across tissues
Experimental Models	Endometrial organoids [91]	Functional validation of candidate genes	Recapitulates native tissue transcriptomics
	scRNA-seq endometrial atlas [91]	Cell-type-specific resolution	Identifies rare cell populations
Reference Data	FinnGen R11 GWAS (18,260 endometriosis cases) [88]	Disease association testing	Large-scale Nordic biobank data
	EUR 1000 Genomes LD reference	Statistical fine-mapping	Population-matched linkage disequilibrium

Application to Endometrial Research: Insights and Workflows

Case Study: Cross-Tissue Analysis of Endometriosis Risk Genes

A recent cross-tissue TWAS of endometriosis exemplifies the power of this approach for endometrial research [88]. The analysis integrated:

• GWAS data: 18,260 endometriosis cases and 119,468 controls from FinnGen R11
• eQTL data: 47 non-male-specific tissues from GTEx v8
• Analytical methods: UTMOST (cross-tissue), FUSION (single-tissue), MAGMA (gene-set)

This approach identified 22 significant gene signals by UTMOST and 615 by FUSION, with six novel candidate susceptibility genes (CISD2, EFRB, GREB1, IMMT, SULT1E1, and UBE2D3) showing strong cross-tissue effects [88]. Follow-up Mendelian randomization confirmed causal relationships between gene expression in multiple tissues and endometriosis risk, with IMMT expression in 21 tissues, CISD2 in 17 tissues, and UBE2D3 in 7 tissues all demonstrating significant causal effects [88].

Endometrial-Specific Analytical Considerations

When applying cross-tissue validation to proliferative phase endometrium research, several specific considerations are essential:

• Menstrual cycle staging: Endometrial gene expression varies dramatically across menstrual cycle phases [91]. Cross-tissue analyses must account for this variability through precise phase-matching or statistical adjustment.

• Cell-type heterogeneity: The endometrium contains diverse cell types (epithelial, stromal, immune, endothelial) with distinct expression profiles [91]. Single-cell resolution is often necessary to resolve cell-type-specific effects.

• Hormonal context: Estrogen and progesterone regulate endometrial gene expression [91]. Cross-tissue analyses should consider hormonal status, particularly when comparing to non-reproductive tissues.

Figure 2: Cross-Tissue Validation Workflow for Endometrial Research

Cross-tissue validation represents a paradigm shift in endometrial research, moving from isolated analysis to integrated multi-tissue frameworks. The methodologies outlined here - from advanced TWAS approaches to network analyses and experimental validation strategies - provide a comprehensive toolkit for decoding the complex genetic architecture of proliferative phase endometrium. As single-cell and spatial technologies continue to advance, together with increasingly diverse multi-ethnic biobanks, the resolution and scope of cross-tissue analyses will continue to improve.

For researchers investigating the endometrial transcriptional landscape, embracing these cross-tissue approaches is no longer optional but essential for distinguishing true biological signals, identifying clinically relevant mechanisms, and advancing our understanding of endometrial biology in both health and disease. The integration of computational predictions with experimental validation in physiologically relevant models like endometrial organoids will be particularly crucial for translating cross-tissue discoveries into mechanistic insights and therapeutic opportunities.

The human endometrium possesses a remarkable regenerative capacity, undergoing approximately 450 cycles of growth, differentiation, breakdown, and repair throughout a woman's reproductive lifespan [20]. This cyclic regeneration is fundamentally driven by tissue-resident stem/progenitor cell populations located primarily in the basalis layer, which serves as a reservoir for regenerating the functionalis layer each menstrual cycle [20] [93]. During the proliferative phase, rising estrogen levels drive extensive cellular proliferation and tissue growth, processes governed by a complex transcriptional landscape that activates genes controlling cell cycle progression, tissue remodeling, and lineage commitment [91] [20].

Understanding the behavior of endometrial progenitor cells and their hormonal responses requires sophisticated experimental models that can recapitulate the tissue's architecture and dynamic nature. Traditional two-dimensional (2D) culture systems have provided foundational knowledge but lack the physiological context necessary for studying stem cell niche interactions and polarized tissue functions [94]. Advances in three-dimensional (3D) organoid technology and sophisticated co-culture systems now enable researchers to model the endometrial microenvironment with unprecedented fidelity, allowing for functional validation of progenitor cell populations and their responses to hormonal cues within a physiologically relevant context [91] [95]. These models are particularly valuable for investigating the transcriptional programs activated during the proliferative phase, offering new insights into the molecular mechanisms governing endometrial regeneration and its associated disorders.

Endometrial Progenitor Cell Populations: Identification and Characterization

Key Progenitor Cell Markers and Their Localization

Endometrial stem/progenitor cells reside in specific niches within the basalis layer and are broadly classified into epithelial and stromal compartments. Definitive markers for these populations have been identified through rigorous investigation, though their overlapping expression patterns suggest a complex cellular hierarchy [20].

Table 1: Endometrial Epithelial Progenitor Cell Markers and Characteristics

Marker	Cellular Localization	Functional Significance	Reference
N-cadherin (CDH2)	Bases of glands in basalis adjacent to myometrium	First specific surface marker enriching for clonogenic cells; co-localizes with ALDH1A1	[20]
SSEA-1	Basalis epithelium and luminal epithelium	Stage-specific embryonic antigen-1; present on epithelial progenitor cells	[20]
SOX9 (nuclear)	Basalis gland bases; some functionalis cells	Nuclear SOX9 identifies putative progenitor cells; may function in transit amplification	[20]
AXIN2	Basalis gland bases	Wnt pathway component; marks epithelial progenitor cells	[20]
ALDH1A1	Co-localizes with N-cadherin+ cells (78%)	Aldehyde dehydrogenase activity; potential role in retinoic acid signaling in progenitors	[20]

For the stromal compartment, mesenchymal stem cells (eMSCs) can be identified by co-expression of PDGFRβ and CD146 or by a single marker, SUSD2 [20]. These perivascular stromal progenitors demonstrate multipotent differentiation capacity and likely contribute to the regeneration of stromal components during each menstrual cycle.

Recent single-cell RNA sequencing (scRNA-seq) studies have further refined our understanding of endometrial cellular heterogeneity. One such study redefined the traditional three menstrual cycle phases into four distinct transcriptional phases based on transcriptomic patterns, providing a more precise framework for understanding progenitor cell dynamics during endometrial regeneration [91].

Isolation Techniques for Progenitor Cell Populations

The isolation of specific progenitor populations relies on techniques that exploit their unique surface markers and physical properties:

• Enzymatic Digestion: Endometrial tissues are digested using collagenase to prepare single-cell suspensions [96].
• Differential Adhesion: Stromal cells attach readily to conventional tissue culture plates, while epithelial cells remain initially suspended, enabling partial separation [96].
• Fluorescence-Activated Cell Sorting (FACS)/Magnetic-Activated Cell Sorting (MACS): These techniques enable precise isolation of specific cell populations using antibodies against progenitor markers such as:
  • Epithelial progenitors: N-cadherin, EpCAM, SSEA-1 [96] [20]
  • Stromal progenitors: SUSD2, CD146, PDGFRβ [20]
  • General selection: CD90, CD73, CD105, HLA I positive with absent CD45 expression [96]
• Side Population Analysis: Based on Hoechst 33342 dye efflux capacity, this functional approach identifies cells with stem-like properties [93].

Advanced In Vitro Models for Functional Validation

Endometrial Organoid Systems

Organoids have emerged as revolutionary 3D biomimetic systems that closely replicate the cellular, transcriptomic, and functional characteristics of native endometrial tissue [91]. These self-organizing structures derived from adult stem/progenitor cells recapitulate key aspects of endometrial physiology, including hormonal response and glandular formation.

Establishment Protocol:

• Source Tissue: Endometrial biopsies or menstrual effluent containing progenitor cells [96] [91]
• Digestion: Collagenase digestion (1-2 mg/mL, 1-2 hours, 37°C) to obtain single cells or small gland fragments [96]
• Embedding: Suspension in Basement Membrane Extract (BME) or synthetic matrices [91] [95]
• Culture Medium: Advanced media containing:
  • Wnt agonists (R-spondin-1)
  • Noggin (BMP inhibitor)
  • EGF
  • Estradiol and progesterone for hormonal studies [91]
• Differentiation: Hormonal stimulation to induce secretory differentiation (cyclic administration of estradiol followed by medroxyprogesterone acetate) [91]

Endometrial organoids have been shown to faithfully mimic the native tissue, expressing appropriate markers of glandular epithelium (PAEP, HB-EGF) and responding to hormonal cues in a physiologically relevant manner [91]. Single-cell RNA-seq analysis of organoids has confirmed their close resemblance to primary endometrial epithelium, making them invaluable for studying progenitor cell biology and hormonal responses [91].

Synthetic Extracellular Matrix Co-Culture Models

Recent advances in bioengineering have led to the development of fully synthetic extracellular matrices that support the co-culture of endometrial epithelial organoids and stromal cells, enabling the study of epithelial-stromal crosstalk in a controlled environment [95].

Matrix Composition and Protocol:

• Base Material: Polyethylene glycol (PEG)-based hydrogel crosslinked with matrix metalloproteinase (MMP)-labile peptides to permit cellular remodeling [95]
• Adhesion Ligands:
  • GFOGER (collagen-derived peptide for integrin α2β1 binding)
  • PHSRN-K-RGD (fibronectin-derived peptide for integrin α5β1 binding) [95]
• Biophysical Properties: Tuned to a stiffness regime similar to native endometrium (~0.5-2 kPa) [95]
• Co-Culture Setup:
  • Epithelial organoids embedded in synthetic matrix
  • Stromal cells incorporated within the same matrix or in adjacent compartments
  • Hormonal stimulation to mimic menstrual cycle phases [95]

This synthetic platform successfully supports hormone-driven expansion and differentiation of both epithelial and stromal compartments, recapitulating key processes across the human menstrual cycle in vitro [95]. The system has been used to study interleukin 1B (IL1B)-induced inflammation, revealing dysregulation of epithelial proliferation mediated by stromal cells [95].

Diagram Title: Experimental Workflow for Endometrial Progenitor Validation

Experimental Workflow for Hormonal Response Validation

The functional validation of progenitor cell responses to hormonal stimuli involves a systematic approach combining molecular, cellular, and structural analyses:

• Hormonal Treatment Protocol:

  • Proliferative Phase Simulation: Estradiol (E2, 10 nM) for 7-14 days
  • Secretory Phase Simulation: Estradiol (10 nM) + Progesterone (P4, 1 μM) for additional 7-14 days
  • Window of Implantation: Addition of cAMP analogs to enhance decidualization response [91] [94]

• Functional Readouts:

  • Proliferation Assays: EdU incorporation, Ki67 immunostaining
  • Differentiation Markers:
    • Secretory phase: PAEP, IGFBP1, PRL
    • Receptivity markers: LIF, CXCL14, GPX3 [91]
  • Transcriptomic Analysis: scRNA-seq to map hormonal response genes
  • Morphological Assessment: Organoid budding, lumen formation, polarization

Signaling Pathways in Progenitor Cell Regulation

Several evolutionarily conserved signaling pathways play crucial roles in regulating endometrial progenitor cell behavior during the proliferative phase. Understanding these pathways is essential for interpreting experimental results from in vitro and organoid models.

Diagram Title: Signaling Pathways Regulating Endometrial Progenitors

The Wnt/β-catenin pathway plays a particularly important role in epithelial progenitor maintenance, with AXIN2 serving as both a marker and functional regulator [20] [93]. Simultaneously, the interplay between WNT and NOTCH signaling regulates the balance between ciliated and secretory epithelial lineages [91]. Estrogen signaling through ESR1 promotes progenitor proliferation during the proliferative phase, while progesterone signaling via PGR drives differentiation during the secretory phase [91] [20].

Single-cell transcriptomic analyses have revealed that these signaling pathways exhibit phase-specific activation patterns throughout the menstrual cycle, creating a dynamic regulatory network that coordinates tissue regeneration and function [91].

Data Presentation and Analysis

Quantitative Analysis of Hormonal Responses

Table 2: Transcriptomic Changes in Endometrial Organoids During Hormonal Stimulation

Gene	Baseline Expression (FPKM)	Proliferative Phase (E2)	Secretory Phase (E2+P4)	Functional Role	Reference
ESR1	15.2 ± 2.1	18.5 ± 3.2 (↑)	12.1 ± 1.8 (↓)	Estrogen receptor	[91]
PGR	8.7 ± 1.5	22.3 ± 4.1 (↑)	35.6 ± 5.2 (↑)	Progesterone receptor	[91]
PAEP	5.2 ± 0.8	3.1 ± 0.5 (↓)	45.3 ± 6.7 (↑)	Glycodelin secretion	[91]
LIF	12.5 ± 2.3	8.7 ± 1.2 (↓)	68.9 ± 8.4 (↑)	Implantation cytokine	[91] [94]
SOX9	25.4 ± 3.7	35.6 ± 4.2 (↑)	12.3 ± 2.1 (↓)	Progenitor marker	[91] [20]
AXIN2	18.9 ± 2.9	28.4 ± 3.8 (↑)	10.2 ± 1.5 (↓)	Wnt pathway/Progenitor	[20]

Research Reagent Solutions for Experimental Studies

Table 3: Essential Research Reagents for Endometrial Progenitor Cell Studies

Reagent Category	Specific Examples	Function/Application	Experimental Notes
Cell Isolation	Collagenase IV, Dispase	Tissue digestion to single cells	Concentration: 1-2 mg/mL; 1-2h at 37°C [96]
Progenitor Markers	Anti-N-cadherin, Anti-SSEA-1, Anti-SUSD2	FACS/MACS isolation of progenitors	Co-expression patterns define hierarchy [20]
Matrix Materials	BME, Synthetic PEG hydrogels	3D support for organoid culture	Synthetic matrices offer tunable properties [95]
Hormones	17β-estradiol, Progesterone, Medroxyprogesterone acetate	Hormonal response studies	Cyclic administration mimics menstrual cycle [91]
Growth Factors	R-spondin-1, Noggin, EGF	Progenitor maintenance in culture	Essential for long-term organoid culture [91]
Signaling Modulators	CHIR99021 (Wnt activator), DAPT (Notch inhibitor)	Pathway manipulation studies	Determine regulatory mechanisms [91] [20]

Advanced in vitro and organoid models have revolutionized our ability to functionally validate endometrial progenitor cell populations and their hormonal responses within the context of the proliferative phase transcriptional landscape. These systems now enable researchers to dissect the complex cell-cell interactions, signaling pathways, and transcriptional networks that govern endometrial regeneration with unprecedented precision.

The integration of synthetic extracellular matrices [95], single-cell transcriptomics [91] [7], and spatial profiling technologies will further enhance our understanding of progenitor cell niche organization and dynamics. These approaches are particularly valuable for investigating endometrial disorders such as thin endometrium, endometriosis, and Asherman's syndrome, which may involve progenitor cell dysfunction [20] [48] [97].

As these models continue to evolve, they will undoubtedly provide deeper insights into the fundamental biology of endometrial regeneration and facilitate the development of novel therapeutic strategies for endometrial pathologies. The ongoing refinement of these systems represents a critical frontier in reproductive medicine, with the potential to significantly impact our understanding of female reproductive health and disease.

Conclusion

The transcriptional landscape of the proliferative phase endometrium is far more than a simple prelude to the secretory phase; it is a dynamically regulated period that lays the essential groundwork for endometrial receptivity and successful pregnancy. The integration of high-resolution technologies like scRNA-seq and spatial transcriptomics has unveiled a complex interplay of epithelial, stromal, and immune cells, governed by precise genetic and splicing mechanisms. Future research must focus on longitudinal studies to track individual patient cycles, deepen the functional characterization of newly identified progenitor cells, and leverage multi-omics integration to build predictive models of endometrial health. These efforts will be pivotal in developing targeted interventions for conditions like RIF, endometriosis, and thin endometrium, ultimately translating this foundational knowledge into improved clinical outcomes in reproductive medicine and drug development.

References

• 1. Endometrial Proliferative Phase-Centered View of ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11121472/]
• 2. Genetic Regulation of Transcription in the Endometrium in ... [https://www.frontiersin.org/journals/reproductive-health/articles/10.3389/frph.2021.795464/full]
• 3. Case Reports from Women Using a Quantitative Hormone ... [https://www.mdpi.com/1648-9144/59/10/1743]
• 4. Regulation of RNA splicing in endometrial tissue and its ... [https://www.sciencedirect.com/science/article/pii/S2589004225014683]
• 5. Global Gene Expression Profiling of Proliferative Phase ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC4052207/]
• 6. Endometrial Proliferative Phase-Centered View of ... [https://www.mdpi.com/1422-0067/25/10/5320]
• 7. Decoding functional and developmental trajectories ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12424247/]
• 8. Time-series single-cell transcriptomic profiling of luteal ... [https://www.nature.com/articles/s41467-024-55419-z]
• 9. A spatial transcriptomics dataset of the endometrium from ... [https://www.nature.com/articles/s41597-025-05995-6]
• 10. Proliferative Endometrium Guide | South Lake OB/GYN [https://southlakeobgyn.net/2024/09/03/proliferative-endometrium/]
• 11. Proliferative Endometrium: Definition, Symptoms of ... [https://www.healthline.com/health/womens-health/proliferative-endometrium]
• 12. Deciphering ESR1-driven transcription in human ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12582374/]
• 13. Decoding functional and developmental trajectories of ... [https://www.sciencedirect.com/science/article/pii/S2589004225016128]
• 14. Overview of dendritic cells subsets and their involvement in ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12008504/]
• 15. Dynamic Changes in the Phenotype of Dendritic Cells ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7516021/]
• 16. TIME for Endometrial Cancer [https://pubmed.ncbi.nlm.nih.gov/41201455/]
• 17. Computational image and molecular analysis reveal ... [https://www.nature.com/articles/s41698-025-00972-z]
• 18. Unlocking the Secrets of the Endometrium: Stem Cells, ... [https://www.mdpi.com/2227-9059/13/10/2435]
• 19. Transcriptional Profiling of SSEA-1+ Endometrial Epithelial ... [https://pubmed.ncbi.nlm.nih.gov/40297954/]
• 20. Endometrial Stem/Progenitor Cells–Their Role in ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9580754/]
• 21. Mesenchymal-to-epithelial transition of perivascular cells ... [https://www.nature.com/articles/s41467-025-65139-7]
• 22. Endometrial receptivity profiled through transcriptomic ... [https://www.nature.com/articles/s41598-025-19633-z]
• 23. Immune-related gene signatures of thin endometrium [https://pmc.ncbi.nlm.nih.gov/articles/PMC12531038/]
• 24. The Transcriptome Signature of the Receptive Bovine Uterus ... [https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0122874]
• 25. The endometrial transcriptome transition preceding receptivity ... [https://bmcgenomics.biomedcentral.com/articles/10.1186/s12864-023-09698-3]
• 26. Deciphering estrogen receptor alpha-driven transcription in ... [https://pubmed.ncbi.nlm.nih.gov/40803503/]
• 27. Single‐cell RNA sequencing technologies and applications [https://pmc.ncbi.nlm.nih.gov/articles/PMC8964935/]
• 28. Advancements in single-cell RNA sequencing and spatial ... [https://www.frontierspartnerships.org/journals/acta-biochimica-polonica/articles/10.3389/abp.2025.13922/full]
• 29. Single-cell RNA sequencing of endometrium uncovers ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12465366/]
• 30. Transcriptome size matters for single-cell RNA-seq ... [https://www.nature.com/articles/s41467-025-56623-1]
• 31. Single-cell transcriptome profiling of the human ... [https://www.nature.com/articles/s41598-025-97433-1]
• 32. Single-cell and spatial transcriptomic profiling revealed ... [https://www.sciencedirect.com/science/article/pii/S2666979X24003665]
• 33. SRT-Server: powering the analysis of spatial transcriptomic data [https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-024-01288-6]
• 34. Mapping the cellular landscape of the human endometrium [https://www.jax.org/news-and-insights/2025/september/mapping-the-cellular-landscape-of-the-human-endometrium]
• 35. Deciphering spatial domains from spatially resolved ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11607964/]
• 36. Spatial Distribution of Senescent Cells and Their Proximity ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12609039/]
• 37. The potential impact of RNA splicing abnormalities on ... [https://www.nature.com/articles/s41419-025-07458-7]
• 38. The roles of chromatin regulatory factors in endometriosis [https://pmc.ncbi.nlm.nih.gov/articles/PMC11052748/]
• 39. Regulation of RNA splicing in endometrial tissue and its ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12359188/]
• 40. Chromatin topology defines estradiol-primed progesterone ... [https://elifesciences.org/articles/66034]
• 41. Single-cell transcriptomic analysis of endometriosis ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8261960/]
• 42. Single-Cell Transcriptomic Analysis Highlights the Impact ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12484105/]
• 43. Advances and challenges in cell–cell communication inference [https://pmc.ncbi.nlm.nih.gov/articles/PMC12204611/]
• 44. An integrated single-cell reference atlas of the human ... [https://www.nature.com/articles/s41588-024-01873-w]
• 45. Integrating single-cell and spatial transcriptomics reveals ... [https://www.nature.com/articles/s41698-025-01028-y]
• 46. Integrating bulk RNA-seq, scRNA-seq, and spatial ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12495838/]
• 47. Immune-related gene signatures of thin endometrium [https://pubmed.ncbi.nlm.nih.gov/41113715/]
• 48. Immune-related gene signatures of thin endometrium [https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2025.1626451/full]
• 49. Single-cell RNA sequencing of endometrium uncovers ... [https://stemcellres.biomedcentral.com/articles/10.1186/s13287-025-04658-y]
• 50. Mapping single-cell transcriptomes of endometrium | ITT [https://www.dovepress.com/mapping-single-cell-transcriptomes-of-endometrium-reveals-potential-bi-peer-reviewed-fulltext-article-ITT]
• 51. Immune-inflammation gene signatures in endometriosis patients - ScienceDirect [https://www.sciencedirect.com/science/article/pii/S0015028216614085]
• 52. Proliferative Endometrium Meaning: 7 Essential Insights ... [https://southlakeobgyn.net/2025/04/18/proliferative-endometrium-meaning/]
• 53. Recurrent implantation failure: A comprehensive summary ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9849692/]
• 54. What are the main causes of embryo implantation failure? [https://www.institutobernabeu.com/en/blog/what-are-the-main-causes-of-embryo-implantation-failure/]
• 55. Factors influencing endometrial receptivity in women with ... [https://bmcwomenshealth.biomedcentral.com/articles/10.1186/s12905-024-03531-z]
• 56. Molecular subtype of recurrent implantation failure reveals ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12257665/]
• 57. Integrated transcriptomic analysis reveals dysregulated ... - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC11749484/]
• 58. Splicing defects in rare diseases: transcriptomics and ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10516351/]
• 59. AS-Quant: Detection and Visualization of Alternative Splicing ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8123109/]
• 60. Detection of aberrant splicing events in RNA-seq data ... [https://www.nature.com/articles/s41467-020-20573-7]
• 61. Transcriptome-wide isoform-level dysregulation in ASD ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC6443102/]
• 62. Vials: Visualizing Alternative Splicing of Genes [https://vcg.seas.harvard.edu/publications/vials-visualizing-alternative-splicing-of-genes]
• 63. Prognostic Potential of Alternative Splicing Markers in ... [https://www.sciencedirect.com/science/article/pii/S2162253119303373]
• 64. Fibroblast Heterogeneity: Existence of Functionally Distinct ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC1850439/]
• 65. Understanding Fibroblast Heterogeneity in Form and ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10452440/]
• 66. Unveiling the Pathological Landscape of Intrauterine Adhesion [https://pmc.ncbi.nlm.nih.gov/articles/PMC12335249/]
• 67. Enhanced myofibroblast differentiation of eMSCs in ... [https://stemcellres.biomedcentral.com/articles/10.1186/s13287-025-04183-y]
• 68. Stromal Heterogeneity in the Human Proliferative ... [https://www.mdpi.com/2075-4426/11/6/448]
• 69. Therapeutic options and drug delivery strategies for the ... [https://www.sciencedirect.com/science/article/abs/pii/S0168365919307254]
• 70. Integrative transcriptomic analysis identifies shared EndMT ... [https://www.nature.com/articles/s41598-025-20302-4]
• 71. Transcriptomics of receptive endometrium in women with ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8722101/]
• 72. The role of transcriptomic biomarkers of endometrial ... [https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-021-02837-y]
• 73. Genetic Regulation of Transcription in the Endometrium ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9580733/]
• 74. Tissue specific regulation of transcription in endometrium and ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7048713/]
• 75. Genetic regulation of disease risk and endometrial gene ... [https://www.nature.com/articles/s41598-018-29462-y]
• 76. The genetic regulation of transcription in human ... [https://pubmed.ncbi.nlm.nih.gov/28177073/]
• 77. Identification of Candidate Genes and eQTLs Related to ... [https://www.mdpi.com/2076-2615/15/7/1038]
• 78. Regulatory Effects of Endometriosis-Associated Genetic ... [https://www.mdpi.com/2079-9721/13/8/248]
• 79. Regulatory Effects of Endometriosis-Associated Genetic ... [https://pubmed.ncbi.nlm.nih.gov/40863222/]
• 80. GWAS meta-analysis identifies five susceptibility loci for ... [https://www.sciencedirect.com/science/article/pii/S2352396425002749]
• 81. Development and validation of a prognostic model for ... [https://pubmed.ncbi.nlm.nih.gov/41204543/?utm_source=FeedFetcher&utm_medium=rss&utm_campaign=None&utm_content=0GaYCevddEDAfC5HA0wlElkFqaKqOUgRmbLrsDcYiaD&fc=None&ff=20251108120403&v=2.18.0.post22+67771e2]
• 82. Identification and analysis of splicing quantitative trait loci ... [https://www.nature.com/articles/s41467-020-20578-2]
• 83. Regulatory Effects of Endometriosis-Associated Genetic Variants [https://pmc.ncbi.nlm.nih.gov/articles/PMC12385710/]
• 84. SplicePlot: a utility for visualizing splicing quantitative trait loci [https://pmc.ncbi.nlm.nih.gov/articles/PMC3967110/]
• 85. Endometrial Proliferative Phase-Centered View of ... [https://pubmed.ncbi.nlm.nih.gov/38791358/]
• 86. The mid-secretory endometrial transcriptomic landscape in ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9022214/]
• 87. Cross-tissue transcriptome-wide association studies ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12587738/]
• 88. Cross-Tissue Regulatory Network Analyses Reveal Novel ... [https://www.mdpi.com/2079-7737/13/11/871]
• 89. Partitioning and aggregating cross-tissue ... [https://www.nature.com/articles/s41467-024-49924-4]
• 90. Cross-tissue gene expression interactions from bulk, single ... [https://bmcgenomics.biomedcentral.com/articles/10.1186/s12864-025-11747-y]
• 91. Organoids as powerful models of endometrium epithelium ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12234953/]
• 92. A relational database to identify differentially expressed ... [https://www.nature.com/articles/s41597-020-00623-x]
• 93. Endometrial stem/progenitor cells: Properties, origins, and ... [https://www.sciencedirect.com/science/article/pii/S2352304222002306]
• 94. Three-dimensional culture models of human endometrium for... [https://rbej.biomedcentral.com/articles/10.1186/s12958-022-00973-8]
• 95. Organoid co-culture model of the human endometrium in a ... [https://www.sciencedirect.com/science/article/pii/S2666634023002271]
• 96. Endometriosis Using Modelling and In Vivo Systems - PMC In Vitro [https://pmc.ncbi.nlm.nih.gov/articles/PMC11766166/]
• 97. Single-cell sequencing uncovers disrupted stromal ... [https://www.nature.com/articles/s42003-025-08634-3]